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1 Summary 
The Megakaryoblastic Leukemia proteins 1 and 2 (MKL1/2) are transcriptional coactivators of 
the nuclear transcription factor serum response factor (SRF) that controls fundamental 
processes like cell growth, cell migration, differentiation and organization of the cytoskeleton.   
Deleted in Liver Cancer 1 (DLC1), encoding a RhoGAP protein, was identified as a tumor 
suppressor whose allele is lost in 50 % of liver, breast, lung and 70 % of colon cancers. Despite 
its significance, the molecular mechanism which drive cancerous transformation remained so 
far unknown. Preliminary data indicated a direct correlation between the subcellular 
localization of MKL1 and the endogenous expression levels of DLC1. In this work, we found 
that loss of DLC1 expression in hepatocellular and breast carcinoma cells caused the nuclear 
translocation of MKL2. We demonstrated that the nuclear MKL1/2 localization in hepatocellular 
and breast carcinoma cells lacking endogenous DLC1 expression was accomplished by the 
constitutive activation of RhoA/actin signaling and simultaneous impairment of MKL1 
phosphorylation resulting in the constitutive activation of the tumor-relevant MKL/SRF 
dependent target genes CTGF and Cyr61. In the context of hepatocarcinogenesis, we found 
that RNAi-mediated silencing of nuclear, active MKL1/2 expression suppressed tumor cell 
proliferation of human hepatocellular carcinoma cells characterized by a DLC1-deficient 
background. Loss of DLC1 and the subsequent RhoA activation were prerequisites for the 
MKL1/2 knockdown-mediated growth arrest. We identified oncogene-induced senescence as 
the underlying molecular mechanism of the observed anti-proliferative effect of MKL1/2 
knockdown. Depletion of MKL1/2 caused the activation of oncogenic Ras signaling that 
resulted in elevated p16Ink4a expression and hypophosphorylation of the retinoblastoma protein 
(Rb) in DLC1-deficient HCC cells. Furthermore, senescent DLC1-deficient HCC cells depleted 
of MKL1/2 were marked by a DNA damage response documented by elevated phosphorylation 
of p53 on serine 15 and revealed an upregulation of the chemokine (C-S-C) motif ligand 10 
and tumor necrosis factor (ligand) superfamily 10, both components of the senescence-
messaging secretome. Notably, reconstitution of DLC1-expression in HuH7 HCC cells also 
provoked the induction of a senescence response. Evaluation of the therapeutic efficacy of 
MKL1/2 knockdown in vivo demonstrated that systemic treatment of nude mice bearing 
subcutaneous DLC1-deficient HuH7 cells derived tumor xenografts with siRNAs targeting 
MKL1 and MKL2 complexed with polyethylenimine (PEI) significantly suppressed the tumor 
growth due to the induction of a senescence response in vivo. Of note, PEI-complexed MKL1 
siRNA alone was sufficient to completely abolish HCC xenograft growth. A DNA-microarray 
based transcriptome analysis of MKL1/2 depleted DLC1-deficient HuH7 cells highlighted 
myoferlin as a novel, hitherto unnoticed MKL1/2 and SRF dependent target gene.  
Summary 
 
2 
We characterized myoferlin as a novel regulator of EGFR activity in DLC1-deficient HCC cells 
and its downregulation enabled sustained EGFR signaling thereby triggering the tumor 
suppressive oncogene-induced senescence response. Our study highlights MKL1/2 as 
promising novel pharmacological targets for the anti-tumor therapy of HCC characterized by 
loss of the tumor suppressor DLC1.   
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2 Introduction 
2.1 The transcription factor serum response factor (SRF) 
Transcription is a well-controlled and coordinated process that requires the cooperation 
between transcription factors and co-regulators. Transcription factors mediate the execution of 
genetic programs in response to extra- and intracellular signals. SRF is a founding member of 
the MADS-box family of transcription factors and constitutes one of the best understood DNA-
binding proteins in the human genome (Shore & Sharrocks, 1995). The MADS box (MCM1, 
Agamous, Deficiens, SRF) constitutes a modular, conserved DNA binding domain composed 
of 56 amino acids (Pellegrini et al, 1995). SRF binds DNA at the palindromic CC(A/T)6GG 
consensus sequence, designated as CArG box or serum response element (SRE) which is 
found in numerous promoters of actin cytoskeleton and immediate early genes (IEG) (Miano 
et al, 2007; Treisman, 1995a). SRF binds to the CArG boxes as a homodimer. Meanwhile, 
approximately 160 different target genes have been found to be directly regulated by SRF 
signaling and about half of these have been experimentally proven (Sun et al, 2006a). The 
majority of SRF target genes is implicated in cell growth, migration, cytoskeletal organization 
and myogenesis (Johansen & Prywes, 1995; Takeda et al, 1992; Treisman, 1986). The first 
prototypical described SRF target gene involved in cell growth, c-fos, is controlled by a single 
CArG-box (Norman et al, 1988). SRF-dependent enhancers of muscle gene expression were 
initially described as duplicated CArG-boxes activating transcription (Chow & Schwartz, 1990; 
Miwa & Kedes, 1987). It has been hypothesized that SRF-dependent target genes involved in 
cell growth are controlled by a single CArG-box whereas SRF-dependent muscle genes are 
controlled by duplicated CArG-boxes. However, it has been shown that most SRF target genes 
are controlled by duplicated CArG-boxes (Sun et al, 2006a). In vitro experiments using 
downregulation of SRF expression or the expression of dominant-negative SRF mutants 
documented that SRF signaling is functionally required for cell growth and skeletal muscle 
differentiation (Kaplan-Albuquerque et al, 2005; Soulez et al, 1996; Wei et al, 1998). Moreover, 
dominant-negative SRF mutants disrupted skeletal as well as cardiac muscle differentiation in 
transgenic mice (Zhang et al, 2001). SRF-null embryos failed to develop mesoderm resulting 
in lethality at gastrulation (Arsenian et al, 1998). The involvement of SRF in cell migration and 
adhesion was substantiated by the findings that embryonic stem cells (ES) lacking SRF 
revealed defects in spreading, adhesion and migration that correlated well with the 
abnormalities of actin stress fibers and loss of the expression of genes encoding the actin 
cytoskeleton such as vinculin and talin (Schratt et al, 2002). Studies with tissue specific 
knockout mice highlighted the importance of SRF expression in the cardiovascular system 
(Parlakian et al, 2004), skin development (Verdoni et al, 2010), skeletal muscle cells (Li et al, 
2005b), liver development (Sun et al, 2009) and central nervous system (Alberti et al, 2005). 
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Transcription factors are relatively weak transcriptional activators and function through the 
recruitment of transcriptional coactivators or corepressors that do not directly bind to DNA but 
regulate transcription through the association with DNA-bound factors like SRF (Spiegelman 
& Heinrich, 2004).  
2.1.1 The ternary complex factor (TCF)-dependent signaling pathway of SRF 
activation 
Historically, Shaw and colleagues showed that SRF bound to the SRE element of the c-fos 
promoter formed a ternary complex with p62 which has been shown to be homologous to Elk-
1 (Ets-like transcription factor 1) (Hipskind et al, 1991; Shaw et al, 1989). The ternary complex 
factors act as transcriptional coactivators and are composed of Elk-1, SAP-1 (SRF accessory 
protein 1) and Net (Erp/Sap-2/Elk-3) which belong to the Ets group of transcription factors, one 
of the largest family of transcription factors (Sharrocks, 2001).  
 
 
Figure 1: The TCF-dependent signaling pathway of SRF activation. 
Activation of the MAPK signaling cascade contributes to the phosphorylation of TCFs which binds via their own Ets 
DNA recognition site near the CArG box of immediate early genes thereby activating SRF-mediated transcription. 
Picture is taken from (Posern & Treisman, 2006).  
Extracellular stimuli which activate MAPK signaling contribute to the phosphorylation of TCFs. 
Phosphorylated TCFs bind to a core sequence GGA(A/T), termed as EBS (Ets binding 
sequence) which is located in the direct proximity of CArG boxes and is required for the ternary 
complex formation between TCFs and SRF (Treisman, 1994; Treisman, 1995b). Upon 
extracellular stimuli, the TCF-factor Elk-1 has been shown to be activated by all three key MAP 
kinases, ERK, JNK and p38, Net by p38 and JNK and SAP-1 by ERK and p38 ( (Buchwalter 
et al, 2004). Besides activation through MAPK signaling, SAP-1 has been shown to be 
activated by the colony stimulating factor 1 (CSF-1) (Hipskind et al, 1994). Immediate early 
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genes like c-fos, egr-1, pip92 and JunB are regulated by TCFs, as IEGs containing SREs are 
the best characterized targets of TCFs (Treisman, 1990; Treisman, 1992). IEGs are rapidly 
induced upon extracellular stimuli and do not require de novo protein synthesis for their 
induction. Despite the large number of studies investigating the physiological roles of TCFs, 
their implication in vivo is not well understood. For example, homozygous mutant Net mice 
developed a specific defect in thoracic lymphatic vessels which was manifested by the 
accumulation of chyle in lungs and these mice died from respiratory failure (Ayadi et al, 2001).  
Net expression has been reported to be required for angiogenesis in normal adult tissue 
(Zheng et al, 2003). By contrast, Elk-1 and Sap-1 null mice revealed few, less severe 
abnormalities suggesting that the members of the TCF family may act redundantly. 
Consequently, further in vivo studies using combinatorial and tissue specific knockouts are 
required to elucidate the exact physiological roles of the TCFs.  
2.1.2 Rho-actin signaling dependent activation of SRF  
First evidence for a secondary, TCF-independent activation of SRF was documented by the 
findings that the mutation of the TCF-binding site within the c-fos promoter did not completely 
abolish the serum-induced activation of the c-fos promoter. These findings led to the 
suggestion that at least two independent pathways activate SRF: the TCF-dependent and 
TCF-independent pathway (Hill & Treisman, 1995). The TCF-independent activation of SRF 
was blocked by Rho inhibition and activated upon expression of active RhoA indicating that 
Rho activation was required for the transcriptional response to serum (Hill et al, 1995). Many 
mechanistic studies linked Rho signaling to the activation of SRF, finally it has been realized 
that cytoskeletal actin dynamics is closely involved in this process. It has been clarified that 
Rho signaling promoted F-actin polymerization and the concomitant reduction of G-actin 
stimulated SRF signaling (Sotiropoulos et al, 1999). Actin polymerization is controlled by mDia, 
a downstream mediator of RhoA which promotes F-actin polymerization (Copeland & 
Treisman, 2002). ROCK stabilizes F-actin via phosphorylation of the Lim-kinase which in turn 
phosphorylates and inactivates the actin depolymerization factor cofilin (Sotiropoulos et al, 
1999). Moreover it has been shown that the Lim-kinase cooperated with mDia to regulate SRF 
activation (Geneste et al, 2002). Furthermore, Posern and colleagues demonstrated that the 
overexpression of non-polymerizable actin mutants failed to activate SRF reporters (Posern et 
al, 2002). So far, no direct interaction between G-actin and SRF could be detected suggesting 
that an unknown cofactor may sense cellular F and G-actin levels and controls thereby SRF 
activity. 
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Figure 2: SRF activity is controlled via actin dynamics. 
Rho signaling promotes F-actin polymerization via the ROCK- Lim-kinase and mDia pathway and the concomitant 
G-actin depletion contributes to the activation of SRF. Picture is taken from (Geneste et al, 2002). 
2.1.3 The family of myocardin-related transcription factors 
In 2002, Wang and colleagues identified a new group of transcriptional coactivators activating 
SRF (Wang et al, 2002) which were designated as the family of myocardin-related transcription 
factors (MRTFs). The founding member of this group, myocardin, was initially identified by an 
in silico screen and described to specifically expressed in cardiac and smooth muscle cells, 
where it functioned as a potent transcriptional coactivator of SRF (Wang et al, 2001). By 
contrast, the two other members of the MRTF family, MRTF-A alternatively termed MAL, MKL1 
(megakaryoblastic leukemia protein 1) or BSAC and MRTF-B, designated as MKL2 
(megakaryoblastic leukemia protein 2) or MAL16 were shown to be ubiquitously expressed in 
a broad spectrum of embryonic and adult tissues including embryonic stem cells (Du et al, 
2004; Wang et al, 2002).   
 Structure of the members of the myocardin-related transcription factors 
The members of the myocardin family feature high sequence similarity and share a series of 
conserved domains. The amino-termini of myocardin and MKLs contain three Arg-Pro-X-X-X-
Glu-Leu (RPEL) domains which form a stable complex with monomeric G-actin (Guettler et al, 
2008; Miralles et al, 2003; Mouilleron et al, 2008). The transcriptional coactivators associate 
with SRF through a basic region and an adjacent glutamin-rich domain (Wang et al, 2001; 
Wang et al, 2002). One of the notable features of the members of the myocardin family 
represents the SAP domain, named after SAF-A/B, Acinus and PIAS which in other proteins 
is well established to be implicated in the regulation of nuclear organization, chromosomal 
dynamics and apoptosis (Aravind & Koonin, 2000). The SAP domain is predicted to be 
composed of two amphipathic α-helices which function as weak DNA-binding sites (Gohring 
et al, 1997; Kipp et al, 2000). Deletion of the SAP domain of either MKL1 or myocardin does 
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not interfere with their transcriptional activity and the ability to form a complex with SRF (Cen 
et al, 2003; Miralles et al, 2003; Wang et al, 2001). The highly conserved coiled-coil-leucine 
zipper-like domain is required for the homo- and heterodimerization among the members of 
the myocardin family. The heterodimerization between myocardin and the other two members 
of the myocardin family has been proposed to support the cooperativity between CArG boxes 
and SRF controlled muscle genes (Wang et al, 2001). Moreover, for MKL1 it has been shown 
that the deletion of the leucin zipper domain exerted only a modest effect on the MKL1 
mediated activation of SRF-reporter genes (Cen et al, 2003). The C-termini of the members of 
the myocardin family share low sequence identity and function as transcription activation 
domains (TADs). Deletion of the TAD domains contributes to the generation of dominant-
negative mutants (Cen et al, 2003). 
 
 
Figure 3: Modular structure of the members of the myocardin family. 
The basic (++) and glutamin-rich (Q) domains are required for the direct interaction of SRF. RPEL domains are 
binding sites for G-actin; SAP domain constitutes a putative DNA-binding element. The Leucine zipper motif is 
required for homo and heterodimerization among the members of the myocardin family. TAD-transactivation 
domain. MEF2 is an interaction domain exclusively found in the cardiac form of myocardin. Picture is taken from 
(Olson & Nordheim, 2010).    
2.1.4 Regulation of the subcellular localization and transcriptional activity of MKL1 
and MKL2 
In 2003, Miralles and colleagues found that the subcellular localization of MKL1 is regulated 
by Rho-actin signaling and MKL1 was characterized as the cofactor which mediates actin-
sensitivity of SRF (Miralles et al, 2003). In unstimulated NIH3T3 fibroblasts, MKLs are 
sequestered in the cytoplasm by binding via their N-terminal RPEL-motifs to monomeric G-
actin (Miralles et al, 2003; Posern et al, 2004). Serum or LPA induced Rho activation stimulates 
F-actin polymerization in the cytoplasm and the concomitant depletion of G-actin induces the 
release of MKLs from the inhibitory complex (Miralles et al, 2003; Posern et al, 2004). 
Dissociation of MKLs from G-actin unmasks a nuclear localization sequence within the RPEL 
domain which is required for the importin α/β mediated nuclear import of MKLs (Pawlowski et 
al, 2010). Upon accumulation in the nucleus, MKLs have to dissociate from nuclear G-actin, 
bind to SRF as a dimer and activate the transcription of target genes (Miralles et al, 2003; 
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Vartiainen et al, 2007). Recently, Baarlink and colleagues showed that serum stimulation 
promoted nuclear actin polymerization which triggered MKL1 mediated SRF activation 
(Baarlink et al, 2013). Nevertheless, how nuclear actin polymerization is recognized and 
transduced into MKL/SRF signaling remains unknown so far. Complex formation between 
nuclear G-actin and MKLs promotes the Crm1-dependent nuclear export of MKLs back into 
the cytoplasm (Vartiainen et al, 2007). Serum or TPA stimulation (phorbol ester 12-O-
tetradecanoyl-13-acetate) promotes not only the nuclear accumulation of MKLs but also 
induces ERK1/2 dependent phosphorylation of MKL1 at serine 454 (Muehlich et al, 2008). 
MKL1 phosphorylation functions as a switch-off stimulus for MKL1/SRF signaling since it 
supports binding between MKL1 and nuclear G-actin thereby facilitating nuclear the export of 
MKL1 (Muehlich et al, 2008). Moreover, it was supposed that the nuclear export rate is the 
determining factor for the subcellular localization of MKL1 (Vartiainen et al, 2007). The 
described nuclear-cytoplasmic shuttling mechanism of MKLs is well established for fibroblasts 
and muscle cells whereas myocardin is constitutively nuclear and specifically expressed in 
cardiac and smooth muscle cells.  
 
Figure 4: Regulation of the subcellular localization and transcriptional activity of MKLs. 
Serum induced Rho activation induces F-actin polymerization and the concomitant G-actin depletion induces the 
dissociation of MKLs from G-actin. MKLs translocate into the nucleus, bind to the homodimer of SRF and activate 
the transcription of target genes. ERK1/2 mediated phosphorylation of MKL1 at serine 454 facilitates binding 
between MKL1 and nuclear G-actin thereby promoting the nuclear export of MKL1. Picture is taken from (Muehlich 
et al, 2008).  
By contrast, in striated muscle cells, expression of STARS proteins drove MKLs into the 
nucleus and triggered their constitutive nuclear localization (Kuwahara et al, 2007). A 
constitutive nuclear accumulation of MKL1 without any stimuli was observed in neurons (Kalita 
et al, 2006; Stern et al, 2009). Therefore it is supposed that the subcellular localization of MKLs 
is a cell-type dependent feature. 
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2.1.5 Biological function of the transcriptional coactivators MKL1 and MKL2 
Overexpression of MKL1 and MKL2 in fibroblasts activated smooth muscle gene expression 
(Du et al, 2004; Selvaraj & Prywes, 2004; Wang et al, 2002). Moreover, MKL1 expression was 
required for skeletal muscle differentiation and expression of dominant negative mutants of 
MKL1 in vivo caused thin muscle fibers suggesting that MKL1 expression is required for muscle 
growth (Li et al, 2005b; Selvaraj & Prywes, 2003). Despite the numerous physiological 
processes in which MKL1 takes part, the majority of MKL1 knockout mice are viable and fertile, 
presumably due to the functional redundancy between MKL1 and the other members of the 
myocardin family. This suggestion is supported by the fact that a single MKL1 or MKL2 
knockout phenotype do not phenocopy SRF knockout. A small subset of MKL1 null embryos 
died from cardiac abnormalities (Sun et al, 2006b). Furthermore, female MKL1 knockout mice 
failed to nurse their offspring due to specific defects in the mammary gland myoepithelial cell 
differentiation that affected ejection of milk from the mammary gland during lactation (Li et al, 
2006; Sun et al, 2006b). MKL1 knockout mice displayed a reduced number of platelets in the 
peripheral blood and a diminished quantity of mature megakaryocytes suggesting that MKL1 
expression plays a crucial role in the differentiation and maturation of megakaryocytes (Cheng 
et al, 2009). A similar effect on megakaryocyte maturation and platelet formation was reported 
for double knockout mice lacking both MKL1 and MKL2 (Smith et al, 2012). Mice with global 
MKL2 knockout revealed a defect in the smooth muscle differentiation and a failure of the 
cardiovascular development leading to death between embryonic day 17.5 and postnatal day 
1 (Oh et al, 2005). The observed phenotype arose presumably from the cell autonomous flaw 
in differentiation of smooth muscle cells from the cardiac neural crest (Li et al, 2005a). 
Conditional knockout of MKL1 and MKL2 in the brain caused morphological abnormalities in 
the hippocampus, cerebral cortex and subventricular zone. The defects were due to a failure 
of actin polymerization and dysfunctional cytoskeletal organization resulting in impaired 
neuronal migration and neurite outgrowth (Mokalled et al, 2010). In acute megakaryoblastic 
leukemia, MKL1 was found to be translocated and fused with RBM15 (RNA-binding motif 
protein 15) also known as OTT (Mercher et al, 2009). The RBM1-MKL1 fusion protein was 
functionally deregulated and caused the constitutive activation of SRF dependent target gene 
expression thereby promoting tumor progression (Cen et al, 2003; Descot et al, 2008). Besides 
the involvement of MKL1 in acute megakaryoblastic leukemia, MKL1 and MKL2 expression 
was required for tumor cell invasion and experimental metastasis (Medjkane et al, 2009). RNAi 
mediated downregulation of MKL1/2 expression abolished cell adhesion, spreading, motility 
and invasion of human breast carcinoma and mouse melanoma cells. Moreover reduced 
MKL1/2 expression abolished the capability of breast carcinoma cells to form lung metastases 
upon intravenous injection into the mouse tail vein. This study documented that the observed 
phenotypes were mediated by the two MKL/SRF dependent target genes MYH9 and MYL9, 
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both encoding cytoskeletal associated proteins (Medjkane et al, 2009). SCAI (suppressor of 
cancer cell invasion) was characterized as a novel binding partner of nuclear MKL1 (Brandt et 
al, 2009). SCAI expression antagonized ß1-integrin driven tumor cell invasion which was 
activated by MKL1/SRF signaling. Interestingly, the epithelial protein in Neoplasma α (Eplin α), 
acting as a cytoskeletal associated tumor suppressor, whose expression correlates inversely 
with tumor progression, was identified as an actin-MKL1 regulated target gene (Leitner et al, 
2010). In contrast to tumor cells where MKL1/2 expression augmented the migratory behavior 
of the cells, Leitner and colleagues found that in non-invasive cells activation of G-actin-MKL 
signaling reduced cell migration via upregulation of cytoskeletal-associated proteins such as 
integrin alpha 5 (Itgα5), plakophilin (Pkp2) and FHL1 (Leitner et al, 2011). Furthermore, 
overexpression of MKL1 in NIH 3T3 fibroblasts induced a strong anti-proliferative effect 
through the upregulation of anti-proliferative target genes such as mig6, functioning as a 
negative regulator of the EGFR-MAPK signaling pathway (Descot et al, 2009). By contrast, 
RNAi mediated silencing of MKL1 and MKL2 expression in the same cell line caused a modest 
anti-proliferative effect (Shaposhnikov et al, 2013). Consequently it seems that the expression 
levels and activation status of MKLs determine the expression of specific clusters of target 
genes through which MKLs exert various, often opposing effects on cell migration and 
proliferation, depending on the cellular context.  
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2.2 Rho GTPases  
The small GTPases of the Rho family form a distinct group within the Ras superfamily of 
monomeric GTP-binding proteins of which RhoA, Rac1 and cdc42 are well characterized. Rho 
GTPases have been described to be involved in a plethora of cellular processes such as 
cytoskeleton organization, gene transcription, cell proliferation, migration, growth and cell 
survival (Jaffe & Hall, 2005). Rho proteins can act as molecular switches by connecting 
changes from the external environment to intracellular signaling pathways. Activation of growth 
factors as well as tyrosine kinase receptors, G protein coupled receptors and integrins results 
in the activation of Rho GTPases which subsequently interact with their effector molecules and 
modulate their activity and subcellular localization.  
 
Figure 5: Rho GTPases are complexly regulated molecular switches.  
Rho GTPases cycle between an inactive, GDP-bound and an active, GTP bound state. GDIs sequester GDP-bound 
GTPases in the cytoplasm. The exchange of GDP to GTP is promoted by GEFs which is often associated with the 
translocation of Rho proteins to the cell membrane. GAPs promote the hydrolysis of GTP to GDP thereby returning 
activated Rho GTPases in their inactive state. Activated GTP-bound Rho proteins bind to effector molecules which 
mediate downstream signaling. This picture is taken from (Sahai & Marshall, 2002). 
Rho proteins shuttle between an active, GTP-bound and an inactive, GDP-bound state which 
is controlled by three classes of regulatory proteins (Figure 5). GEFs (guanine nucleotide 
exchange factors) promote the activation of Rho proteins by catalyzing the exchange of GDP 
to GTP (Rossman et al, 2005). On the other hand, GAPs (GTPase activating proteins) 
accelerate the intrinsic catalytic activity of Rho GTPases to hydrolyze bound GTP. Thus, the 
activity of Rho GAPs promotes the return of Rho GTPases in their inactive, GDP bound state 
(Bos et al, 2007). A third class of Rho GTPase inhibitors constitute GDIs (guanine nucleotide-
dissociation inhibitors) which bind to GTPases and sequester them in their inactive, GDP-
bound state in the cytoplasm (Dransart et al, 2005).  
2.2.1 Rho GTPases and their role in cancer 
Besides the involvement of Rho GTPase signaling in physiological processes, there is 
emerging evidence that deregulated Rho GTPase signaling contributes to cancer initiation, 
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tumor progression, unlimited proliferation potential, survival, evasion from apoptosis, invasion 
and the establishment of metastasis (Vega & Ridley, 2008). In contrast to the small GTPase 
Ras, no gain or loss-of-function mutations have been reported for Rho GTPases in human 
tumors, instead Rho proteins were found to be frequently overexpressed (Sahai & Marshall, 
2002). In addition to unlimited cell proliferation, tumor cells adopt typical morphological 
characteristics which are necessary for invasion and metastasis. RhoA induces stress fiber 
assembly which are required as contractile structures, whereas cdc42 is essential for the 
formation of filopodia and Rac1 promotes lamellipodia formation.    
 
 
Figure 6: Requirement of Rho protein signaling at different stages during tumor progression.   
(A) Normal epithelial polarity is maintained by RhoA, Rac1 and cdc42 whereas RhoA and Rac1 are required for the 
formation of cell junctions. (B) Loss of cell polarity is caused by RhoA and Rac1 signaling. (C) Augmented RhoA, 
ROCK, Rac1 and cdc42 signaling increases the motility of tumor cells thereby favoring the local invasion of tumor 
cells. (D) Metastasis to distinct sites is facilitated by Rho and ROCK signaling promoting transendothelial migration. 
Rho signaling increases the expression of pro-angiogenetic factors. Picture is taken from (Sahai & Marshall, 2002).  
The polarity of normal epithelial cells is maintained by RhoA, Rac1 and cdc42. Loss of epithelial 
cell polarity is an important step during the process of epithelial-mesenchymal transition where 
cells render a more motile phenotype. Activation of RhoA signaling is able to trigger the loss 
of cell polarity. Loss of cell polarity and cell-cell junctions, increased migratory behavior and 
remodeling of the extracellular matrix (ECM) are required for tumor cells to become locally 
invasive. Modulation of Rac1 and Rho/ROCK activation can promote the loss of polarity 
whereas increased RhoA, ROCK, Rac1 and cdc42 activity increase the cell motility. Moreover 
RhoA and Rac1 regulate the expression of MMPs (matrix metalloproteinases) which affect 
remodeling of the basement membrane and other extracellular matrix compounds thereby 
promoting tumor cell invasion. For metastasis to distant sites, tumor cells have to enter the 
blood and lymphatic vasculature. It has been shown that the activity of RhoA and ROCK was 
required for the transendothelial migration of tumor cells (Adamson et al, 1999; Worthylake et 
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al, 2001). Moreover, tumor cells are not able to grow without the appropriate blood vessel 
support, hence angiogenesis is essential for the tumor formation in vivo. Increased Rho 
GTPase expression promoted the expression of pro-angiogenetic factors which facilitated 
vascularization of the tumors (Turcotte et al, 2003; van Golen et al, 2000). Alternative 
mechanism for increased Rho GTPase signaling in cancer can be envisaged such as the 
constitutive activation of a GEF, deletion of a GAP or altered expression of GDIs. A subset of 
GEFs were found to be mutated or aberrantly expressed in malignancies thereby functioning 
as oncogenes. For example, the RhoA specific GEF LARG (leukemia associated Rho GEF) 
was found in a fused version with the mixed lineage leukemia gene (MLL) in acute myeloid 
leukemia (AML) thereby promoting tumor progression (Kourlas et al, 2000; Reuther et al, 
2001). Furthermore the Vav family of Rho GEF proteins was described to play a crucial role in 
human cancers (Lazer & Katzav, 2011). By contrast, the human genome encodes about 70 
members of the RhoGAP family and their downregulation was found in different types of 
cancers like ArhGAP8 in colorectal and breast cancer, ArhGAP20 in leukemia and PIK3R1 in 
prostate cancer (Hellwinkel et al, 2008; Herold et al, 2011; Johnstone et al, 2004; Tcherkezian 
& Lamarche-Vane, 2007). Nevertheless, the family of Deleted in Liver Cancer proteins 
constitutes the best characterized group of RhoGAP proteins in the context of tumorigenesis.  
2.2.2 The Deleted in Liver Cancer proteins 
Three genes of the human genome encode for a RhoGAP subfamily termed “deleted in liver 
cancer “(DLC) proteins. The first member of this group, DLC1 also termed as ArhGAP7 or 
StarD12 was originally identified by Yuan and colleagues in 1998 by a representational 
difference analysis (a PCR-based subtractive hybridization technique) as a gene frequently 
deleted in primary human hepatocellular carcinoma (HCC) which shared high homology with 
the rat p122 RhoGAP gene (Yuan et al, 1998). The gene locus of DLC1 was mapped to 
chromosome 8p22, a region that recurrently shows LOH or heterozygous deletions in 
numerous solid tumors and hematological malignancies. Consequently, it was proposed that 
DLC1 is a candidate tumor suppressor (Yuan et al, 1998). DLC1 was found to be widespread 
expressed in normal tissues like brain, heart, kidney, liver, lung and spleen (Durkin et al, 2002). 
Since DLC1 has been characterized as a tumor suppressor, its expression was analyzed in 
various types of human cancers and was found to be downregulated or lost in many human 
cancers including breast, lung, colon, ovarian, stomach and brain (Guan et al, 2006; Kim et al, 
2003; Plaumann et al, 2003; Seng et al, 2007; Ullmannova & Popescu, 2006; Xue et al, 2008; 
Yuan et al, 1998). The principle mechanism for DLC1 inactivation can be attributed to the 
frequent chromosomal deletions of its gene locus. Moreover the promoter region of the DLC1 
gene is GC-rich with typical CpG islands that function as methylation sites. Thus, aberrant 
promoter methylation is thought to be the second mechanism that contributes to the silence of 
DLC1 expression in various types of human cancers (Wong et al, 2003; Yuan et al, 2003a). In 
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addition, transcriptional silencing has been linked to histone hypoacetylation due to the 
recruitment of histone deacetylases to chromatin (Marks et al, 2001). As DLC1 expression 
could be restored after the treatment with a histone deacetylase inhibitor in different human 
cancer cell lines, it was supposed that alterations in histone modifications could constitute the 
third mechanism accounting for the frequently observed suppression of DLC1 expression 
(Guan et al, 2006; Kim et al, 2003). Somatic mutations in the coding region of DLC1 were 
thought to be rare since it has been reported to occur in prostate and colon cancers (Liao et 
al, 2008). The other two members of the deleted in liver cancer family feature high similarity to 
DLC1. DLC2 also termed STARD13 is located on chromosome 13q12 and seems to be 
underexpressed in hepatocellular carcinoma. DLC3, also known as STARD8, was mapped to 
chromosome Xq13 and reduced DLC3 mRNA expression levels were detected in many human 
cancer tissues like prostate, kidney, lung, breast, uterus and ovary (Durkin et al, 2007a). 
Recently, the DLC1 isoform 4 (DLC1-i4) was discovered and reported to be absent in a large 
number of nasopharyngeal, esophageal, gastric, breast, colorectal, cervical and lung 
carcinoma cell lines as well as in primary tumors due to its epigenetic silencing (Low et al, 
2011).   
 Structure of the Deleted in Liver Cancer proteins 
DLC1-3 are multidomain proteins that are structurally composed of three functional domains. 
The N-terminal sterile alpha motif (SAM) features a five-helical structure and is a common 
protein-protein interaction motif, found in a variety of human signaling proteins (Kim & Bowie, 
2003). Unlike this common feature, it has been reported that the SAM motifs of DLC1 and 
DLC2 adopt a four-alpha helical structure (Kwan & Donaldson, 2007; Li et al, 2007). SAM 
domains can form homo-and hetero-oligomers with other SAM-domain containing proteins or 
bind to other proteins, RNA and DNA (Qiao & Bowie, 2005). However the general role of the 
SAM-domain for the DLC1 function remains largely unknown. One study to the structure 
related function of the SAM domain pointed out that it seems to be autoinhibitory for the 
catalytic function of the RhoGAP domain (Kim et al, 2008). Using protein precipitation and 
mass spectrometry, the eukaryotic elongation factor 1A1 (EF1A1) was identified as a novel 
interaction partner of the SAM domain of DLC1, but not of DLC2. Zhong and colleagues 
showed that the interaction facilitated the distribution of EF1A1 to the membrane periphery and 
ruffles and suppressed significantly cell migration (Zhong et al, 2009). 
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Figure 7: The modular structure of the DLC protein family, representing three major functional domains. 
Picture taken from (Lukasik et al, 2011).  
 
Next to the SAM domain, there follows a region lacking a secondary structure which shows 
hardly any sequence identity to known conserved protein motifs. This unstructured middle part 
is an important feature since the open and extended conformation enables the interaction with 
other proteins and the attachment of post-translational modifications like phosphorylation 
(Tompa, 2003). Multiple serine threonine kinase phosphorylation sites were identified for 
DLC1, most of them are located in the middle region (Durkin et al, 2007b). For example, it has 
been shown that DLC1 is phosphorylated by protein kinase D (PKD) at serines 327 and 431 
and this phosphorylation is required for the interaction with 14-3-3 proteins (Scholz et al, 2009). 
This phosphorylation prevented DLC1-mediated hydrolysis of GTP-bound Rho. In addition, 
Kawai and colleagues found in this unstructured region a focal adhesion targeting (FAT) 
domain which is responsible for the focal adhesion localization of DLCs (Kawai et al, 2009). 
Several studies reported that DLCs were targeted to focal adhesion sites via binding to the Src 
Homology 2 (SH2) domain of tensin proteins (Kawai et al, 2010; Liao et al, 2007; Qian et al, 
2007). The focal adhesion localization seems to be critical for the tumor suppressive properties 
of DLCs. Moreover it has been shown that the family of DLC proteins interact with the 
phosphotyrosine binding (PTB) domain of tensin 2 proteins (Chan et al, 2009; Chen et al, 2012; 
Kawai et al, 2010; Yam et al, 2006). However, the best characterized domain of the DLC 
protein family constitutes the around 200 amino acid long RhoGAP domain, the most highly 
conserved region among the three proteins. The GAP domain catalyzes the conversion of 
active GTP-bound Rho proteins to their inactive GDP-bound form. The conserved arginine 
residue of all three DLC proteins is essential for their RhoGAP activity (Fidyk & Cerione, 2002). 
DLC1-3 exert a strong GAP activity towards RhoA and to a lesser extent towards cdc42 
whereas they have almost no effect on the GTPase activity of Rac1 (Ching et al, 2003; Durkin 
et al, 2007a; Qian et al, 2007; Sekimata et al, 1999; Wong et al, 2003). The carboxyterminal 
START (steroidogenic acute regulatory protein (StAR)-related lipid transfer) domain is 
described to bind to lipids and sterols (Iyer et al, 2001). Altogether, fifteen human proteins 
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containing a START domain have been discovered which are implicated in different 
physiological processes like transfer between intracellular compartments, lipid metabolism and 
regulation of cell signaling (Alpy & Tomasetto, 2005; Ponting & Aravind, 1999). The exact 
physiological function as well as the interaction partners of the DLC1-3 START domains are 
not well characterized. In the case of DLC2, Ng and colleagues found that the DLC2 START 
domain colocalizes with mitochondria (Ng et al, 2006). Moreover, recently an interaction 
between the START domain of DLC1 and the tumor suppressor caveolin was identified 
affecting the tumor suppressive functions of DLC1 in a RhoGAP independent manner (Du et 
al, 2012).  
 The biological function of DLC1 and its pivotal role in cancer 
As a RhoGAP protein with a proven activity towards the small GTPases of the Rho family, a 
major function of DLC1 constitutes certainly its involvement in the regulation of the cytoskeletal 
organization. Overexpression of DLC1 caused a rounded morphology of adherent cells 
accompanied by the disruption of actin stress fibers and focal adhesions, cellular processes 
which are well established to be reversely controlled by RhoA signaling (Kim et al, 2007; 
Sekimata et al, 1999; Wong et al, 2005). Knockout studies evidenced a crucial role of DLC1 
expression for the embryonic development as homozygous mutant embryos died before 10.5 
day postcoitus due to defects in the neural tube, brain, heart and placenta (Durkin et al, 2005). 
Analysis of fibroblasts isolated from DLC1 mutant embryos revealed disruption of the actin 
cytoskeleton thereby confirming the pivotal role of DLC1 for the cytoskeletal organization 
(Durkin et al, 2005). Moreover this study provided evidence that DLC2 and DLC3 were not 
able to compensate for the DLC1 deficiency during embryonic development suggesting that 
the different DLC isoforms may not act redundantly. First evidence for the tumor suppressive 
function of DLC1 derived from experiments where ecotopic DLC1 was expressed in different 
human cancer cell lines who have lost endogenous DLC1 expression. Restoration of DLC1 
expression suppressed cell proliferation, colony formation and anchorage-independent growth 
of hepatocellular, breast and lung carcinoma cell lines (Ng et al, 2000; Plaumann et al, 2003; 
Qian et al, 2007; Wong et al, 2005; Yuan et al, 2003b; Zhou et al, 2004). The limitation of cell 
proliferation of HCC and renal carcinoma cells originated from the induction of apoptosis 
(Zhang et al, 2009; Zhou et al, 2004). Besides, overexpression of DLC1 in human breast, non-
small lung and hepatocellular carcinoma cells suppressed tumorigenicity in vivo (Wong et al, 
2005; Yuan et al, 2004; Yuan et al, 2003b; Zhou et al, 2004). Underexpression of DLC1 
consistently correlated with the invasive and metastatic potential of cancer cell lines. In line 
with this, DLC1 was characterized as a metastasis suppressor in breast cancer cells (Goodison 
et al, 2005). Consistent with this description, reconstitution studies of DLC1 expression 
revealed inhibition of cell motility and invasiveness of HCC, breast, ovarian and lung cancer 
cell lines (Goodison et al, 2005; Qian et al, 2007; Syed et al, 2005; Wong et al, 2005). RNAi 
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mediated silencing of DLC1 expression in breast cancer cells increased migration in a mDia1 
dependent but ROCK-independent manner (Holeiter et al, 2008). Recently, Tripathi and 
colleagues found that DLC1 expression modulated the invasiveness of metastatic prostate 
carcinoma cells by increasing E-cadherin expression which functioned as suppressor of cancer 
cell invasion (Tripathi et al, 2013). Using a novel mouse model of liver cancer, which allowed 
to identify and characterize new oncogenes and tumor suppressors in their appropriate genetic 
context, highlighted DLC1 as a bona fide tumor suppressor in HCC in vivo (Xue et al, 2008; 
Zender et al, 2006). ShRNA mediated DLC1 knockdown promoted in the context of Myc 
overexpression and p53 deficiency the formation of liver tumors (Xue et al, 2008). Many studies 
support the assumption that the tumor suppressive properties of DLC1 are attributed to its 
functional GAP activity as it has been shown that mutants lacking GAP activity were incapable 
to inhibit tumor cell growth (Wong et al, 2005). Mutational analysis of tumor samples of patients 
with prostate carcinoma revealed two missense mutations within the FAT region resulting in a 
significant reduction of RhoGAP activity thereby abrogating the tumor suppressive activity of 
DLC1 (Liao et al, 2008). Nonetheless, there is given evidence for GAP independent tumor 
suppressive activities of DLC1. Indeed, expression of a GAP-defective mutant abolished 
colony formation of small lung cancer cells and partially blocked the cell migration of NIH3T3 
fibroblasts (Healy et al, 2008; Zhong et al, 2009). It is likely that DLC1 makes use of both GAP-
dependent and GAP-independent mechanism for its tumor suppressive functions, however 
future investigations are required to figure out the underlying mechanism.  
2.3 Cellular senescence and cancer 
Cancer cells acquire the capability of sustained proliferative signaling and are characterized 
by the bypass of restriction points normally limiting their uncontrolled expansion (Hanahan & 
Weinberg, 2000). Excessive proliferation is counteracted by so called cellular “failsafe 
programs” which constitute stress-responsive, genetically encoded programs with the task to 
eliminate damaged, inappropriately proliferating cells from the cell cycle to maintain cellular 
integrity (Schmitt, 2003). Apoptosis is regarded as the most prominent and best-studied 
failsafe mechanism (Lowe & Lin, 2000). It has become clear that additional programs are 
presumably involved in controlling the proliferative capacity of tumor cells. Cellular stress or 
active oncogenic signaling does not necessarily result in programmed cell death but can force 
cells to escape the cell cycle in order to enter a permanent cell cycle arrest state which reminds 
on cellular senescence.  
2.3.1 Cellular senescence 
Four decades ago, Hayflick and colleagues established the term “cellular senescence” as a 
stable proliferation arrest of human diploid fibroblasts in culture when cells lost their ability to 
divide due to the accumulation of cell doublings (Hayflick & Moorhead, 1961). Some years 
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later, excessive telomere shortening was found to be the initial event contributing to the 
irreversible growth arrest that was designated as “replicative senescence” (Harley et al, 1990; 
Hayflick & Moorhead, 1961). Senescent cells were detected to accumulate in aging skin, 
fibroblasts and primates as well as in other tissues like liver or retina implying that senescence 
is tightly linked to the process of aging (Dimri et al, 1995; Herbig et al, 2006; Mishima et al, 
1999; Paradis et al, 2001). In the past years, it has been established that the irreversible growth 
arrest can be additionally caused by various stress stimuli such as excessive mitogenic 
signaling, oxidative stress, DNA damage, chemotherapeutic agents as well as genetic defects, 
referred to as “premature senescence” which seemed to be independent on progressive 
telomere shortening (Collado & Serrano, 2006). 
2.3.2 Common features of cellular senescence 
The typical hallmark of senescence is an irreversible growth arrest by blocking the cell in the 
G1-phase although cells are viable and remain metabolically active (Sherwood et al, 1988). 
Cells can enter a reversibly arrested state, termed quiescence, where they survive for 
extensive periods of time. Quiescent cells can resume proliferation upon physiological stimuli 
whereas senescent cells are insensitive to mitogenic signals and are incapable to re-enter the 
cell cycle (Campisi & d'Adda di Fagagna, 2007). Senescent cells undergo typical structural 
and morphological changes, adopting an enlarged, flattened morphology and displaying a 
vacuole enriched cytoplasm (Dimri et al, 1995). Most senescent cells are resistant to apoptosis 
and reveal an altered gene expression pattern compared to normal cycling or quiescent cells 
(Hampel et al, 2004; Shelton et al, 1999).  
 
Figure 8: Different stimuli induce the senescent phenotype.  
DNA damage, excessive mitogenic signals, dysfunctional telomeres and cytotoxic agents can induce the cellular 
senescence response. The senescent phenotype is defined by an irreversible growth arrest, resistance to apoptosis 
and altered gene expression pattern. Picture is taken from (Campisi & d'Adda di Fagagna, 2007).  
Typically, senescent cells are marked by increased lysosomal activity of the cytoplasmic ß-
galactosidase enzyme which can be histochemically stained and is considered as the 
Introduction 
 
19 
goldstandard procedure for the detection of senescent cells in vitro and in vivo (Dimri et al, 
1995; Lee et al, 2006). A further characteristic feature of most senescent cells is the 
upregulation of proteins such as p16Ink4a, p53, alternate-reading-frame protein (ARF) or product 
of the promyelocytic leukemia gene (PML) (Dimri et al, 2000; Ferbeyre et al, 2000; Kamijo et 
al, 1997; Pearson et al, 2000; Serrano et al, 1997).  
2.3.3 Oncogene-induced senescence 
Besides a variety of cellular stimuli, numerous lines of evidence indicate that the 
overexpression of active forms of oncogenes is able to provoke a senescence like cell cycle 
arrest designated as “oncogene-induced senescence” (OIS). The story started in 1997 when 
Serrano and colleagues overexpressed an active oncogenic version of H-Ras (H-RasGV12) in 
rodent and human fibroblasts and observed a senescent like growth arrest accompanied by 
the upregulation of proteins such as p16Ink4a, p53 and p21CIP/WAF1 (Serrano et al, 1997). 
Following studies demonstrated that overexpression of oncogenic versions of the members of 
the Ras signaling pathway like Raf, Mek or Braf caused the oncogene-induced senescence 
response (Lin et al, 1998; Michaloglou et al, 2005; Zhu et al, 1998). Oncogene-induced 
senescence has become a central issue of investigations and constitutes a multifaceted 
process depending on different effector mechanism.  
 Signaling pathways of the oncogene-induced senescence response 
As senescence is characterized as a permanent cell cycle arrest, significant attention has been 
placed on proteins involved in controlling cell cycle progression. In fact, several cell cycle 
regulators and their signaling pathways are closely related with the induction of a senescence 
response. It has already been shown that upon accumulation of cell doublings and certain 
stress stimuli, the transcriptional activity of the tumor suppressor p53 is increased (Serrano et 
al, 1997). The Arf/p53/p21CIP1/WAF1 pathway plays a crucial role in the mediation of the 
senescence response upon certain stress stimuli like oncogenic signaling (Levine & Oren, 
2009; Vousden & Lane, 2007). The steady state levels of p53 are controlled by the E3 ubiquitin 
ligase HDM2 which promotes the degradation of p53. Senescence inducing signals activate 
the INK4aArf locus (ARF) which blocks the HDM2 mediated degradation of p53 (Levine & 
Oren, 2009). Subsequently, p53 activates its transcriptional target p21CIP1/WAF1, a cyclin 
dependent kinase inhibitor which executes the senescence response (Brown et al, 1997). On 
the other hand there exists the well-established p16Ink4a/Rb tumor suppressor pathway which 
is critically implicated in the regulation of the G1 to S-phase transition. P16Ink4a, a principal 
member of the Ink4a family of Cdk inhibitors, was found to be transcriptionally overexpressed 
during replicative as well as premature senescence (Alcorta et al, 1996; Hara et al, 1996; 
Serrano et al, 1997). P16Ink4a binds to CDK4/6 thereby inhibiting their kinase activity that 
prevents the phosphorylation of Rb and contributes to the maintenance of the Rb protein in its 
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active, hypophosphorylated state. In its active form, Rb associates with the transcription factors 
of the E2F family and silences the transcription of E2F target genes like cyclin E or A which 
are required for the G1/S phase transition (Burkhart & Sage, 2008; Serrano et al, 1997). Both 
pathways can interact mechanistically with each other at different stages, however they 
possess the ability to halt independently the cell-cycle progression. Additionally which tumor 
suppressor pathway is mainly engaged depends on both cell-type-specific and species-
specific differences.   
 
Figure 9: Senescence response is mediated by the ARF/p53/p21 CIP1/WAF1 and p16Ink4a/Rb signaling 
pathway. 
Normally, the tumor suppressor p53 is degraded by the E3-ubiquitin ligase HDM2 which is negatively regulated by 
ARF. Senescence stimulating signals activate ARF which consequently inhibits HDM2 thereby activating p53. 
Active p53 induces the expression of p21 CIP1/WAF1, a cyclin dependent inhibitor which executes the senescence 
response. Senescence triggers engage the p16Ink4a/Rb tumor suppressor pathway by primarily inducing the 
expression of the Cdk inhibitor p16Ink4a which inhibits cyclin D/Cdk4/6 thereby abrogating the phosphorylation of Rb 
and its inactivation. Rb controls the senescence induction by repression of the transcription factors of the E2F family 
which stimulate the expression of genes required for cell-cycle progression. It is thought that the ARF/p53/p21 
CIP1/WAF1 and p16Ink4a/Rb pathway can influence themselves reciprocally and can interact at different stages 
depending on the cellular context. Picture is taken from (Campisi & d'Adda di Fagagna, 2007).  
 DNA damage response (DDR) 
The involvement of the DNA damage response in the induction of a replicative senescence 
response due to dysfunctional telomeres has already been well established (d'Adda di 
Fagagna, 2008). DNA damage response is activated by single or double strand breaks or other 
DNA discontinuities which are sensed by the MRE11-RAD50-NBS1 complex. Detection of 
DNA damage leads to the activation of the downstream protein kinases such as ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and Rad-3 related (ATR) which trigger 
immediate events such as phosphorylation of the histone variant H2AX. The modified 
chromatin structure recruits multiple proteins and some of these proteins enhance signaling by 
the kinases, participate in transducing the damage signals and optimize repair activities by 
other proteins. ATR and ATM activate the downstream kinases checkpoint-1 (CHK1) and 
CHK2 which activate and phosphorylate the tumor suppressor p53. Activated p53 induces the 
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cell cycle arrest through activation of p21CIP/WAF1 which governs the senescence response 
(d'Adda di Fagagna, 2008). 
 
Figure 10: DNA damage response triggers senescence induction. 
DDR is activated through DNA damage which is sensed by the MRE-RAD50-NBS1 complex. The kinases ATM, 
ATR, CHK1 and CHK2 are activated upon DNA damage. CHK1 and CHK2 activate and phosphorylate p53 which 
induces the senescence response via activation of p21CIP/WAF1. Picture is taken from (Becker et al, 2013). 
In the case of oncogene-induced senescence it has been shown that activated oncogenes 
enforce uncontrolled, constitutive replication cycles which lead to DNA replication stress 
thereby causing DNA damage (Bartkova et al, 2006; Di Micco et al, 2006). For example, 
inactivation of CHK2 abrogates oncogenic H-Ras induced senescence thereby highlighting the 
importance of a DDR for the induction of the oncogene-induced senescence (Di Micco et al, 
2006). Of note, DDR activation seems not to be a universal requirement for oncogene-induced 
senescence, as several studies reported the occurrence of oncogene-induced senescence 
without the induction of a DDR and despite the lack of DDR effector proteins (Efeyan et al, 
2009; Kuilman et al, 2008; Olsen et al, 2002). Consequently, DDR seems to participate in the 
establishment of oncogene-induced senescence, however depending on the setting of 
oncogene-induced senescence induction. 
 Senescence-associated heterochromatin foci (SAHF) 
Senescent cells undergo profound changes of the chromatin structure which are thought to be 
important mediators of the senescence response. Their manifestation is caused by the 
formation of facultative heterochromatin structures termed as senescence-associated 
heterochromatin foci which were initially found microscopically when senescent cells were 
stained with 4`,6-diamidino-2-phenylindole (DAPI) (Narita et al, 2003). SAHFs reveal a specific 
enrichment of histone 3 lysine 9 trimethylation (H3K9me3) and are devoid of euchromatin 
structures such as histone H3 lysine 9 acetylation or histone H4 lysine 4 methylation. 
Moreover, histone H2A variant macroH2A, heterochromatin protein 1 (HP1) and high mobility 
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group A (HMGA) were found as heterochromatin structures of SAHFs (Narita et al, 2006; Narita 
et al, 2003; Zhang et al, 2007). Functionally, the heterochromatin structures of SAHFs 
contribute to the silencing of proliferation-promoting genes such as E2F target genes like cyclin 
A. Moreover it has been well documented that oncogenic signaling caused the formation of 
SAHFs (Martin et al, 2010; Michaloglou et al, 2005; Narita et al, 2003). Recent investigations 
from Di Micco and colleagues led to the suggestion that SAHFs could damper the extent of 
DNA damage signaling which may prevent senescent cells from undergoing apoptosis induced 
by high DNA damage signaling thereby preserving the viability of senescent cells (Di Micco et 
al, 2011). Thus, chromatin remodeling contributes to the maintenance of the irreversible growth 
arrest and reinforces the senescence response.  
 Senescence-messaging secretome (SMS) 
A further characteristic of cells undergoing the oncogene-induced senescence response 
constitutes the secretion of a broad spectrum of soluble and insoluble as well as other factors 
which is collectively termed as “senescence-messaging secretome” (SMS) or alternatively 
called “senescence-associated secretory phenotype” (SASP) (Coppe et al, 2010; Kuilman & 
Peeper, 2009). The SMS factors can be classified into different categories such as interleukins, 
chemokines, other inflammatory factors, proteases and regulators, growth factors, receptors 
and their ligands as well as extracellular components (Coppe et al, 2010). Moreover it has 
been shown that a persistent DNA damage response was required for the expression of SMS 
factors (Rodier et al, 2009).  
 
 
 
Figure 11: Senescent cells are characterized by the induction of a senescence-messaging secretome. 
Senescent cells secrete a plethora of different soluble and insoluble factors, depending on the individual cell type. 
SMS factors contributes to the maintenance of the stable cell cycle arrest and can feature both tumor-suppressive 
as well as pro-tumorigenic properties. Picture is taken from (Pawlikowski et al, 2013). 
In addition, signaling of SMS factors like interleukin 6 or 8 (IL-6/IL-8) was shown to reinforce 
the stable proliferation arrest upon oncogenic signaling thereby suggesting that SMS induction 
is an essential effector mechanism for the establishment of a senescence response (Acosta 
et al, 2008b; Kuilman et al, 2008). Functionally, the SMS creates a complex signaling network 
which affects not only senescent cells but also allows them to communicate with their 
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microenvironment in a paracrine fashion to promote their senescence response, for example 
via  IL-1 and TGF-ß signaling (Acosta et al, 2013). In some cases, SMS factors feature tumor 
suppressive properties by attracting the innate immune system for the clearance of senescent 
cells in vitro and in vivo (Kang et al, 2011; Krizhanovsky et al, 2008; Xue et al, 2007). By 
contrast, secretion of SMS factors can also promote tumorigenesis of neighboring, 
premalignant cells by stimulating their cell growth, enhancing their migratory and invasiveness 
properties and promoting EMT (Coppe et al, 2010; Krtolica et al, 2001). Thus, SMS reflects a 
defined and essential feature for the senescence response that can both limit and boost tumor 
progression depending on the cellular context.   
 Oncogene-induced senescence – its role in tumorigenesis  
Tumor cells are characterized by an unlimited lifespan and are exposed to many cellular stress 
stimuli, therefore induction of a senescence response would represent an important tumor 
suppressive mechanism counteracting unrestrained proliferation. Several studies have 
demonstrated that the occurrence of the oncogene-induced senescence response in 
premalignant stages of murine and human tumors and its absence in malignant types (Braig 
et al, 2005; Chen et al, 2005; Collado et al, 2005; Michaloglou et al, 2005). For example, using 
an in vivo mouse model, endogenous expression of oncogenic K-Ras (K-RasG12V) was able to 
trigger oncogene-induced senescence during premalignant stages of lung and pancreatic 
tumors (Collado et al, 2005). The first evidence for oncogene-induced senescence in human 
tumors was brought by investigations of Michaloglou and colleagues showing that melanocytes 
expressing oncogenic BRAFV600E underwent oncogene-induced senescence (Michaloglou et 
al, 2005). Moreover, Braig and colleagues described oncogene-induced senescence as an 
initial barrier in lymphoma development (Braig et al, 2005). Thus, oncogenic signaling causes 
an early senescent growth arrest in premalignant lesions.  
 
Figure 12: Model for oncogene-induced senescence during tumorigenesis.  
Oncogenic driven cells can enter the senescence state or bypass senescence and develop an oncogenic 
transformed, malignant phenotype. Moreover it is supposed that genetic defects in the senescence effector 
molecules can facilitate the establishment of malignant cells. Therapeutic approaches might aim for reverting 
malignant cells into a senescent state. Picture is taken from (Braig & Schmitt, 2006).  
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Nevertheless, it remains unresolved whether transformed, fully malignant cells directly 
originate from an oncogenic driven cell that bypassed senescence or secondary lesions like 
mutations in crucial senescence effector molecules are required. However, it is supposed that 
genetic defects inactivating senescence effectors are not directly sufficient to transform cells 
harboring the initiate oncogene (Braig & Schmitt, 2006). In a therapeutic setting, specific 
markers for oncogene-induced senescence could be used as indicators for premalignant tumor 
lesions. Detection of oncogene-induced senescence will facilitate staging tumor lesions and to 
monitor the therapeutic efficacy of anti-tumor strategies (Collado & Serrano, 2006). Of note, 
DNA-damaging agents like anti-cancer drugs have already been reported to induce oncogene-
induced senescence in tumor cells, therefore it might be conceivable that induction of 
oncogene-induced senescence in malignancies could be viewed as a novel, pharmacological 
approach (Chang et al, 1999; Schmitt et al, 2002; te Poele et al, 2002). A future goal might be 
to identify and characterize novel oncogene-induced senescence inducing molecules as well 
as drugs to understand and improve the outcome of the senescence response in the context 
of tumor progression. 
2.4 Myoferlin 
Myoferlin, also named Fer-1-like protein 3, belongs to the family of ferlin proteins which 
consists of dysferlin (DYSF), myoferlin (MYOF) and otoferlin (OTOF). Recently, three further 
members of the ferlin family, Fer1L-4, Fer1L-5 and Fer1L-6 has been identified but their 
function remains so far unknown. All members share structural similarity, consisting of several 
cytosolic C2 domains and a single-pass transmembrane domain at their C-termini (Bansal & 
Campbell, 2004). A common feature of C2 domains is the capability to bind phospholipids and 
other proteins in a calcium dependent manner (Nalefski & Falke, 1996).  
 
 
 
Figure 13: Structure of myoferlin. 
The structure of myoferlin contains several cytosolic C2 domains and a C-terminal single-pass transmembrane 
domain. Picture is taken from (McNeil & Kirchhausen, 2005). 
Initially, myoferlin expression was found to be restricted to cardiac and skeletal muscle cells 
and it was supposed as a potential modifier of muscular dystrophy and cardiomyopathy (Davis 
et al, 1996). However several studies were able to report myoferlin expression in other cell 
tissues and cell types, such as endothelial and breast carcinoma cells (Bernatchez et al, 2007; 
Eisenberg et al, 2011). Myoferlin has been reported to play a role in a variety of processes, 
such as endocytosis, endothelial membrane repair and vesicular transport (Bernatchez et al, 
2009; Cipta & Patel, 2009; Sharma et al, 2010). Interestingly, numerous studies reported an 
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influence of myoferlin on growth factor stability. In endothelial cells, myoferlin was found to 
control the biological activity of the vascular endothelial growth factor receptor 2 (VEGFR2) via 
inhibition of its polyubiquitination and proteasomal degradation (Bernatchez et al, 2007). Loss 
of myoferlin expression thereby reduced cell proliferation, migration and release of nitric oxide 
(NO) in response to VEGF (Bernatchez et al, 2007). Moreover in the same cell type, 
downregulation of myoferlin expression reduced the expression of angiopoietin-1 receptor 
(TIE2), another receptor tyrosine kinase, mainly expressed in the vascular endothelium (Yu et 
al, 2011). Additionally, Demonbreu and colleagues described that myoferlin deficiency caused 
defective insulin growth factor-like (IGFR1) trafficking as well as decreased IGFR1 signaling 
(Demonbreun et al, 2010). So far, there exists only little knowledge about the role of myoferlin 
expression in tumor cells. Silencing of myoferlin expression diminished the invasiveness of 
human breast carcinoma cells and decreased the tumor growth of mouse Lewis lung 
carcinoma cells in vivo (Eisenberg et al, 2011; Leung et al, 2013; Li et al, 2012a). Recently, 
Turtoi and colleagues characterized myoferlin as a specific regulator of the epidermal growth 
factor (EGF) receptor in human breast carcinoma cells (Turtoi et al, 2013). Downregulation of 
myoferlin blocked the degradation of phosphorylated EGF receptor and inhibited 
simultaneously EGF-induced cell migration and epithelial-to-mesenchymal transition (EMT) 
(Turtoi et al, 2013). Thus, the discovery of the role of myoferlin in the context of tumorigenesis 
has just started and the evaluation of the underlying molecular mechanism will help to better 
understand the complexity of tumor progression.  
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3 Aim of the thesis 
The subcellular localization of MKL1 and MKL2 is tightly linked to their transcriptional activity. 
In fibroblasts and muscle cells, a nuclear-cytoplasmic shuttling mechanism is well described 
for MKL1/2, nevertheless their subcellular localization seems to be a cell-type specific feature. 
Preliminary studies of our group illustrated a correlation between the subcellular localization of 
MKL1 and the endogenous expression levels of the tumor suppressor DLC1.  
 
Figure 14: Nuclear accumulation of MKL1 in DLC1-deficient hepatocellular and breast carcinoma cell lines 
(Muehlich et al, 2012). 
 
Our data demonstrate a predominantly nuclear MKL1 localization in hepatocellular and breast 
carcinoma cell lines lacking endogenous DLC1 expression. Originally, DLC1 was identified as 
a tumor suppressor in hepatocellular carcinoma, but a representative oligonucleotide 
microarray analysis (ROMA) illustrated a heterozygous deletion of DLC1 in about 50 % of liver, 
breast and lung and 70 % of colon cancers, almost as frequently as p53 in these cancers (Xue 
et al, 2008). DLC1 encodes a RhoGAP protein which modulates the activity of RhoGTPases. 
Interestingly, the subcellular localization of MKL1/2 is well known to be regulated by Rho-actin 
signaling. In addition, a landmark publication by the group of Richard Treisman highlighted that 
MKL1/2 signaling is required for tumor cell invasion and experimental metastasis of human 
breast carcinoma cells (Medjkane et al, 2009). Consequently, we hypothesize a direct 
functional relationship between DLC1 expression and MKL1/2 signaling in the context of 
tumorigenesis.  
 
Thus three main issues will be addressed within this thesis: 
I. Molecular mechanism which drive nuclear MKL1/2 signaling in human cancer cells 
upon loss of DLC1 expression 
II. Does nuclear MKL1/2 signaling influence the tumor growth of human hepatocellular 
carcinoma cells characterized by a DLC1-deficient background in vitro and in vivo 
III. Identification and characterization of novel MKL1/2 dependent target genes which 
expression influence the tumor growth of DLC1-deficient hepatocellular carcinoma 
cells 
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4 Materials 
4.1 Cell culture 
4.1.1 Cell lines 
Cell line Organism/ Cell Type Culture 
conditions 
Provider/ Origin 
HEK293T Human embryonic kidney DMEM Kind gift of Anna-Lena 
Forst, Ludwig- 
Maximilians-University 
Munich 
HuH7 Human hepatocellular 
carcinoma 
DMEM Kind gift of Stephan 
Singer, University of 
Heidelberg 
HuH6 Human hepatoblastoma DMEM Kind gift of Stephan 
Singer, University of 
Heidelberg 
Amphotropic 
Phoenix cells 
Modified HEK293T cells 
expressing gag-pol and 
envelop proteins  
DMEM Kind gift of Antonio 
Sarikas, Technical 
University of Munich 
HepG2 Human hepatoma RPMI Kind gift of Stephan 
Singer, University of 
Heidelberg 
HLF Human hepatocellular 
carcinoma 
RPMI Kind gift of Stephan 
Singer, University of 
Heidelberg 
MCF7 Human breast carcinoma DMEM Kind gift of Dr. Ramon 
Parsons, Mount Sinai 
Hospital, New York, USA 
MDA-MB-468 Human breast carcinoma DMEM Kind gift of Dr. Ramon 
Parsons, Mount Sinai 
Hospital, New York, USA 
HepG2 MLC Human hepatoma cells stably 
expressing control shRNA  
RPMI Kind gift of Scott Lowe, 
Memorial Sloan-Kettering 
Cancer Center, New York, 
USA 
HepG2 
shRNA DLC1 
Human hepatoma cells stably 
expressing DLC1 shRNA 
RPMI Kind gift of Scott Lowe, 
Memorial Sloan-Kettering 
Cancer Center, New York, 
USA 
Murine 
hepatocytes 
control 
shRNA 
Embryonic liver progenitor 
cells expressing control 
shRNA 
DMEM (Xue et al, 2008) 
Murine 
hepatocytes 
DLC1 shRNA 
Embryonic liver progenitor 
cells expressing DLC1 shRNA 
DMEM (Xue et al, 2008) 
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HepG2 Tet 
off 
Human hepatoma cells 
expressing Tet-responsive 
trans-activator (tTA) 
RPMI (Sun & Nassal, 2006) 
HuH7 Tet off Human hepatocellular 
carcinoma cells expressing 
Tet-responsive trans-activator 
(tTA) 
DMEM (Sun & Nassal, 2006) 
4.1.2 Cell culture media and solutions 
Reagent Provider 
Dulbecco`s Modified Eagle Medium (DMEM) Sigma-Aldrich, Taufkirchen, Germany 
RPMI 1640 Medium Sigma-Aldrich, Taufkirchen, Germany 
Opti-MEM Gibco® Invitrogen, Karlsruhe, Germany 
Fetal Bovine Serum Gibco® Invitrogen, Karlsruhe, Germany 
Penicillin-Streptomycin (5000 U/mL) Gibco® Invitrogen, Karlsruhe, Germany 
4.1.3 Transfection Reagents 
Reagent Provider 
Lipofectamine® 2000 Invitrogen, Karlsruhe  
Lipofectamine® RNAiMAX Invitrogen, Karlsruhe 
GenJetTM DNA In Vitro Transfection Reagent SignaGen Laboratories, Rochville, USA 
4.1.4 Plasmid constructs 
Plasmid construct Vector Provider 
Wildtype human Flag-DLC1 Flag-pEFrPGKpuro Kind gift of Prof. Monilola Olayioye, 
University Stuttgart 
Flag-RhoA-V14 pRevTRE Kind gift of Prof. Ron Prywes, 
Columbia University 
Flag-MKL1 mutant N100 pCin4 Kind gift of Prof. Ron Prywes, 
Columbia University 
Wildtype human GFP-DLC1 pcDNA5/FRT/TO-
GFP-DLC1 
Kind gift of Prof. Monilola Olayioye, 
University Stuttgart 
4.1.5 Lentiviral and retroviral expression constructs 
Construct Vector Provider 
H-RasV12 pBabe-puro Kind gift of Dr. Antonio Sarikas, 
Technical University of Munich 
nontarget shRNA vector, 
SHC002 
pLKO.1-puro Sigma-Aldrich, Taufkirchen, Germany 
shRNA MKL1/2 pLKO.1-puro (Lee et al, 2010b) 
shRNA Myoferlin 
(TRCN0000010628) 
pLKO.1-puro Sigma-Aldrich, Taufkirchen, Germany 
pD8.9 pCMV Kind gift of Prof. Ron Prywes, 
Columbia University 
pVSVG pCMV Kind gift of Prof. Ron Prywes, 
Columbia University 
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4.1.6 siRNA sequences 
All siRNA oligonucleotides were custom synthesized by Sigma-Aldrich, Taufkirchen, Germany. 
Lyophilized siRNA oligonucleotides were dissolved in water to a concentration of 50 μM and 
stored in aliquots at -20°C.  
target Sequence [5`- 3`] 
siRNA hDLC1 UUA AGA ACC UGG AGG ACU A [dT] [dT] 
siRNA hMKL1 GAA UGU GCU ACA GUU GAA A  [dT] [dT] 
siRNA hMKL1/2 AUG GAG CUG GUG GAG AAG AA [dT] [dT] 
siRNA hMKL2 GUA ACA GUG GGA AUU CAG C [dT] [dT] 
siRNA hMYOF CCC UGU CUG GAA UGA GA [dT] [dT] 
siRNA Neg. ctrl CGU ACG CGG AAU ACU UCG A [dT] [dT] 
siRNA hp16Ink4a CGC ACC GAA UAG UUA CGG U [dT] [dT] 
siRNA hSRF GAU GGA GUU CAU CGA CAA CAA [dT] [dT] 
4.1.7 Selection antibiotics for cell culture 
Antibiotic Stock solution Final concentration Provider 
Doxycycline 
hyclate 
1 mg/mL 0.5 μg/mL Sigma Aldrich, Taufkirchen, 
Germany 
Geneticin (G418 
Sulfate) 
50 mg/mL 200 μg/mL Carl Roth, Karlsruhe, 
Germany 
Hygromycin B 
solution Cellpure® 
50 mg/mL 200 μg/mL Carl Roth, Karlsruhe, 
Germany 
Puromycin 
Dihydrochloride 
1 mg/mL 1-10 μg/mL Calbiochem, Darmstadt, 
Germany 
4.1.8 Inhibitors and stimulants 
Inhibitor Final concentration Provider 
UO126 1,4-diamino-2,3-dicyano-
1,4- bis (2-aminophenylthio) 
butadiene 
10 mM Tocris Bioscience, Germany 
Lysophosphatidic acid (LPA) 10 μM Sigma-Aldrich, Taufkirchen, 
Germany 
Human recombinant epidermal 
growth factor EGF 
10 nM Sigma-Aldrich, Taufkirchen, 
Germany 
4.2 Antibodies 
4.2.1 Primary antibodies 
Primary antibody Dilution Provider 
Active caspase 3 (rabbit polyclonal) 1:500 Promega, Mannheim 
Active Ras (mouse monoclonal) 1:500 NewEast Bioscience, Malvern, USA 
Active RhoA (mouse monoclonal) 1:500 NewEast Bioscience, Malvern, USA 
Alexa Fluor Phalloidin 1:500 Invitrogen, Karlsruhe 
CTGF (L-20) (polyclonal goat) 1:250 Santa Cruz Biotechnology, CA, USA 
DLC1 (mouse monoclonal) 1:500 BD Bioscience, Heidelberg, Germany 
DLC1 H-260 (rabbit polyclonal) 1:500 Santa Cruz Biotechnology, CA, USA 
EGFR antibody (mouse monoclonal) 1:250 Spring Bioscience, USA 
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ERK (C14) (rabbit polyclonal) 1:10000 Santa Cruz Biotechnology, CA, USA 
Flag M2 (mouse monoclonal) 1:500 Sigma-Aldrich, Taufkirchen, Germany 
GAPDH (mouse, monoclonal)  1:500 Sigma-Aldrich, Taufkirchen, Germany 
HA (3F10) (goat monoclonal) 1:500 Roche Applied Science, Germany 
H3K9me3 (rabbit polyclonal) 1:500 Actif Motif, Carlsbad, USA 
HSP90 (mouse monoclonal) 1:500  Santa Cruz Biotechnology, CA, USA 
MKL1 (rabbit polyclonal) 1:500 (Cen et al, 2003) 
MKL2 (rabbit polyclonal) 1:500 (Cen et al, 2003) 
MRTF-A (C-19) (goat polyconal) 1:100 Santa Cruz Biotechnology, CA, USA 
Myoferlin (D-11) (mouse monoclonal) 1:500 Santa Cruz Biotechnology, CA, USA 
p16Ink4a (mouse monoclonal) 1:500 MTM Laboratories, Heidelberg, 
Germany 
p53 Clone DO1 (mouse monoclonal) 1:1000 Actif Motif, Carlsbad, USA 
Phospho EGF receptor (Tyr1173) 
(rabbit monoclonal) 
1:1000 Cell Signaling Technology, Danvers, 
USA) 
Phospho MKL1 Serine 454 (rabbit, 
polyclonal) 
1:500 (Muehlich et al, 2008) 
Phospho p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (rabbit polyclonal) 
1:1000 Cell Signaling Technology, Danvers, 
USA 
Phospho p53 Serine 15 (rabbit, 
polyclonal) 
1:1000 Santa Cruz Biotechnology, CA, USA 
Ras (rabbit polyclonal) 1:500 NewEast Bioscience, Malvern, USA 
Retinoblastoma protein Clone EP44 
(rabbit polyclonal) 
1:1000 Epitomics, Burlingame, USA 
RhoA (rabbit polyclonal) 1:500 NewEast Bioscience, Malvern, USA 
Smooth muscle actin (SMA) Clone 1A4 
(mouse monoclonal) 
1:500 Dako, Hamburg, Germany 
4.2.2 Secondary antibodies 
Secondary antibody Target Dilution Provider 
Alexa Fluor® 488 mouse  1:1000 Invitrogen, Karlsruhe 
Alexa Fluor® 488 rabbit 1:1000 Invitrogen, Karlsruhe 
Alexa Fluor® 555 goat 1:1000 Invitrogen, Karlsruhe 
Anti-rabbit IgG HRP-conj rabbit 1:10000 Cell Signaling Technology, USA 
Anti-mouse IgG HRP-conj mouse 1:10000 Cell Signaling Technology, USA 
Anti-goat IgG HRP-conj goat 1:50000 Santa Cruz Biotechnology, CA, USA 
4.3 Nucleotides 
4.3.1 Random Hexamers 
Nucleotide Sequence [5’-3’] Provider 
Random Hexamers  NNN NNN Metabion International AG, 
Martinsried, Germany 
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4.3.2 Real-time PCR primers 
Target gene specific primers were designed with the software Universal Probe Library from 
Roche (https://www.roche-applied-science.com). Custom-synthesized primers were 
purchased by Metabion International AG, Martinsried, Germany. The real-time PCR primers 
were diluted to a concentration of 100 µM and stored at -20°C. 
h=human; F=forward; R=reverse 
Name Sequence [5`- 3`] 
h18S rRNA F TCG AGG CCC TGT AAT TGG AAT  
h18S rRNA R CCC TCC AAT GGA TCC TCG TTA 
hc-fos F AAC CAC AGG GAA AGG AGA CC 
hc-fos R ATG GTG CCT GCG TGA TAC T 
hCNN1 F GCT GTC AGC CGA GGT TAA GA 
hCNN1 R CCC TCG ATC CAC TCT CTC AG 
hCTGF F TTG GCA GGC TGA TTT CTA GG 
hCTGF R GGT GCA AAC ATG TAA CTT TTG G 
hCXCL10 F  GAA AGC AGT TAG CAA GGA AAG GT 
hCXCL10 R GAC ATA TAC TCC ATG TAG GGA AGT GA 
hCyr61 F AAG AAA CCC GGA TTT GTG AG 
hCyr61 R GCT GCA TTT CTT GCC CTT T 
hDLC1 F GCG AAT GAG TTC TGT CAT TTC A 
hDLC1 R GAG CAG TGT CAT GCC TTG G 
hGLIPR1 F  TCT TTC CAA TGG AGC ACA TTT 
hGLIPR1 R TCT TAT ATG GCC AAG TTG GGT AA 
hKi-67 F TCA AGG AAC TGA TTC AGG AGA AG 
hKi-67 R GTG CAC TGA AGA ACA CAT TTC C 
hMAP1B F  GAC GCT TTG TTG GAA GGA AA 
hMAP1B R CTG AGT CAT GAG TTG GGA TCA G 
hMKL1 F CCC AAT TTG CCT CCA CTT AG  
hMKL1 R CCT TGG CTC ACC AGT TCT TC 
hMKL2 F CTT ACC CCC TCT GAA CGA 
hMKL2 R CTC TCG TCC TCC TTT GTTGC 
hMYH9 F GGT TGG TGG TGA ACT CAG CTA 
hMYH9 R TGG AGG ACC AGA ACT GCA A 
hMYOF F CCA TTA CTG GCT TCT AAG CTG AC 
hMYOF R TTC CCC TGA GGA AGC ATA AA 
hSM22 F GGC CAA GGC TCT ACT GTC TG 
hSM22 R CCC TTG TTG GCC ATG TCT 
hSRF F AGC ACA GAC CTC ACG CAG A 
hSRF R GTT GTG GGC ACG GAT GAC 
hTGFß1 F ACT ACT ACG CCA AGG AGG TCA C 
hTGFß1 R TGC TTG AAC TTG TCA TAG ATT TCG 
hTNFSF10 F CCT CAG AGA GTA GCA GCT CAC A 
hTNFSF10 R CAG AGC CTT TTC ATT CTT GGA 
hVGLL3 F TCC CAG TAT CTG CCC AAC C 
hVGLL3 R CTG CAT CTT GCT GAA TAC CG 
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4.4 Bacterial strains and media 
Bacterial strain Provider 
E.coli DH5α Takara BIO 
 
LB agar 
1 % sodium chloride 
1 % bacto tryptone 
0.5 % yeast extract 
1.5 % bacto agar 
4.5 Kits 
Reagent Provider 
RhoA Activation Assay Kit NewEast Biosciences, Malvern, USA 
Ras Activation Assay Kit NewEast Bioscience, Malvern, USA 
G-LISA RhoA Activation Assay Biochem 
Kit 
Cytoskeleton, Denver, CO 
Ambion WT Expression Kit Affymetrix, CA, USA 
GeneChip WT Terminal Labeling and 
Control Kit 
Affymetrix, CA, USA 
GeneChip Hybridzation, Wash and 
Stain Kit 
Affymetrix, CA, USA 
GenEluteTM HP Plasmid Midiprep Kit Sigma-Aldrich, Taufkirchen, Germany 
Senescence ß-Galactosidase Staining 
Kit 
Cell Signaling Technology, Danvers, 
USA 
4.6 Reagents 
Reagent Provider 
Horse serum Sigma-Aldrich, Taufkirchen, Germany 
Protease Inhibitor, Cocktail Set III, 
Animal Free 
Calbiochem, Darmstadt, Germany 
SpectraTM Multicolor Broad Range 
Protein Ladder 
Fermentas, St. Leon-Rot, Germany 
Rec-Protein G-Sepharose® 4B 
conjugate 
Invitrogen, Karlsruhe, Germany 
Roti®-Quant Carl Roth, Karlsruhe, Germany 
Roti®-Lumin 1; Roti®-Lumin 2 Carl Roth, Karlsruhe, Germany 
Super Signal West Femto Trialkit 
(Enhancer peroxide solution) 
Thermo Scientific, Schwerte, Germany 
Trizol® LS Reagent Invitrogen, Karlsruhe, Germany 
4.7 DNA Chips 
GeneChip Human Gene 1.0 ST Array Affymetrix, CA, USA 
LB liquid medium 
1 % sodium chloride 
0.5 % yeast extract 
1 % bacto tryptone 
adjustment to pH 7.5 with 10 N NaOH 
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4.8 Enzymes  
SuperScript II Reverse Transcriptase  Invitrogen, Karlsruhe, Germany 
RNaseA Fermentas, St. Leon-Rot, Germany 
Trypsin-EDTA 0.05 % Sigma-Aldrich, Taufkirchen, Germany 
4.9 Athymic nude mice 
CD-1® Nude Mouse Crl:CD1-Foxn1nu Charles River Laboratories, 
Sulzfeld, Germany 
4.10 Buffers and solutions 
2.5 M CaCl2 solution 
87.6 g CaCl2*6H2O 
ad 200 mL with distilled water, sterilfiltration 
 
2 x HBS 
8.0 g NaCl 
0.2 g Na2HPO4*7H2O 
6.5 g HEPES 
adjustment of pH to 7.0 
ad 500 mL with distilled water 
 
4 x Laemmli Sample Buffer (4xLSB) 
1 M TRIS/HCl (pH 8.8) 
0.01 % (w/v) Bromphenolblau 
20 % (w/v) SDS 
2 % (v/v) Glycerol 
0.5 M ETDA 
5 % (v/v) ß-mercaptoethanol 
 
10 x PBS pH 7.4 
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
 
 
 
 
 
 
 
 
 
Kralewski cell lysis buffer 
50 mM HEPES (pH 7.4) 
150 mM NaCl 
1 % Triton X-100 
1 mM EDTA 
10 % Glycerol 
10 x Gel running buffer (pH 8.3) 
0.25 M TRIS 
2 M Glycin 
1 % (w/v) SDS 
H2O ad 1000 ml 
10 x TBST 
0.2 M TRIS 
1.4 M NaCl 
1 % Tween 20 
H2O ad 5000 mL 
10 x TBS 
0.2 M TRIS 
1.4 M NaCl 
H2O ad 5000 mL 
10 x Blotting buffer 
0.25 M TRIS 
2 M Glycine 
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1.5 M TRIS (pH 6.8) 
121.1 g TRIS 
adjustment of pH with 1 N HCl to 6.8 
H2O ad 1000 ml 
 
FACS staining solution 1 
10 mM Sodium chloride 
3.8 mM Trisodium citrate 
0.3 mL /L Nonidet P-40 
0.5 % (v/v) Propidium iodide 
 
Enhanced Chemiluminescence solution (ECL) S1 and S2 
S1 solution  
80 mL H2O 
10 mL 1M TRIS/HCl pH 8.5 
1 mL 250 mM 3-Aminophthalhydrazide  
0.44 mL 90 mM p-Coumaric acid 
ad 100 mL with H2O  
 
S2 solution  
80 mL H2O 
10 mL 1M TRIS/HCl pH 8.5 
60 μL 30% H2O2 
ad 100 mL with H2O  
Both solution were stored at -20°C and thawed prior to use. Both solutions were mixed at a 
ratio of 1:1 to yield the ready-to-use assay solution.  
 
1 % Toluidine staining solution 
0.1 g toluidine blue dye 
0.1 g Sodium tetraborate decahydrate  
dissolved in 100 mL distilled water 
 
  
1.5 M TRIS (pH 8.8)  
121.1 g TRIS 
adjustment of pH with 1 N HCl to 8.8 
H2O ad 1000 ml 
FACS staining solution 2 
70 mM Citric acid 
0.25 M Saccharose 
0.5 % (v/v) Propidium iodide 
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4.11 Chemicals 
Chemicals Provider 
2-Propanol Carl Roth, Karlsruhe, Germany 
4,6`Diamidino-2-phenylindole (DAPI) Sigma Aldrich, Taufkirchen, Germany 
Agarose PEQLAB, Erlangen, Germany 
Ammonium peroxodisulfate Carl Roth, Karlsruhe, Germany 
Ampicillin Gibco® Invitrogen, Karlsruhe, Germany 
Bovine serum albumin Carl Roth, Karlsruhe, Germany 
Bromphenol blue Carl Roth, Karlsruhe, Germany 
Calcium chloride Carl Roth, Karlsruhe, Germany 
Chloroform VWR, Ismaning, Germany 
Citric acid Carl Roth, Karlsruhe, Germany 
Desoxynucleosid triphosphates (dATP, dCTP, 
dGTP, dTTP) 
Invitrogen, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Dithiothreitol (DTT) Carl Roth, Karlsruhe, Germany 
DMF (N,N-Dimethylformamide) Sigma Aldrich, Taufkirchen, Germany 
ECM gel from Engelbert-Holm-Swarm mouse 
sarcoma 
Sigma-Aldrich, Taufkirchen, Germany 
Ethylenediaminetetraacetic acid Carl Roth, Karlsruhe, Germany 
Ethanol Carl Roth, Karlsruhe, Germany 
Glycine Carl Roth, Karlsruhe, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
HEPES Carl Roth, Karlsruhe, Germany 
Immersion Oil (TM) 518F Zeiss, Oberkochen, Germany 
Low fat milk powder Vitalia, Bruckmühl, Germany 
Methanol Carl Roth, Karlsruhe, Germany 
Mounting Fluoromount Sigma Aldrich, Taufkirchen, Germany 
NonidetTM P-40 Sigma-Aldrich, Taufkirchen, Germany 
Paraformaldehyd Carl Roth, Karlsruhe, Germany 
Phenylmethylsulfonylfluorid (PMSF) Calbiochem, Darmstadt, Germany 
Potassium dihydrogen phosphate Carl Roth, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Protease Inhibitor, Cocktail Set III, Animal Free Calbiochem, Darmstadt, Germany 
Saccharose Carl Roth, Karlsruhe, Germany 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Sodium hydrogen phosphate Carl Roth, Karlsruhe, Germany 
Sodium tetraborate decahydrate Carl Roth, Karlsruhe, Germany 
ß-Mercaptoethanol Serva, Heidelberg, Germany 
TEMED Carl Roth, Karlsruhe, Germany 
TRIS tris(hydroxymethyl)aminomethane Carl Roth, Karlsruhe, Germany 
Trisodium citrate Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Tryptone Carl Roth, Karlsruhe, Germany 
Toluidine blue dye Carl Roth, Karlsruhe, Germany 
Tween® 20 Carl Roth, Karlsruhe, Germany 
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4.12 Technical devices and other equipment 
24-well Transwell® inserts 8 μM  Milllipore, Germany 
BioPhotometer Eppendorf, Hamburg, Germany 
Blotting equipment Mini PROTEAN® Tetra Cell BIORAD, Munich 
Cell culture dishes Sarstedt, Nümbrecht, Germany 
Centrifuge 5424R Eppendorf, Hamburg 
Centrifuge 5804R Eppendorf, Hamburg 
Centrifuge Heraeus Biofuge Stratos Thermo Scientific, Freiburg, Germany 
Chemiluminescent imager Chemismart 5100 PEQLAB, Erlangen, Deutschland 
Confocal microscope LSM 510 Zeiss, Jena, Germany 
Cryo vials CryoPure 1.6 mL Sarstedt, Nümbrecht, Germany 
Eppendorf tubes Eppendorf, Hamburg 
Falcon tubes Sarstedt, Germany 
Flow cytometer BD FACS Calibur Flow 
Cytometer  
BD Bioscience, New Jersey, USA 
Incubator for Bacteria Thermo Scientific, Germany 
Incubator for Mammalian Cell Culture Thermo Scientific, Germany 
Laminar Flow HERACell 150i Thermo Scientific, Germany 
LightCycler 480 Roche Applied Biosystems, Germany 
Microscope Axiovert 135M Zeiss, Göttingen 
Neubauer cell counting chamber Marienfeld, Lauda-Königshofen, 
Deutschland 
PCR machine Biometra GmbH, Göttingen 
pH meter Lab850 Schott Instruments, SI Analytics, Mainz, 
Germany 
Power supply PeqPower 300 PEQLAB, Erlangen, Germany 
Precision balance Acculab, Sartorius, Göttingen, Germany 
PVDF-membrane Millipore, Billerica, MA 
SDS-PAGE equipment BIORAD, Munich 
Thermoblock Eppendorf, Germany 
UV-transparent cuvettes Sarstedt, Nümbrecht, Germany 
Water bath Memmert, Schwabach, Germany 
Whatman Paper 0.8 mm Optilab, Munich, Germany 
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5 Methods 
5.1 Cell culture methods 
5.1.1 Culturing and maintenance of mammalian cell lines 
Cells were cultured as monolayers in the appropriate medium, containing 10 % (v/v) heat-
inactivated fetal calf serum and 5 % (v/v) penicillin/streptomycin. All mammalian cell lines were 
cultured in 60 cm2 cell culture dishes and maintained at 37°C in a humidified atmosphere 
containing 5 % CO2. Passaging of cells was performed twice per week. Culture medium was 
aspirated and the adherent cells were washed with 10 mL sterile phosphate buffered saline 
(PBS). The cells were detached with 2 mL prewarmed trypsin and carefully resuspended in 8 
mL culture medium. An appropriate amount of cell the suspension (dilution typically ranging 
from 1:3 to 1:40) was added to a fresh cell culture dish containing 10 mL of medium. 
 
For cryoconservation and long-term storage, cells were trypsinized and resuspended in fresh 
medium to inactivate the trypsin. Cells were pelleted by centrifugation at 1000 rpm for 5 
minutes and resuspended in ice-cold freezing medium (fetal bovine serum with 10 % DMSO). 
Cell suspensions were aliquoted in 2 mL cryogenic vials and placed in an isopropanol 
cryofreezing container which allows freezing of the cells at a cooling rate of 1°C/min. Thereafter 
the vials were stored in liquid nitrogen. 
5.1.2 Liposome-mediated transient transfection 
Mammalian cells were plated 24 h prior to transfection. At about 60 to 70 % confluency, cells 
were transfected using Lipofectamine 2000 reagent according to the manufacturer's 
instructions. The transfection mix was prepared in OptiMEM and added to the cells for 6 hours. 
Thereafter, the medium was replaced by fresh medium and cells were incubated for at least 
24 hours prior further treatment or cell analysis.  
 
For liposome-mediated transfection of the human hepatocellular carcinoma cell line HepG2, 
the GenJet transfection reagent was used according to the manufacturer’s instructions. 
Therefore, 4.5 x 105 HepG2 cells were seeded onto 6-wells 24 hours prior transfection and 
thereafter transfected with DNA-plasmid diluted with the GenJet transfection reagent at a ratio 
of 1:3. 18 hours posttransfection, medium was replaced by fresh medium supplemented with 
serum and antibiotics and cells were incubated for at least 24 hours.  
5.1.3 Transient silencing of target genes using siRNA 
Knockdown of target genes by RNA interference (RNAi) results in a transient gene-specific 
reduction in gene expression. For RNA interference, cells were transfected with either 50 nM 
gene-specific small interfering RNA (siRNA) or 50 nM of negative control siRNA using 
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Lipofectamine RNAiMAX according to the manufacturer’s instructions. Reverse transfection 
showed the highest transfection efficiency. This method worked as follows: 5 µL Lipofectamine 
RNAiMAX were directly incubated with the appropriate amount of siRNA in 500 µL OptiMEM 
for 20 minutes at room temperature in a 6-well dish. Meanwhile cells were detached, pooled 
and resuspended in OptiMEM and 4.5 x 105 HepG2 or 2.5 x 105 HuH7 cells in 1.5 mL OptiMEM 
were added to the prepared reaction mix. Cells were incubated at 37°C and 5 % CO2 overnight 
and on the next day medium was replaced by 2 mL fresh medium supplemented with serum 
and antibiotics. Depending on the gene of interest, either at 48 or 96 hours posttransfection, 
knockdown efficiencies were assessed by quantitative real-time PCR and immunoblotting.  
5.1.4 Calcium-phosphate transfection method 
Cells were transiently transfected by the calcium DNA-precipitation method. Therefore 1 x 106 
HEK293T or amphotrophic Phoenix cells were seeded onto 6-well plates the day before 
transfection. 2 hours prior to transfection, medium was replaced by 2 mL fresh medium 
supplemented with 10 % serum but without antibiotics. The following table illustrates the 
required volumes for a single transfection experiment in a 3.5 cm dish. 
 
Solution A Amount 
Plasmid DNA 2 to 4 µg 
2 M CaCl2 3.5 µL 
dd H2O ad 62.5 µL 
 
Table 1: Required volumes for a single transfection experiment in a 3.5 cm dish. 
 
The DNA-CaPO4 cocktail was added drop by drop while vortexing in HBS. Thereafter the 
transfection mix was incubated at room temperature for 5 minutes and subsequently added 
dropwise to the cells. 16 hours after transfection the medium was replaced by 2 mL fresh 
medium, supplemented with 10 % serum and antibiotics. 
5.1.5 Establishment of stables cell lines via lentiviral transduction 
Cell lines with a stable, gene-specific knockdown were generated by lentiviral transduction. 
Lentiviral particles were produced by transient cotransfection of HEK293T cells with the 
plasmids VSVG (0.25 μg), pD8.9 (0.75 μg) and shRNA (1.0 μg) by the calcium phosphate DNA 
precipitation method. The medium was replaced by 2 mL fresh medium supplemented with 10 
% serum and antibiotics one day after transfection. Overnight conditioned medium was pooled 
and filtered through a 0.45 μm sterile filter and supplemented with 4 µg/mL polybrene. 4 mL of 
the lentiviral supernatant were directly added to the target cells which had been plated the day 
before in 6 cm dishes. After 3 hours incubation, 4 mL fresh medium and after additional 5 hours 
incubation 8 mL fresh medium were directly added to the target cells. One day after 
Solution B Amount 
2 x HBS buffer 62.5 µL 
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transduction, infected cells were detached, resuspended in fresh medium and transferred in 
1:5 dilutions to new 10 cm cell culture dishes containing 10 mL of medium. The selection 
antibiotic puromyin was added to the medium and cells expressing the shRNA vectors were 
selected with puromycin for 7 days. Concentration of puromycin was dependent on the cell 
type. Cells were analyzed for gene-specific knockdown by immunoblotting and quantitative 
real-time PCR one week after lentiviral transduction. 
5.1.6 Retroviral transduction  
Expression of the constitutively active H-RasV12 allele in HuH7 and HuH6 cells was done by 
retroviral transduction. Generation of retroviral particles was performed by transient 
transfection of the amphotrophic Phoenix packaging cells, a specific producer cell line for the 
generation of helper-free amphotropic retroviruses, with the pBabe-puro H-RasV12 plasmid (2 
μg) or the pBabe-puro control vector using the calcium phosphate DNA precipitation method. 
One day after transfection, medium was replaced by 2 mL fresh medium with 10 % serum. 
Overnight conditioned medium was sterile-filtered through a 0.45 μm filter and 4 mL of the 
retroviral supernatant were pipetted on the target cells which had been plated in 6 cm dishes 
before. 24 hours after infection, medium was replaced by fresh medium. 5 days after post-
transduction, cells were processed for immunoblot analysis. 
5.1.7 Serum starvation 
Cells were serum-starved by washing twice with PBS followed by incubation in culture medium 
supplemented with 0.2 % serum for 16 hours overnight. 
5.1.8 Serum stimulation 
After serum starvation, cells were stimulated with 20 % fetal bovine serum for the indicated 
time intervals. The serum was directly added to the growth medium used for starvation. 
5.1.9 Drug treatment  
Stock solutions of drugs were diluted to the required working concentration with medium.  For 
drug treatment, seeded or transfected cells were washed with medium and exposed to the 
drug at 37°C and 5 % CO2 atmosphere. 
5.1.10 Cell harvest and lysis 
During harvest and lysis, the cells were kept on ice to avoid degradation of proteins. The cell 
culture medium was aspirated and monolayers of cells were washed twice with cold PBS. A 
selected volume of lysis buffer supplemented with protease inhibitor cocktail 1:100, 
phenylmethanesulfonylfluoride (PMSF) 1:500 and dithiothreitol (DTT) 1:250 was added to the 
cells which were scrapped off and transferred to an Eppendorf tube. The samples were 
incubated on ice for 10 minutes and pelleted by centrifugation at 12,700 rpm for 10 minutes at 
4°C. The supernatant containing the extracted proteins was transferred into a new Eppendorf 
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tube, supplemented with 4 x Laemmli buffer and boiled at 95°C for 10 minutes. The protein 
lysates were stored at -20°C or directly used for immunoblot analysis. If applicable, total protein 
concentration was measured prior to addition of Laemmli buffer using the Bradford method. 
5.2 Protein biochemistry 
5.2.1 Measurement of total protein content 
For determination of total protein concentration in cell lysates prior to immunoblot analysis, 
Roti®-Quant Bradford reagent was used according to the manufacturer’s instructions. 2 µL lysis 
buffer served as blank and 2 µL of each sample were diluted with 1000 µL Roti®- Quant 
Bradford Reagent (Coomassie Brilliant Blue G-250 was diluted 1:5 with H2O) and incubated at 
room temperature for 5 minutes.  The protein concentration was analyzed by measuring the 
absorbance at 595 nm with the BioPhotometer. Typically, 10 to 40 µg of total protein were 
subjected to immunoblot analysis. 
5.2.2 RhoA Activation Assay 
Active, GTP-bound RhoA levels were determined using the RhoA Activation Assay kit based 
on immunoprecipitation of the GTP-bound form of RhoA. Cells were plated the day before in 
10 cm dishes to reach about 80 % to 90 % confluency. For activation of RhoA, cells were 
serum-starved for 16 hours overnight and stimulated with 10 μM lysophosphatidic acid (LPA) 
for exactly 2 minutes. Subsequently, cells were washed twice with ice-cold PBS and lysed in 
500 μL lysis buffer (50 mM TRIS-HCl pH 8, 150 mM NaCl, 1 % TritonX-100 and 10 % glycerol). 
After incubation for 45 minutes on ice, lysates were cleared by centrifugation at 12,000 rpm for 
10 minutes at 4°C. For determination of total cellular RhoA levels, 20 μL were taken from the 
supernatant and mixed with 4 x Laemmli sample buffer. The remaining supernatant was 
incubated with 1 µL of the anti-active RhoA monoclonal mouse antibody by rotating head-over-
end overnight at 4°C. For the negative beads-only control, the supernatant was incubated 
without the antibody. For immunoprecipitation, 50 µL ProteinG-Sepharose beads were mixed 
with 50 μL washing buffer (50 mM TRIS-HCl, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 % 
TritonX-100) and added to the probe. All probes were incubated by slowly rotating head-over-
end at 4°C for at least 3 hours. For washing, the beads were settled by centrifugation at 12,700 
rpm for 30 seconds and washed four times with 500 μL washing buffer. All washing steps were 
carried out on ice. Finally the supernatant was discarded and the beads were incubated with 
15 μL 4 x Laemmli buffer and heated at 95°C for 3 minutes to dissolve the proteins from the 
beads. For the subsequent immunoblot analysis, the beads were sedimented and the 
supernatant was subjected together with the lysates for total cellular RhoA levels to 
immunoblot analysis using the anti-RhoA rabbit polyclonal antibody.      
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5.2.3 Ras Activation Assay 
The GTP bound form of Ras was determined by using the Ras Activation Assay kit according 
to the manufacturer’s protocol. HuH7 cells were plated the day before in 10 cm dishes to reach 
about 80 % confluency. On the next day, cells were washed twice with ice-cold PBS, lysed in 
500 μL lysis buffer (50 mM TRIS-HCl, pH 8, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 % 
TritonX-100) and incubated on ice for 10 minutes. Subsequently lysates were cleared by 
centrifugation at 12,000 rpm for 10 minutes at 4°C. For determination of total cellular Ras 
levels, 20 μL were taken from the supernatant and mixed with 4 x Laemmli buffer. The 
remaining supernatant was incubated with 1 μL of the anti-active Ras monoclonal mouse 
antibody by rotating head-over-end for 60 minutes at 4°C. Thereafter 20 μL of protein A/G 
agarose beads were added and incubated by rotating head-over-end for additional 60 minutes 
at 4°C. For washing, the beads were centrifuged at 12,700 rpm for 30 seconds and washed 
four times with cold lysis buffer. All washing steps were carried out on ice. Finally, the 
supernatant was discarded and the beads were incubated with 15 μL 4 x Laemmli buffer and 
heated at 95°C for 3 minutes to dissolve the proteins from the beads. For the subsequent 
immunoblot analysis, the beads were sedimented and the supernatant was subjected together 
with the lysates for total cellular Ras levels to immunoblot analysis using the anti-Ras rabbit 
polyclonal antibody.      
5.2.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE method was used to separate proteins according to their molecular weight 
(Laemmli, 1970). Table 2 below illustrates the required volumes for a single 1.5 mm 
polyacrylamide gel. 
 
Separating gel 5 % 10 % 12 % 15 % 
H2O [mL] 4.25 1.99 2.4 1.65 
30 % polyacrylamide [mL] 1.25 1.67 3 3.75 
1.5 M TRIS (pH 8.8) [mL] 1.875 1.25 1.95 1.95 
10 % SDS [μL] 75 50 75 75 
10 % APS [μL] 100 50 75 75 
TEMED [μL] 6 2 3 3 
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Stacking gel  
H2O [mL] 2.7 
30 % polyacrylamide [mL] 0.67 
1.5 M TRIS (pH 6.8) [mL] 1 
10 % SDS [μL] 40 
10 % APS [μL] 40 
TEMED [μL] 4 
 
Table 2: Composition of a 1.5 mm polyacrylamide gel. 
 
Water, acrylamide and the corresponding TRIS buffer were pre-mixed. To start the 
polymerization reaction, APS and TEMED were added. The polymerized gel was clamped in 
the gel electrophoresis apparatus (BioRad) and then filled with gel running buffer. The gel was 
loaded with the protein lysate probes dissolved in Laemmli buffer. As molecular weight marker, 
the Spectra Multicolor Broad Range protein standard was used. The gel electrophoresis ran 
at a constant current of 100 V.  
5.2.5 Immunoblotting 
After gel electrophoresis, proteins were transferred from the SDS-gel onto an activated 
polyvinylidene fluoride (PVDF) membrane using the minigel system (BIORAD) (Towbin et al, 
1979). Using the wet blotting method, the proteins were blotted at a constant current of 350 
mA for 75 minutes. Membranes were blocked directly in 5 % nonfat dry milk in TBS containing 
0.1 % Tween-20 (TBS-T) for 1 hour at room temperature and then probed with the primary 
antibody in TBS-T with 5 % milk or 5 % BSA overnight at 4°C with gentle agitation. Next day, 
membrane was washed three times with TBS-T for 15 minutes and thereafter probed with the 
horseradish peroxidase-conjugated secondary antibody in TBS-T for 1 hour at room 
temperature. Final washing was done three times for 5 minutes with TBS-T. Protein bands 
were visualized via the enhanced chemiluminescence detection method at a luminescent 
imager. 
5.2.6 RhoA GLISA Assay 
RhoA activity was quantitatively measured using the RhoA G-LISA Activation assay Biochem 
kit according to the manufacturer’s instructions. Therefore, cells were plated in 10 cm dishes 
and grown to a confluency of about 70 %. For RhoA activation, cells were serum-starved for 
16 hours overnight and stimulated with 10 μM lysophosphatidic acid (LPA) for exactly 2 
minutes. Subsequently cells were washed twice with ice cold PBS and lysed in 250 μL cold 
lysis buffer. Lysates were immediately cleared by centrifugation at 10,000 rpm for 2 minutes 
at 4°C. 20 μL lysate were saved for protein quantification and the remaining lysate was snap 
frozen with liquid nitrogen. Thawed probes were equalized to a total cellular protein 
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concentration of 1.5 mg/mL with cold lysis buffer. Thereafter, the 96-well plate coated with a 
GTP-binding domain of RhoA where specifically the active GTP-bound form of RhoA can bind 
was incubated with the probes for 30 minutes at 4°C while shaking at 400 rpm.  After several 
washing steps for removal of inactive GDP-bound RhoA, detection of the bound active RhoA 
was done by incubation with a specific primary RhoA antibody followed by the incubation with 
a secondary-HRP conjugated antibody. Absorbance was measured at λ=490 nm using an 
ELISA reader. 
5.2.7 Indirect immunofluorescence 
Cells were grown on glass coverslips placed in cell culture dishes. Prior to fixation, cells were 
washed with PBS. Cells were fixed in 4 % aqueous formaldehyde solution for 10 minutes at 
room temperature and permeabilized with 0.2 % Triton X-100 in PBS for 7 minutes.  Blocking 
of unspecific binding sites was performed by incubation in 1 % bovine serum albumin in PBS 
for 60 minutes at room temperature. Afterwards the cells were incubated with the primary 
antibody (dilution dependent on antibody, range 1:100 to 1:500 in PBS) for at least 1 hour at 
room temperature. Thereafter cells were washed two times each with PBS, PBS-T and PBS 
and incubated with fluorescently labelled ALEXA conjugated secondary antibodies (1:1000 in 
PBS) for 1 hour at room temperature. In the final washing step, cells were washed two times 
each with PBS, PBS-T and PBS. Finally, cells were embedded in the mounting medium 
(Fluoromount®), supplemented with 1 μg/mL 4`6-diamidion-2-phenylindole (DAPI) to visualize 
nuclei. Images were obtained on a Zeiss LSM 510 microscope. 
5.3 Cell proliferation assay 
105 mammalian cells were seeded in 6 wells. In 24 hours intervals, cells were washed with 2 
mL PBS, detached with 500 μL trypsin and resuspended in 500 μL medium. The cell number 
was counted using the hematocytometer method.  
5.4 Flow cytometry analysis 
Cells were harvested, washed with PBS and resuspended in 1 mL staining solution I 
supplemented with propidium iodide. To avoid unspecific binding of propidium iodide to RNA, 
cells were treated with 5 μL RNaseA (10 mg/mL). After 60 minutes incubation at room 
temperature, 1 mL of the second staining solution supplemented with propidium iodide was 
added. After further 30 minutes incubation, stained cells were analyzed by flow cytometry. 
5.5 Senescence-associated ß-galactosidase activity assay 
Cellular senescence was determined by using the senescence ß-galactosidase staining kit 
according to the manufacturer’s protocol. In 0.5 % glutaraldehyde-fixed cells were stained with 
a freshly prepared senescence-associated ß-galactosidase staining solution containing 1 
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mg/mL of 5-bromo-4-chloro-3-indolyl-ß-galactopyranoside and incubated at 37°C overnight. 
By counting the number of blue colored cells and the total cells per field (0.5 x 0.5 cm2) using 
a Zeiss inverted microscope, the percentage of the SA-ß-gal positive cells was calculated. 
More than 1000 cells were counted from four fields of vision.  
5.6 Invasion assay 
The invasive capacity of tumor cells was measured using 6.5 mm diameter tissue culture-
treated polycarbonate membranes with 8 μm pores. Membranes were coated with 100 μL ECM 
gel, diluted 1:2 in cold DMEM medium according to the manufacturer’s instructions. 4 x 104 
HuH7 cells in 200 μL medium supplemented with 1 % serum were placed in the upper chamber 
of the Transwell® insert whereas the lower chamber was filled with 600 μL medium containing 
10 % serum as a chemoattractant. HuH7 cells were allowed to invade for 24 hours at 37°C. 
Invaded cells were visualized by toluidine staining. Non-invading cells were removed from the 
top of the ECM gel with a cotton swap. For fixation of invaded cells, inserts were incubated in 
100 % methanol for 2 minutes and subsequently stained in 1 % toluidine blue solution for 2 
minutes. Excess dye was removed by washing the inserts in distilled water. The inserts were 
allowed to air dry. Cells were quantified by counting the cell number of invaded, purple-colored 
cells using a Zeiss inverted microscope.  
5.7 Nucleic acid biochemistry 
5.7.1 RNA preparation 
For RNA preparation, cells were washed twice with PBS and 1 mL TRIzol® reagent per 6 cm 
dish was directly added to the cells. Cells were scrapped off and transferred into an Eppendorf 
tube and incubated for 5 minutes at room temperature. Thereafter 0.2 mL chloroform per 1 mL 
TRIzol® Reagent was added and the tube was shaken vigorously for 15 seconds, followed by 
an incubation for 3 minutes at room temperature. For phase separation, the sample was 
centrifuged at 12,700 rpm for 15 minutes at 4°C. The aqueous phase, containing the RNA was 
removed and placed in a new tube. 
For precipitation of the RNA, 0.5 mL isopropanol was added to the aqueous phase followed by 
incubation at room temperature for 10 minutes. To collect the RNA precipitate, the sample was 
centrifuged at 12,000 rpm for 10 minutes at 4°C and the supernatant was carefully removed. 
The RNA pellet was washed with 1 mL 75 % ethanol and then centrifuged at 12,000 rpm for 
10 minutes at 4°C. The supernatant was discarded and the RNA was allowed to air dry. The 
RNA was resuspended in nuclease-free water and completely dissolved by incubation at 55°C 
for 10 minutes. RNA concentration and purity were determined by photometric measurement 
of the absorbance at 260 nm and 280 nm, respectively. A ratio of about 2.0 was accepted as 
pure RNA. 
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5.7.2 cDNA synthesis 
1 μg of total RNA was primed with 1 μL of Random Hexamers (50 μM)  in reaction volume of 
5 µL and heated in a thermo cycler at 70°C for 5 minutes to denaturate the template followed 
by incubation at 4°C for 5 minutes. To this mixture, 4 μL 5 x Frist Strand buffer, 2 μL DTT, 1 
μL dNTPs (10 μM), 1 μL Superscript Reverse Transcriptase II and 7 μL H2O were added to a 
final volume of 20 μL. The mixture was kept in a thermocycler at 25°C for 5 minutes and then 
at 42°C for 60 minutes. Thereafter the reverse transcriptase was inactivated by heating to 70°C 
for 15 minutes and the reaction was stopped by placing the tube on ice. The prepared cDNA 
was stored at -20°C or directly used for qPCR. 
5.7.3 Real-time PCR 
Each quantitative PCR (final reaction volume 20 μl) included 6 µL cDNA (1:10 diluted with H2O, 
for 18S rRNA diluted 1:100), 10 µL LightCycler®480 SyBr Green Master I Mix, 2 µL nuclease-
free H2O and 1 µL of forward and reverse primer (10 μM). Quantification was performed with 
the LightCycler 480 Real-Time PCR system using the program listed below. 
Step Temperature 
profile 
Time Function  
1 95°C 5 min preincubation  
 
 
 
2 95°C 10 sec amplification 
 55°C 10 sec amplification 
 72°C 10 sec elongation 
3 95°C 10 sec melting curve 
 60°C 1 min melting curve 
 95°C 10 sec melting curve 
4 40°C 30 sec cooling 
 
Table 3: Times and temperatures for a quantitative real-time PCR reaction. 
 
The mid-linear range was used to establish the threshold of each oligonucleotide set. Gene 
expression was normalized with respect to the endogenous housekeeping gene 18S rRNA, 
which was determined not to significantly change under different conditions. Relative 
expression of each gene was calculated using the ΔΔCT method.  
5.7.4  Microarray analysis 
For DNA GeneChip Array analysis, total cellular RNA from HuH7 cells stably expressing 
control shRNA or MKL1/2 shRNA was isolated using RNaesy Mini Kit according to the 
manufacturer’s instructions. Sensestrand cDNA from total cellular RNA was synthesized using 
the Ambion WT Expression Kit according to the manufacturer’s protocol which allows to prime 
specifically non-ribosomal RNA. Subsequently, the sense-strand cDNA was fragmented and 
50 cycles 
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biotin-labeled using the Affymetrix GeneChip® WT Terminal Labeling Kit according to the 
manufacturer’s protocol. Hybridization was performed with fragmented cRNA on the Human 
Gene 1.0 ST array at 45°C for 17 hours. Washing and staining by streptavidin-phycoerythrin 
was performed on a microfluide workstation (Affymetrix) and arrays were scanned by a laser 
scanner (Affymetrix). Gene expression analysis was done by using the Partek Microarray 
Analysis software.  
5.7.5 Transformation into chemically competent E.coli DH5alpha bacteria cells 
Aliquots of competent E.coli DH5alpha bacterial cells, prepared in our lab, were stored at – 
80°C. For each transformation, one aliquot was thawed for 15 minutes. DNA was carefully 
added to the bacterial cells and incubated on ice for 30 minutes. Subsequently, DNA uptake 
was carried out at 42°C for exactly 90 seconds and cells were chilled on ice for 2 minutes. 900 
μL prewarmed LB medium (without antibiotics) were added and the suspension was shaken 
at 150 rpm at 37°C for one hour. 150 μL of the bacterial suspension were plated on prewarmed 
agar plates containing the selection antibiotic and incubated overnight at 37°C. Until further 
processing, the agar plate was sealed with Parafilm and stored at 4°C.  
5.7.6 Midi scale plasmid preparation 
A single bacterial clone was picked up with a sterile pipette tip and transferred in 50 mL LB 
medium containing the selection antibiotic and thereafter incubated for 16 hours overnight 
while shaking at 300 rpm at 37°C. Next day, bacterial cells were centrifuged at 3500 rpm for 
10 minutes at 4°C and the supernatant was discarded. DNA was extracted using the GenElute 
HP Plasmid Midiprep Kit. Thereafter DNA concentration and purity were determined by 
photometric measurement of the absorbance at 260 or 280 nm, respectively. 
5.8 Subcutaneous tumor xenograft mouse model 
Effects of RNAi mediated knockdown of MKL1 and MKL2 on HuH7 tumor xenograft growth in 
vivo were determined by systemic injection of siRNA complexed with polyethylenimine as 
described previously (Hobel et al, 2010). Athymic nude mice were held under pathogen-free 
conditions with ad-libitum access to food and water. Experiments were approved by the 
government of Upper Bavaria and performed according to legal terms for animal experiments 
of the local administration. 2 x 106 HuH7 cells were injected subcutaneously into both flanks of 
6 week old female athymic nude mice (Crl:CD1-Foxn1nu). After 7 days, when solid tumors 
were established, mice were randomized into control and treatment groups with 6 animals per 
group. Mice were intraperitoneally injected three times per week with 15 μg nonspecific or 
specific siRNAs, each complexed with PEI F25-LMW. For the siRNA MKL1+2 treatment group, 
7.5 μg siRNA MKL1 and 7.5 μg siRNA MKL2 were mixed and complexed with PEI L25-LMW. 
Untreated mice or mice treated with nonspecific siRNA served as negative control. Tumor 
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volume was measured three times per week and calculated according the formula length x 
width x width/2. Mice bearing subcutaneous tumors were sacrificed on day 22 after therapy 
start, tumors excised and shock-frozen in liquid nitrogen for subsequent RNA and protein 
preparation. For RNA isolation from tumor samples, in TRIzol® reagent shock-frozen 
xenografts were thawed at room temperature and homogenized with the TissueRuptor. 
Thereafter, 0.2 mL chloroform per 1 mL TRIzol® reagent was added to the probe and RNA was 
prepared according to chapter 5.7. For protein cell lysate preparation, HuH7 cells derived 
xenografts were homogenized with the TissueRuptor in ice-cold lysis buffer, supplemented 
with protease inhibitor, phenylmethanesulfonylfluoride and dithiotreitol. Subsequently, 
samples were shortly sonicated and incubated on ice for 10 minutes. Thereafter samples were 
centrifuged at 12,700 rpm for 10 minutes at 4°C. The supernatant containing the extracted 
proteins was transferred to an Eppendorf tube and stored at -20°C or prepared for immunoblot 
analysis as described in chapter 5.2.  
5.9 Statistical analysis 
Unless otherwise indicated, data were expressed as mean ± standard deviation (SD). 
Statistical analysis among two groups was carried out using the Student’s unpaired t-test. P-
values are *p≤0.05, **p≤0.01, ***p≤0.001. 
5.10 Software and databases 
GraphPad Prism® (GraphPad Software, La Jolla, CA, USA) was used for calculations and 
statistical analysis. Research publications were obtained from the online database NCBI 
PubMed (http://www.ncbi.mlm.nih.gov/pubmed) and managed with EndNote X7. DNA 
sequences were obtained from NCBI (http://www.ncbi.nlm.nih.gov/nuccore). Gene array data 
were managed using the Partek Microarray Analysis software. Blots and microscopic images 
were processed with ImageJ (Wayne Rasband, National Institute of Health, Bethesda, MD, 
USA) and Adobe Photoshop.  
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6 Results 
6.1 Role of the transcriptional coactivators MKL1 and MKL2 in human 
hepatocellular and breast carcinoma cells 
Preliminary studies of our group pointed out a direct correlation between the subcellular 
localization of MKL1 and the endogenous expression levels of the tumor suppressor DLC1. A 
prevalent nuclear localization of MKL1 was found in hepatocellular and breast carcinoma cells 
lacking endogenous DLC1 expression. Therefore in the first part of this work, we aimed to 
investigate the functional role of DLC1 expression on the subcellular localization and the 
transcriptional activity of MKL1 and MKL2.  
6.1.1 Nuclear MKL2 localization in DLC1-deficient human cancer cell lines 
We found a changed subcellular localization of MKL1 in different human hepatocellular and 
breast carcinoma cell lines with loss of endogenous DLC1 expression. Consequently, we 
addressed the subcellular localization of MKL2 in these cell lines. We analyzed the subcellular 
distribution of MKL2 by indirect immunofluorescence analysis in human hepatoma HepG2 
cells, breast epithelial MCF7 cells, hepatocellular carcinoma HuH7 cells and breast carcinoma 
MDA-MB-468 cells.  
 
Figure 15: Nuclear localization of MKL2 in human hepatocellular and breast carcinoma cells with DLC1 
loss. 
HepG2, MCF7, HuH7 and MDA-MB-468 cells were fixed and immunostained by the anti-MKL2 antibody. In each 
cell line, the subcellular localization of MKL2 was scored as predominantly cytoplasmic, evenly distributed or 
predominantly nuclear. Represented is the percentage of cells with predominantly nuclear localized MKL2. 
Quantifications were based on at least three independent experiments where at least one hundred cells were 
analyzed. Values are represented as mean ± SD. 
The results of the quantitative analysis of the subcellular distribution of MKL2 illustrated that 
HepG2 and MCF7 cells, both characterized by the expression of endogenous DLC1, showed 
a prevalent cytoplasmic localization of MKL2 (Figure 15). By contrast, 94 % of HuH7 cells and 
87.6 % of MDA-MD-468 cells, both characterized by the lack of endogenous DLC1 expression, 
displayed a predominantly nuclear localization of MKL2 (Figure 15). Our data illustrated a 
correlation between the subcellular distribution of both, MKL1 and MKL2, and the endogenous 
expression levels of the tumor suppressor DLC1. These data indicate that human 
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hepatocellular and breast carcinoma cell lines with loss of endogenous DLC1 expression 
display a common nuclear localization of both MKL1 and MKL2. 
6.1.2 Downregulation of DLC1 expression in murine hepatocytes induces the nuclear 
translocation of MKL2 
As we reported a nuclear localization of MKL1 and MKL2 in DLC1-deficient cancer cells it 
raised the question if loss of DLC1 expression is able to trigger the nuclear translocation of 
MKL2. To address this question, we used established murine hepatocytes stably expressing 
shRNA targeting the tumor suppressor DLC1 (Xue et al, 2008). The subcellular localization of 
MKL2 was analyzed by indirect immunofluorescence analysis and downregulation of DLC1 
expression was analyzed by immunoblotting.  
 
 
Figure 16: Downregulation of DLC1 expression triggers the nuclear translocation of MKL2. 
(A) Murine hepatocytes stably expressing either control shRNA or DLC1 shRNA were immunostained by the anti-
MKL2 antibody. Using indirect immunofluorescence analysis, the percentage of cells with predominantly nuclear 
MKL2 localization was determined. Representative images are shown. Quantifications were based on three 
independent experiments where at least one hundred cells were analyzed. Values are given as mean ± SD.  
(B) Lysates of cells as described in (A) were prepared and equal amounts of total cellular protein were subjected to 
immunoblotting using anti-DLC1 antibody. Loading was controlled by re-probing the blot for HSP90. 
Indirect immunofluorescence analysis illustrated that murine hepatocytes expressing control 
shRNA showed a clearly cytoplasmic MKL2 staining. By contrast, RNA interference mediated 
downregulation of DLC1 expression in murine hepatocytes induced nuclear translocation of 
MKL2 as shown by immunostaining (Figure 16a). These observations were confirmed by 
quantification of the number of hepatocytes with nuclear MKL2 staining. The results 
demonstrated that 88.5 % of murine hepatocytes expressing DLC1 shRNA revealed a 
predominantly nuclear MKL2 distribution in contrast to the murine hepatocytes expressing 
control shRNA where only 13 % of the analyzed cells exhibited a nuclear localization of MKL2 
(Figure 16a). Downregulation of DLC1 expression on protein level was confirmed by 
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immunoblotting (Figure 16b). These data indicate that the endogenous expression levels of 
the tumor suppressor DLC1 have an influence on the subcellular distribution of MKL2. 
Additionally our observations in the murine hepatocytes with stable DLC1 knockdown are in 
agreement with the reported nuclear localization of MKL1 and MKL2 in human hepatocellular 
and breast carcinoma cells lacking endogenous DLC1 expression.  
6.1.3 Reconstitution of DLC1 expression induces cytoplasmic relocalization of MKL1 
and MKL2 
Next we investigated if the reconstitution of DLC1 expression in the DLC1-deficient 
hepatocellular carcinoma cells HuH7 is able to induce a relocalization of MKL1 and MKL2 from 
the nucleus back to the cytoplasm. HuH7 cells were transiently transfected with human 
wildtype Flag-tagged DLC1 or with the corresponding control expression vector. The 
subcellular localization of MKL1 and MKL2 was determined by indirect immunofluorescence 
analysis.  
 
 
Figure 17: Reconstitution of DLC1 expression induces the relocalization of MKL1 and MKL2 from the 
nucleus back to the cytoplasm. 
HuH7 cells were transiently transfected with human wildtype Flag-tagged DLC1 or with the corresponding control 
expression vector. 24 hours after transfection, cells were immunostained with (A) anti-MKL1, (B) anti-MKL2 and 
anti-Flag antibodies. Shown are representative images for the subcellular localization of (A) MKL1 and (B) MKL2.  
Indirect immunofluorescence analysis illustrated that HuH7 cells expressing Flag-tagged DLC1 
revealed a cytoplasmic redistribution of both MKL1 and MKL2 opposed to HuH7 control cells 
depicting the nuclear localization of MKL1 and MKL2 (Figure 17a and b). These observations 
indicated that the restoration of DLC1 expression in HuH7 cells was able to induce the 
cytoplasmic redistribution of MKL1 and MKL2. These findings led to the assumption that 
expression of the tumor suppressor DLC1 played a critical role in the regulation of the 
subcellular localization of the transcriptional coactivators MKL1 and MKL2. 
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6.1.4 DLC1-deficiency increases RhoA activity in human cancer cells 
It is well established that the subcellular localization of MKL1/2 is regulated by the Rho/actin 
signaling pathway (Miralles et al, 2003). As DLC1 encodes a RhoGAP protein, we were 
interested if the DLC1 expression levels affected the RhoA activation state of hepatocellular 
and breast carcinoma cells, thereby influencing the subcellular distribution of MKL1/2. We 
compared the active GTP-bound RhoA levels between DLC1-expressing MCF7 cells versus 
DLC1-deficient MDA-MB-468 cells by immunoprecipitation using an antibody that specifically 
recognized the active GTP-bound form of RhoA. Simultaneously, the active GTP-bound RhoA 
levels were quantified by a RhoA G-LISA assay.  
 
 
Figure 18: Increased active GTP-bound RhoA levels in DLC1-deficient MDA-MB-468 cells.  
(A) MCF7 and MDA-MB-468 cells were immunoprecipitated with anti-active RhoA antibody and immunoblotted with 
anti-RhoA antibody. Equal amounts of lysates were directly immunoblotted with anti-RhoA antibody. For the beads 
only control, no antibody was added to the immunoprecipitation. (B) Active GTP-bound RhoA levels of MCF7 and 
MDA-MB-468 cells were quantitatively analyzed by an ELISA-assay. Absorbance was measured at 490 nm. Values 
are represented as mean ± SD of three independent experiments.  
Immunoprecipitation illustrated that the amount of active GTP-bound RhoA was considerably 
increased in the DLC1-deficient MDA-MB-468 cells compared to the DLC1-expressing MCF7 
cells (Figure 18a). By contrast, total cellular RhoA expression levels of both MCF7 and MDA-
MB-468 cells were similar (Figure 18a). The results of quantitative measurement demonstrated 
that the level of active GTP-bound RhoA was elevated two-fold in MDA-MB-468 cells as 
compared to MCF7 cells (Figure 18b).  
 
As we found that DLC1-deficiency augmented RhoA activity, we looked whether the absence 
of DLC1 expression was able to cause constitutive activation of RhoA. To test this, HepG2, 
HuH7, MCF7 and MDA-MB-468 cells were serum-starved and stimulated with 
lysophosphatidic acid (LPA) which activates RhoA via the Galpha 12/13 pathway (Kranenburg et 
al, 1999). For the HepG2 and HuH7 cells, active RhoA levels were analyzed by 
immunoprecipitation using a specific antibody that binds to the GTP-bound form of RhoA. 
Active RhoA levels of MCF7 and MDA-MB-468 cells were measured by a RhoA G-LISA assay.  
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Figure 19: Constitutive activation of RhoA in hepatocellular and breast carcinoma cells with DLC1 
deficiency.  
(A) HepG2 and HuH7 cells were serum-starved for 16 hours, stimulated with 10 μM lysophosphatidic acid (LPA) for 
2 minutes and subsequently lysed. Analysis of GTP-bound RhoA was done by immunoprecipitation with anti-active 
RhoA antibody and afterwards subjected to immunoblotting using total anti-RhoA antibody. Equal amounts of 
lysates were directly immunoblotted with anti-RhoA antibody. The blot is representative for three independent 
experiments. (B) MCF7 and MDA-MB-468 cells were serum-starved for 16 hours, stimulated with 10 μM 
lysophosphatidic acid (LPA) for 2 minutes and subsequently lysed. Active GTP-bound RhoA was quantitatively 
measured by an ELISA assay. Values are mean ± SD of two individual experiments. 
The results from immunoprecipitation demonstrated that unstimulated, serum-starved HuH7 
cells contained higher basal GTP-bound RhoA levels than HepG2 cells. The amount of active 
RhoA in HepG2 cells was strongly increased upon stimulation with LPA. In contrast, no further 
RhoA activation upon LPA stimulation was detectable in HuH7 cells concluding that RhoA was 
constitutively activated (Figure 19a). However, total cellular expression levels of RhoA were 
not affected by LPA treatment. The same effects were observed by quantitative analysis of the 
active RhoA levels in MCF7 and MDA-MB-468 cells. LPA stimulation of MCF7 cells increased 
the amount of GTP-bound RhoA whereas the RhoA activation status in MDA-MB-468 cells 
remained unchanged (Figure 19b). Our data illustrate that the lack of endogenous DLC1 
expression in hepatocellular and breast carcinoma cells leads to the constitutive activation of 
RhoA. 
6.1.5 Analysis of the actin cytoskeleton of DLC1-deficient cancer cells 
Increased RhoA signaling causes the polymerization of F-actin and the formation of stress 
fibers (Ridley & Hall, 1992). Thus, we were interested if cytoskeletal alterations in the DLC1-
deficient cancer cells could account for the nuclear localization of MKL1/2. The actin 
cytoskeleton of HepG2, HuH7, MCF7 and MDA-MB-468 cells was visualized by F-actin 
staining, using phalloidin, a bicyclic peptide which belongs to the family of toxins isolated from 
Amanita phalloides and specifically binds to F-actin (Dancker et al, 1975). 
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Figure 20: Increased F-actin formation in DLC1-deficient cancer cells. 
The actin cytoskeleton of HepG2, HuH7, MCF7 and MDA-MB-468 cells was visualized by F-actin staining using 
ALEXA Fluor 488 phalloidin. Cells were analyzed by indirect immunofluorescence analysis and representative 
images are shown.  
Immunofluorescence analysis illustrated hardly any F-actin staining in the endogenous DLC1-
expressing HepG2 and MCF7 cells (Figure 20). By contrast, the DLC1-deficient HuH7 and 
MDA-MB-468 cells revealed a strong increase in the amount and intensity of F-actin staining 
(Figure 20). These data suggest an elevation of F-actin amount in DLC1-deficient cancer cells 
that contributes to the nuclear accumulation of MKL1/2. 
6.1.6 Impaired nuclear export mechanism of MKL1 in DLC1-deficient cancer cells 
Besides the importance of RhoA/actin signaling for the nuclear import of MKL1/2, it is 
established that nuclear export is the critical mechanism for the subcellular localization of 
MKL1 (Vartiainen et al, 2007). It was found that serum-inducible phosphorylation of MKL1 at 
serine 454 enhances G-actin binding and facilitates the nuclear export of MKL1 (Muehlich et 
al, 2008; Vartiainen et al, 2007). We investigated the nuclear export mechanism of MKL1 in 
DLC1-deficient cancer cells. At first, the phosphorylation status of MKL1 at serine 454 was 
determined in hepatocellular and breast carcinoma cell lines with different endogenous DLC1 
expression levels.  
As phosphorylation of MKL1 at serine 454 is serum-inducible (Muehlich et al, 2008), HepG2, 
HuH7, MCF7 and MDA-MB-468 cells were serum starved and stimulated with serum for 30 
minutes. The phosphorylation status of MKL1 was analyzed by immunoblotting using an 
antibody that specifically recognizes MKL1 phosphorylated at serine 454.  
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Figure 21: Impaired phosphorylation of MKL1 at serine 454 in DLC1-deficient cancer cells.  
HepG2, HuH7, MCF7 and MDA-MB-468 cells were serum-starved for 16 hours overnight and afterwards stimulated 
with 20 % serum for 30 minutes. Equal amounts of total protein were analyzed by immunoblotting using the specific 
anti-phospho-MKL1 serine 454 and total anti-MKL1 antibody. Loading was controlled by re-probing the blot for 
GAPDH. The blots are representative for three individual experiments. 
Unstimulated, serum-starved hepatocellular and breast carcinoma cells showed barely any 
phosphorylation level of MKL1 at serine 454. By contrast, upon serum stimulation, 
phosphorylation of MKL1 was strongly induced in the endogenous DLC1-expressing HepG2 
and MCF-7 cells (Figure 21). On the contrary, in the DLC1-deficient HuH7 and MDA-MB-468 
cells no serum-inducible phosphorylation of MKL1 was detectable. All probed cell lines showed 
similar expression levels of endogenous total MKL1 that were not affected by serum stimulation 
(Figure 21). Remarkably, serum-inducible phosphorylation of MKL1 at serine 454 occurred 
exclusively in hepatocellular and breast carcinoma cells expressing endogenous DLC1 
whereas it was completely absent in the DLC1-deficient cancer cells.   
 
Extracellular signal-regulated kinase 1/2 (ERK1/2) was identified as the serum-inducible 
kinase mediating the phosphorylation of MKL1 at serine 454 (Muehlich et al, 2008). 
Consequently, it raised the question if the lack of MKL1 phosphorylation in the DLC1-deficient 
cancer cells reflects the absence of activated ERK1/2.  
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Figure 22: Inhibition of serum-inducible ERK1/2 kinase activation in DLC1-deficient cancer cells. 
HepG2 and HuH7 cells were serum-starved for 16 hours and subsequently stimulated with 20 % serum for the 
indicated time points. Equal amounts of total protein were immunoblotted with anti-ERKpT202/pY204 and total anti-ERK 
antibodies. The shown blots are representative of three individual experiments. Relative levels of ERKpT202/pY204 to 
total ERK were calculated from three independent experiments and graphically depicted as the mean ± SD. Shown 
is the fold induction of ERK1/2 phosphorylation upon serum stimulation in comparison to unstimulated cells. 
Serum stimulation of HepG2 cells resulted in increased phosphorylation level of ERK1/2 
(Figure 22). Quantification demonstrated a 6-fold induction of ERK1/2 activation upon serum 
stimulation. ERK1/2 phosphorylation reached a maximum after 15 minutes of serum 
stimulation. By further stimulation a decline of serum-inducible ERK1/2 activation was 
observed. However, serum stimulation of HuH7 cells was not able to induce ERK1/2 
phosphorylation. This observation was confirmed by quantification clearly pointing the absence 
of ERK1/2 phosphorylation upon serum stimulation. Our data imply that ERK1/2 activation is 
suppressed in carcinoma cells lacking endogenous DLC1 expression and accounts 
presumably for the impaired phosphorylation of MKL1 at serine 454.  
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6.1.7 Activation of MKL/SRF-dependent target gene expression in DLC1-deficient 
cancer cells 
The transcriptional activities of MKL1 and MKL2 are tightly linked with their nuclear localization. 
As DLC1 was characterized as a tumor suppressor whose loss contributes to HCC, we 
addressed the question if the nuclear accumulation of MKL1 and MKL2 in human carcinoma 
cells contributes to the activation of tumor-relevant SRF target gene expression. 
The Connective Tissue Growth Factor (CTGF, CCN2) and the cysteine-rich protein 61 (Cyr61, 
CCN1) belong to the CCN protein family. CCN proteins play a key role in biological processes 
such as cell differentiation, proliferation, adhesion, migration and angiogenesis (Leask & 
Abraham, 2006). CTGF was characterized as an immediate early gene which expression is 
regulated by SRF (Muehlich et al, 2007). It has been reported that CTGF expression is involved 
in tumor progression of hepatocellular and breast carcinoma cells (Mazzocca et al, 2010; Xie 
et al, 2001; Xiu et al, 2012). In a recently conducted microarray study, CTGF was identified as 
a MKL1/2-dependent target gene (Medjkane et al, 2009). Additionally, Cyr61 was classified as 
a MKL/SRF-dependent target gene and was described to be involved in the tumorigenic 
process of hepatocellular carcinoma (Li et al, 2012b; Medjkane et al, 2009; Selvaraj & Prywes, 
2004). Thus, we investigated the CTGF and Cyr61 expression levels in endogenous DLC1-
expressing HepG2 and MCF7 cells versus DLC1-deficient HuH7 and MDA-MB-468 cells. Cells 
were serum-starved and then serum-stimulated for 2 hours. Expression levels of CTGF and 
Cyr61 were determined by quantitative real-time PCR analysis. Serum-starved HuH7 and 
MDA-MB-468 cells revealed significantly enhanced CTGF mRNA expression levels in 
comparison to HepG2 and MCF7 cells. Serum stimulation of HepG2 and MCF7 cells strongly 
induced CTGF mRNA expression whereas HuH7 and MDA-MDA-MB 468 cells displayed 
constitutive activation of CTGF mRNA expression (Figure 23a). The same expression pattern 
was observed for Cyr61 mRNA expression in HepG2 and HuH7 cells (Figure 23b). Hence, the 
nuclear localization of MKL1/2 in DLC1-deficient hepatocellular and breast carcinoma cells 
was accompanied by the constitutive activation of MKL/SRF dependent CTGF and Cyr61 gene 
expression, both described to promote tumor progression (Li et al, 2012b; Mazzocca et al, 
2010; Xiu et al, 2012). 
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Figure 23: Upregulation of CTGF and Cyr61 mRNA expression in DLC1-deficient carcinoma cells. 
(A) HepG2, HuH7, MCF7 and MDA-MB-468 cells were serum-starved for 16 hours and afterwards stimulated with 
20 % serum for 120 minutes. Cells were harvested and total RNA was isolated and subjected to quantitative RT-
PCR using CTGF-specific primers. The amount of RNA of each sample was normalized to the endogenous 
housekeeping gene 18S rRNA. Shown is the fold increase in the amount of CTGF mRNA expression in comparison 
to unstimulated HepG2 cells. Values are represented as mean ± SD of three independent experiments. (B) Cyr61 
mRNA expression in HepG2 and HuH7 cells was measured as described in (A) using Cyr61-specific primers. 
Values are mean ± SD of two independent experiments. 
Based on our findings we supposed a direct link between endogenous DLC1 expression levels 
and the activation of MKL/SRF dependent gene expression. We used an RNAi approach and 
examined the effects of DLC1 expression on the protein expression levels of CTGF by 
immunoblotting. Downregulation of DLC1 expression in HepG2 cells induced elevated CTGF 
expression (Figure 24a). To substantiate our observation, DLC1 expression was reconstituted 
in DLC1-deficient HuH7 cells by transient transfection of wildtype human DLC1. As shown by 
real-time PCR analysis, expression of Flag-tagged DLC1 significantly suppressed CTGF 
mRNA expression (Figure 24b). Therefore it is obvious that the expression levels of the tumor 
suppressor DLC1 significantly influence the expression of tumor-relevant MKL/SRF dependent 
target genes.  
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Figure 24: Activation of CTGF expression depends on the expression levels of DLC1. 
(A) HepG2 cells were transfected with Neg. ctrl siRNA or DLC1-specific siRNA (50 nM). 96 hours posttransfection, 
cells were lysed and equal amounts of total protein were analyzed by immunoblotting using the anti-DLC1 and anti-
CTGF antibodies. Loading was controlled by re-probing the blot for HSP90. (B) HuH7 cells were transiently 
transfected with a plasmid encoding human Flag-DLC1 or the corresponding control expression vector. 24 hours 
after transfection, total cellular RNA was isolated and subjected to quantitative RT-PCR using CTGF-specific 
primers. Shown is the fold induction of CTGF-specific mRNA expression compared to HuH7 cells expressing control 
vector. Values are mean ± SD of three independent experiments. Analysis of Flag-tagged DLC1 expression was 
done by immunoblotting using anti-Flag and anti-HSP90 antibodies.  
6.1.8 MKL1/2 knockdown induces alterations of the actin cytoskeleton structure of 
DLC1-deficient cancer cells 
Recently, it was shown that depletion of MKL1 and MKL2 in highly invasive cancer cells 
reduced cell adhesion, cell motility and experimental metastasis (Medjkane et al, 2009). 
Besides, our group demonstrated that downregulation of MKL1/2 was able to revert the pro-
migratory effect caused by the loss of DLC1 (Muehlich et al, 2012). As changes in cell motility 
are associated with structural alterations of the actin cytoskeleton, we investigated the 
structure of the actin cytoskeleton of DLC1-deficient hepatocellular and breast carcinoma cells 
in dependence of MKL1/2 expression. Therefore, HuH7 and MDA-MB-468 cells with stable 
knockdown of MKL1 and MKL2, established in our laboratory, were stained with fluorescently 
labeled phalloidin.  
 
Indirect immunofluorescence analysis illustrated that depletion of MKL1/2 in DLC1-deficient 
HuH7 and MDA-MB-468 cells provoked a disorganization of stress fibers (Figure 25). Besides, 
the number of stress fibers crossing the cells was remarkably decreased upon MKL1/2 
downregulation. The quantity and length of protrusive structures, known as filopodia, were 
strongly diminished in MKL1/2 depleted HuH7 and MDA-MD-468 cells in comparison to the 
control cells. We tentatively assume that the effect of MKL1/2 depletion on the structure of the 
actin cytoskeleton is due to the influence of MKL1/2 on the transcription of genes encoding for 
actin dynamics (Olson & Nordheim, 2010).  
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Figure 25: MKL1/2 depletion in DLC1-deficient cancer cells induces disorganization of stress fibers and 
reduces the amount of filopodia. 
The actin cytoskeleton of HuH7 and MDA-MB-468 cells stably expressing either control shRNA or MKL1/2 shRNA 
was visualized by F-actin staining using ALEXA Fluor 488 phalloidin. One representative image for each cell line is 
shown.  
6.2 Effects of MKL1 and MKL2 expression on the tumor growth of 
hepatocellular carcinoma cells in vitro and in vivo 
Recently, our group reported a correlation between decreased DLC1 expression in primary 
human hepatocellular carcinomas (HCC) and the nuclear localization of MKL1 in vivo 
(Muehlich et al, 2012). It has been found that the nuclear accumulation of MKL1 correlated 
with significantly increased expression of the proliferation marker Ki-67. Expression of the 
human protein Ki-67 correlates directly with cell proliferation and is an established marker for 
the progression of hepatocellular carcinoma (Gerdes et al, 1983; King et al, 1998). As DLC1 
was initially identified as a tumor suppressor with frequent deletions in human hepatocellular 
carcinomas (Yuan et al, 1998), we focused us in the second part of this work on the effects of 
MKL1/2 expression on the growth of hepatocellular carcinoma cells with a DLC1-deficient 
background. 
6.2.1 Characterization of human hepatocellular carcinoma cell lines 
We analyzed the human hepatoma cell lines HuH7, HLF, HepG2 and HuH6 for their 
endogenous DLC1 expression levels. As shown by immunoblotting, HLF and HepG2 cells 
expressed endogenous DLC1, whereas its expression was lacking in HuH7 and HuH6 cells 
(Figure 26a). However, all probed cell lines displayed similar expression levels of endogenous 
MKL1 and MKL2 (Figure 26a). In chapter 6.1.1 and 6.1.2, the subcellular distribution of MKL1/2 
and the RhoA activation state was already shown for HepG2 and HuH7 cells. Consequently, 
HuH6 and HLF cells were analyzed. Accordingly, measurement of the RhoA activation state 
by a RhoA GLISA assay clearly depicted elevated active GTP-bound RhoA levels in the DLC1-
deficient HuH6 cells in comparison to the DLC1-expressing HLF cells (Figure 26b). Indirect 
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immunofluorescence analysis demonstrated a prevalent nuclear MKL1 staining in HuH6 cells 
meanwhile HLF cells displayed a cytoplasmic distribution of MKL1 (Figure 26c). This 
observation was confirmed by quantification clearly illustrating the nuclear distribution of MKL1 
in the DLC1-deficient HuH6 cells (Figure 26c). Hence, endogenous DLC1 expressing HepG2 
and HLF cells are characterized by a cytoplasmic localization of MKL1/2 and low RhoA activity, 
whereas the DLC1-deficient HuH6 and HuH7 cells are distinguished by nuclear accumulation 
of MKL1/2 and high active RhoA levels.  
 
 
Figure 26: Characterization of hepatocellular carcinoma cell lines with different endogenous DLC1 
expression levels. 
(A) Lysates of HuH7, HLF, HepG2 and HuH6 cells were prepared and equal amounts of total protein were 
immunoblotted with anti-DLC1, anti-MKL1, anti-MKL2 and anti-HSP90 antibody as loading control.  
(B) Active RhoA-GTP levels of HLF and HuH6 cells were assessed by an ELISA assay. Data are expressed as 
mean ± SD of two independent experiments. (C) HLF and HuH6 cells were immunostained with anti-MKL1 antibody 
and nuclei were counterstained with DAPI. Subcellular localization of endogenous MKL1 was predominantly scored 
as nuclear in 100 cells per experiment. Quantification is based on three independent experiments and data are 
represented as mean ± SD. Representative images for each cell line are shown.    
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6.2.2 Establishment of hepatocellular carcinoma cell lines with stable knockdown of 
MKL1 and MKL2 
To investigate the effects of MKL1/2 expression on tumor cell proliferation, we generated 
hepatocellular carcinoma cell lines with a stable knockdown of MKL1 and MKL2 that allows 
long-term analysis of cell proliferation. Cells were transduced with a lentiviral shRNA vector 
containing one sequence that enables simultaneously targeting both MKL1 and MKL2 (Lee et 
al, 2010b; Medjkane et al, 2009). We choose the double-knockdown strategy as studies in 
fibroblasts had shown that a single knockdown of MKL1 was not sufficient to reduce immediate 
early gene expression (Cen et al, 2003). Control cells were transduced with a lentiviral vector 
harboring a sequence that does not target known genes. The shRNA expression vector co-
expressed a puromycin-resistance gene that enabled selection of transduced cells within 7 
days. As shown by immunoblotting, transduction of HuH7, HuH6, HepG2 and HLF cells with 
MKL1/2 shRNA clearly reduced the protein expression levels of both MKL1 and MKL2 (Figure 
27). MRNA expression analysis of MKL1 and MKL2 revealed an overall knockdown efficiency 
of about 40-80 % in MKL1/2 shRNA transduced cells. For the validation of functional MKL1/2 
depletion, expression of the well-established MKL/SRF dependent target gene smooth muscle 
actin (SMA) was analyzed in MKL1/2 depleted HuH7 and HepG2 cells (Cen et al, 2003). 
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Figure 27: Establishment of hepatocellular carcinoma cell lines with a stable knockdown of MKL1 and 
MKL2. 
HuH7, HuH6, HepG2 and HLF cells were lentivirally transduced with either control shRNA or MKL1/2 shRNA and 
thereafter cells were selected with puromycin for 7 days. Lysates of cells expressing control shRNA or MKL1/2 
shRNA were prepared and equal amounts of total protein were immunoblotted using anti-MKL1, anti-MKL2 and 
anti-SMA antibodies. Loading was controlled by re-probing the blots for HSP90. Total RNA was isolated of the 
indicated cell lines and subjected to quantitative RT-PCR analysis using MKL1 and MKL2-specific primers. The 
amount of each RNA sample was normalized to the endogenous housekeeping gene 18S rRNA. Shown is the fold 
change of MKL1 and MKL2 specific mRNA expression in MKL1/2 shRNA transduced cells in comparison to control 
shRNA transduced cells. Quantifications are based on three independent experiments and data are represented as 
mean ± SD. For HuH6 cells, quantification of MKL1 and MKL2 mRNA expression is based on two independent 
experiments. 
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6.2.3 Inhibition of tumor cell proliferation of DLC1-deficient hepatocellular carcinoma 
cells upon MKL1/2 depletion 
After the establishment and characterization of hepatocellular carcinoma cell lines with stable 
MKL1/2 knockdown, we analyzed their cellular proliferation rate for 6 days. The DLC1-deficient 
HuH7 and HuH6 cells stably expressing MKL1/2 shRNA displayed a significant reduction in 
the amount of proliferating cells in comparison to the control cells (Figure 28a). The cell number 
of endogenous DLC1-expressing HepG2 and HLF cells remained unchanged upon MKL1/2 
depletion (Figure 28b). These data suggested that downregulation of MKL1/2 expression 
provoked an anti-proliferative effect in hepatocellular carcinoma cells characterized by a DLC1 
loss.   
 
 
 
Figure 28: Downregulation of MKL1/2 expression in DLC1-deficient hepatocellular carcinoma cells 
provokes an anti-proliferative effect. 
(A) The DLC1-deficient HuH7 and HuH6 cells stably expressing control shRNA or MKL1/2 shRNA were counted 
daily for 6 days. Values are mean ± SEM of three independent experiments. 
(B) Endogenous DLC1-expressing HepG2 and HLF cells stably expressing control shRNA or MKL1/2 shRNA were 
counted daily for 6 days. Values are mean ± SEM of three independent experiments. 
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6.2.4 DLC1 knockdown renders cells responsive to the anti-proliferative effect of 
MKL1/2 depletion 
The previous experiments suggested that DLC1 expression constitutes the decisive factor for 
the responsiveness of the anti-proliferative effect upon MKL1/2 knockdown. To test this, we 
used established HepG2 cells stably expressing a shRNA vector targeting human DLC1 and 
verified the reduction of endogenous DLC1 expression levels by immunoblotting that depicted 
a knockdown efficiency of 83 % on protein level (Figure 29a). MKL1 and MKL2 expression was 
downregulated by an RNAi approach, using a siRNA sequence that corresponded to the 
MKL1/2 shRNA sequence. We selected the siRNA method because we intended to analyze 
cell proliferation within a shorter period of 4 days. As shown by immunoblotting, transfection of 
HepG2 cells stably expressing DLC1 shRNA with the siRNA targeting MKL1/2 resulted in 
decreased expression of MKL1 and MKL2 compared to cells transfected with inert control 
siRNA (Neg. ctrl) (Figure 29b). Enhanced cell proliferation was observed in HepG2 cells 
expressing DLC1 shRNA in comparison to HepG2 cells expressing control shRNA. 
Downregulation of MKL1/2 expression in HepG2 cells expressing DLC1 shRNA significantly 
reversed the proliferative effect of DLC1 knockdown (Figure 29c). These data imply that DLC1 
knockdown renders cell responsive to the anti-proliferative effect of MKL1/2 downregulation.  
 
 
Figure 29: DLC1 knockdown renders cells responsive to the anti-proliferative effect of MKL1/2 
knockdown. 
(A) Protein lysates of HepG2 cells stably expressing either control shRNA or DLC1 shRNA were prepared and 
equal amounts of total protein were subjected to immunoblotting using anti-DLC1 antibody. Loading was controlled 
by re-probing the blot for HSP90. (B) HepG2 cells expressing DLC1 shRNA were transfected with either Neg. ctrl 
siRNA or siRNA MKL1/2 (50 nM). At day 4 posttransfection, cells were harvested and equal amounts of total protein 
were immunoblotted using the anti-MKL1 and anti-MKL2 antibodies. Loading was controlled by re-probing the blot 
for HSP90. (C) HepG2 cells expressing DLC1 shRNA were transfected with Neg. ctrl siRNA or siRNA MKL1/2 (50 
nM) and counted daily for 4 days. Values are represented as mean ± SEM of three independent experiments. 
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6.2.5 Increased RhoA activity is required for the anti-proliferative effect upon MKL1/2 
knockdown 
Since lack of DLC1 expression is an essential requirement for the growth arrest upon MKL1/2 
knockdown, we speculated whether the enhanced RhoA activity due to the loss of DLC1 (as 
described in chapter 6.1.4) constitutes a prerequisite for the observed growth arrest. We 
generated HepG2 cells overexpressing constitutively active RhoA (RhoAV14) the expression 
of which is driven by a rather weak Tet-off-regulated promoter. Established HepG2 cells, stably 
expressing the Tet-responsive transactivator, were transfected with the plasmid encoding the 
Tet-responsive promoter controlled Flag-tagged RhoAV14 or with the corresponding control 
expression vector. Expression of RhoAV14 was regulated by the absence or presence of 
doxycline in the culture medium for at least two days. Overexpression of constitutively active 
RhoAV14 in HepG2 cells was confirmed by immunoblotting (Figure 30a). Upon removal of 
doxycline, indirect immunofluorescence analysis illustrated a nuclear translocation of MKL1 in 
HepG2 cells expressing Flag-tagged RhoAV14 in comparison to HepG2 cells transfected with 
the control expression vector displaying a cytoplasmic distribution of MKL1 (Figure 30b). 
RhoAV14 expression was switched off by addition of doxycline and caused a cytoplasmic 
redistribution of MKL1. Simultaneously, downregulation of MKL1/2 expression in RhoAV14 
expressing HepG2 cells significantly reduced their cell proliferation (Figure 30c). However, 
unmodified HepG2 cells with low RhoA activity and cytoplasmic MKL1 localization showed no 
changes in the cell proliferation upon MKL1/2 knockdown. These findings strongly suggest that 
increased RhoA activity and the concomitant nuclear localization of MKL1 are required for the 
growth arrest induced by MKL1/2 knockdown.  
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Figure 30: Increased RhoA activity is necessary for the reduction of cell prolferation upon MKL1/2 
knockdown. 
(A) HepG2 cells expressing the Tet-responsive transactivator (Tet-Off) were transfected with either pRevTRE 
control or pRevTRE Flag-RhoAV14 expression vector, lysed and equal amounts of total protein were immunoblotted 
with anti-RhoA and anti-HSP90 antibodies. (B) HepG2 Tet-off and HepG2 Tet-off cells transfected with pRevTRE 
Flag-RhoAV14 were incubated with and without 0.5 µg/mL doxycycline (dox) for at least 2 days. Thereafter cells 
were fixed and immunostained with anti-MKL1 and anti-FLAG antibodies. Nuclei were counterstained with DAPI. 
Representative images are shown. (C) HepG2 Tet off cells expressing pRevTRE RhoAV14 were transduced with 
either control shRNA or MKL1/2 shRNA and counted daily for 4 days. Values are represented as mean ± SEM of 
three independent experiments.  
6.2.6 Determination of apoptosis 
The reduced cell proliferation upon MKL1/2 knockdown in DLC1-deficient hepatocellular 
carcinoma cells prompted us to investigate the mechanism of the anti-neoplastic effect of 
MKL1/2 knockdown. It is well established that cell proliferation and apoptotic cell death are 
tightly linked to tumor progression (Kerr et al, 1994; Williams, 1991). Apoptosis, programmed 
cell death, is a failsafe feature in malignancies and is associated with the delay or suppression 
of tumor growth (Kerr et al, 1994). Therefore we analyzed the effect of MKL1/2 on apoptosis 
by measuring activated, caspase-3 (apoptosis-related cysteine peptidase 3) because 
activation of caspases are fundamental steps in the execution of apoptosis. Caspase-3 
belongs to the group of cysteine-aspartic acid proteases and is required as a critical mediator 
for the programmed cell death in mammalian cells (Fernandes-Alnemri et al, 1994; Nicholson 
et al, 1995). HuH7 cells expressing either control shRNA or MKL1/2 shRNA were 
immunostained with an anti-active caspase-3 antibody which enables to specifically detect 
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apoptotic cells. Using indirect immunofluorescence analysis, no active-caspase-3 stained 
positive cells could be detected in either control shRNA or MKL1/2 shRNA expressing HuH7 
cells (Figure 31). Therefore we supposed that apoptosis was not responsible for the observed 
growth arrest. 
 
Figure 31: Analysis of apoptosis in MKL1/2 depleted HuH7 cells. 
HuH7 cells expressing control shRNA or MKL1/2 shRNA were immunostained with anti-active caspase-3 antibody 
and DAPI for nuclear counter staining. Representative images are given.  
6.2.7 Depletion of MKL1/2 induces a G1-phase cell cycle arrest in DLC1-deficient 
HuH7 cells 
We analyzed the cell cycle phase distribution of HuH7 and HepG2 cells expressing control 
shRNA or MKL1/2 shRNA by flow cytometry. Cells were stained with the propidium iodide dye 
which binds stoichiometrically to nuclei acids. The binding of propidium iodide is proportional 
to the DNA content of cells (Nicoletti et al, 1991). Analysis of the cell cycle phase distribution 
revealed that 37.1 % of HuH7 control cells are in G1-phase. In contrast, in HuH7 MKL1/2 KD 
cells the percentage of cells in G1-phase was significantly increased to 48.35 %. 
Simultaneously, the percentage of cells in the S-phase was significantly reduced from 45.55 
% in HuH7 control cells to 33.85 % in HuH7 MKL1/2 KD cells (Figure 32). The percentage of 
cells in the G2 phase did not differ between HuH7 control and HuH7 MKL1/2 KD cells. Analysis 
of HepG2 cells that did not respond to the anti-proliferative effect of MKL1/2 depletion, showed 
no effect of MKL1/2 knockdown on the cell cycle phase distribution (Figure 32). These data 
indicate that MKL1/2 depletion in DLC1-deficient hepatocellular carcinoma cells causes a G1-
arrest that is in line with the observed anti-proliferative-effect. 
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Figure 32: MKL1/2 depletion provokes a G1-arrest in DLC1-deficient HuH7 cells. 
HuH7 and HepG2 cells stably expressing control shRNA or MKL1/2 shRNA were stained with propidium iodide and 
the cell cycle phase distribution was examined by flow cytometry analysis. Flow cytometry analysis was kindly done 
by Natalie Frank. 
6.2.8 MKL1/2 depleted HuH7 cells feature a senescent cell morphology 
Further we investigated the cell morphology of MKL1/2 depleted HuH7 cells undergoing the 
growth arrest. In contrast to the control cells, MKL1/2 depleted HuH7 cells adopted a flattened 
and enlarged cell shape (Figure 33). Furthermore HuH7 MKL1/2 KD cells displayed increased 
granularity and a vacuole-enriched cytoplasm. As already described in chapter 6.1.8, HuH7 
cells with MKL1/2 knockdown displayed a reduction and disorganization of the actin stress 
fibers (Figure 33). 
 
Figure 33: Structural and morphological alterations of MKL1/2 depleted HuH7 cells.  
The cell morphology of HuH7 cells expressing control shRNA or MKL1/2 shRNA was analyzed by a transmitted 
light microscope. The actin cytoskeleton was visualized by Alexa Fluor 488 phalloidin binding. Representative 
images are shown.  
The described morphological and structural alterations of MKL1/2 depleted HuH7 cells were 
reminiscent of cells undergoing senescence (Angello et al, 1989; Goldstein, 1990). Cellular 
senescence is characterized as an irreversible G1-phase proliferation arrest which can be 
triggered by numerous cellular stimuli and constitutes a multifaceted process (Rittling et al, 
1986; Sherwood et al, 1988).  
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6.2.9 MKL1/2 depletion increases the senescence-associated ß-galactosidase activity 
in DLC1-deficient HCC cells 
To confirm our assumption that MKL1/2 downregulation provokes the growth arrest by 
senescence induction, we tested hepatocellular carcinoma cell lines with stable MKL1/2 
knockdown for the senescence-associated ß-galactosidase activity (SA-ß-gal). Increased 
lysosomal ß-galactosidase activity, detectable at pH 6.0, is a well-established marker for the 
determination of cellular senescence (Dimri et al, 1995). We detected a significant increase in 
the percentage of SA-ß-gal positive HuH7 cells upon MKL1/2 knockdown (Figure 34). The 
same effect was observed in DLC1-deficient HuH6 cells upon MKL1/2 knockdown, however 
to a lesser extent in comparison to HuH7 MKL1/2 KD cells. No induction of SA-ß-gal activity 
upon MKL1/2 knockdown was observed in DLC1-expressing HepG2 and HLF cells (Figure 
34). 
 
Figure 34: Increased senescence-associated ß-galactosidase activity in DLC1-deficient HCC cells upon 
MKL1/2 knockdown. 
HuH7, HuH6, HepG2 and HLF cells were transduced with either control shRNA or MKL1/2 shRNA. At day 7 
posttransduction, cells were stained for senescence-associated ß-galactosidase activity. The percentage of SA-ß-
Gal positive cells was counted under an inverted microscope. Values are given as mean ± SD of three independent 
experiments. Representative images of SA-ß-Gal positive stained cells are shown for HuH7 and HuH7 MKL1/2 KD 
cells. 
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Is the DLC1 expression status crucial for the induction of cellular senescence upon MKL1/2 
knockdown? To address this issue, we generated HepG2 cells with double knockdown of 
DLC1 and MKL1/2. As SA-ß-gal activity is a late senescence marker, a stable knockdown of 
MKL1/2 was required. HepG2 cells expressing DLC1 shRNA were lentivirally transduced with 
control shRNA and MKL1/2 shRNA and thereafter selected with puromycin for 7 days. As 
shown by immunoblotting, transduction of HepG2 DLC1 KD cells with MKL1/2 shRNA reduced 
the protein expression levels of both MKL1 and MKL2 (Figure 35). Downregulation of DLC1 
expression in HepG2 cells led to a significant upregulation of the percentage of SA-ß-gal 
positive cells upon MKL1/2 depletion in contrast to the wildtype HepG2 cells which did not 
respond (Figure 35). The phenotype of cellular senescence due to MKL1/2 depletion was 
consistent with the observed proliferation arrest caused by MKL1/2 knockdown in HCC cells 
lacking DLC1 expression.  
 
Figure 35: DLC1 depletion renders cells responsive to the induction of cellular senescence upon MKL1/2 
depletion.  
HepG2 cells expressing DLC1 shRNA and MKL1/2 shRNA were immunoblotted with anti-MKL1, anti-MKL2 and 
anti-HSP90 antibodies. Senescence-associated ß-galactosidase staining was performed and the percentage of SA-
ß-gal positive cells was counted under an inverted microscope. Values are mean ± SD of two independent 
experiments.  
6.2.10 MKL1/2 depletion in DLC1-deficient HCC cells induces oncogene-induced 
senescence via activation of oncogenic Ras signaling 
As we found that the downregulation of MKL1/2 expression triggered the cellular senescence 
response in hepatocellular carcinoma cells with a DLC1-deficient background, we aimed to get 
mechanistic insights into the MKL1/2 knockdown mediated senescence response. First of all, 
we were interested if MKL1/2 depletion activates oncogenic signaling and triggers the tumor 
suppressive oncogene-induced senescence response. The active GTP-bound Ras levels of 
HuH7 and HepG2 cells expressing control shRNA or MKL1/2 shRNA were determined by 
immunoprecipitation using an antibody that specifically detects active GTP-bound Ras.  
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Figure 36: MKL1/2 depletion increases the amount of GTP-bound Ras in DLC1-deficient HuH7 cells. 
HuH7 and HepG2 cells stably expressing either control shRNA or MKL1/2 shRNA were immunoprecipitated with 
anti-active Ras antibody and immunoblotted with total anti-Ras antibody. Equal amounts of lysates were directly 
immunoblotted with total anti-Ras antibody. The black line delineates a boundary caused by juxtaposing lanes that 
were non-adjacent in the same gel. The relative ratio of active Ras versus total Ras was quantitated and graphically 
depicted. Data are represented as mean ± SD of three independent experiments.  
The results from immunoblotting demonstrated an increased amount of GTP-bound Ras in 
HuH7 MKL1/2 KD cells compared to HuH7 control cells both expressing equal amounts of total 
Ras (Figure 36). Quantification illustrated an almost twofold upregulation of the active, GTP-
bound Ras levels in MKL1/2 depleted HuH7 cells. On the contrary, no effects on the amount 
of GTP-bound Ras levels were detected in HepG2 MKL1/2 KD cells that did not respond to the 
senescence induction. Our data provide evidence that MKL1/2 depletion activates oncogenic 
Ras signaling in HuH7 cells characterized by DLC1-deficiency. In concert with this, it is 
established that activation of oncogenic signaling can provoke the premature form of 
senescence that is termed as oncogene-induced senescence (Lin et al, 1998; Michaloglou et 
al, 2005; Serrano et al, 1997). As oncogenic signaling can elicit the oncogene-induced 
senescence response via different intrinsic pathways like the Arf/p53/p21CIP/WAF1, DNA damage 
and p16Ink4a-Rb pathway, we intended to determine their involvement in the MKL1/2 depletion 
mediated senescence response.  
6.2.11 Activation of ERK1/2 upon MKL1/2 depletion in DLC1-deficient HCC cells 
As Ras signaling activates the Raf-MEK1-ERK1/2 pathway, we tested for ERK activation by 
determining its phosphorylation status (Crews & Erikson, 1993). ERK1/2 phosphorylation 
levels were strongly increased upon MKL1/2 knockdown in the DLC1-deficient HuH7 and 
HuH6 cells but not in endogenous DLC1-expressing HepG2 and HLF cells (Figure 37). 
Moreover, ERK1/2 phosphorylation occurred to a lesser extent in HuH6 MKL1/2 KD cells in 
comparison to HuH7 MKL1/2 KD cells presumably due to other differences in the genetic 
background.  
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Figure 37: Increased ERK1/2 phosphorylation upon MKL1/2 knockdown in DLC1-deficient HCC cells.  
Protein lysates of HuH7, HuH6, HepG2 and HLF cells expressing either control shRNA or MKL1/2 shRNA were 
prepared. Equal amounts of total protein were subjected to immunoblotting using anti-ERKpT202/pY204 and total anti-
ERK antibodies.  
6.2.12 Activation of MAPK signaling is required for the MKL1/2 knockdown mediated 
proliferation arrest 
To demonstrate that activation of the Ras-Raf-MEK1-ERK1/2 signaling pathway triggers the 
MKL1/2 knockdown mediated proliferation arrest, HuH7 cells were transfected with Neg. ctrl 
siRNA and siRNA MKL1/2 and afterwards incubated with the MEK1 inhibitor UO126. As shown 
by immunoblotting, siRNA MKL1/2 transfected HuH7 cells showed reduced protein expression 
levels of MKL1 and MKL2. Suppression of ERK1/2 activation by UO126 treatment abrogated 
the anti-proliferative effect of MKL1/2 downregulation in HuH7 cells (Figure 38). Efficiency of 
UO126 treatment was determined by its ability to inhibit ERK1/2 phosphorylation (Figure 38). 
This strongly suggests that Ras-ERK signaling is involved in the anti-proliferative response 
caused by MKL1/2 knockdown. 
 
 
Figure 38: Inhibition of ERK1/2 activation abrogates the MKL1/2 knockdown mediated proliferation arrest.  
Neg. ctrl or MKL1/2 siRNA (50 nM) transfected HuH7 cells were treated with and without 10 µM UO126 and cells 
were daily counted for 4 days. Data are represented as mean ± SD of three independent experiments. Lysates of 
the transfected cells were subjected to immunoblotting using anti-MKL1, anti-MKL2, anti-HSP90, anti-ERKpT202/pY204 
and total anti-ERK antibodies. 
6.2.13 Accumulation of p16Ink4a expression in DLC1-deficient HCC cells upon MKL1/2 
depletion 
P16Ink4a functions as a tumor suppressor by inhibiting the cyclin-dependent kinases 4 and 6 
(CDK4 and CDK6) thereby inducing a G1-cell cycle arrest (Sherr & Roberts, 1999). It has been 
found that p16Ink4a expression was specifically upregulated in senescent cells and its 
expression was sufficient to trigger the senescence response (Alcorta et al, 1996; Hara et al, 
1996). As activation of mitogenic signaling promoted p16Ink4a expression, we determined the 
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p16Ink4a expression levels in the MKL1/2 depleted HCC cell lines (Lin et al, 1998; Serrano et 
al, 1997; Zhu et al, 1998). We found an accumulation of p16Ink4a protein expression in DLC1-
deficient HuH7 and HuH6 cells upon MKL1/2 depletion but not in DLC1-expressing HepG2 
cells (Figure 39). 
 
 
Figure 39: Accumulation of p16Ink4a expression in DLC1-deficient HCC cells upon MKL1/2 depletion. 
HuH7, HuH6 and HepG2 cells transduced with control shRNA or MKL1/2 shRNA were lysed and equal amounts of 
total protein were immunoblotted using anti-p16Ink4a and anti-HSP90 antibodies.  
6.2.14 Hypophosphorylation of the retinoblastoma protein upon MKL1/2 knockdown in 
DLC1-deficient HCC cells 
The retinoblastoma protein (Rb) is a well-established downstream target of p16Ink4a that 
functions as a tumor suppressor and constitutes a master regulator for the G1-S phase 
transition (Weinberg, 1995). In its active, hypophosphorylated form, the Rb protein suppresses 
the transcription of genes of the E2F transcription factor family that promote the transition from 
the G1-phase to the S-phase (Burkhart & Sage, 2008).  We analyzed the activity of the Rb 
protein by detecting changes in the electrophoretic mobility which indicated the 
phosphorylation state of the Rb protein (Connell-Crowley et al, 1997). Compared to the control 
cells, downregulation of MKL1/2 in the DLC1-deficient HuH7 and HuH6 cells produced a faster 
migrating, hypophosphorylated form of the Rb protein (Figure 40). By contrast, in HepG2 
MKL1/2 KD cells there were no detectable changes in the mobility of Rb.  
 
 
 
Figure 40: Downregulation of MKL1/2 induces hypophosphorylation of the Rb protein in HCC cells with 
DLC1-deficiency. 
HuH7, HuH6 and HepG2 cells transduced with control shRNA and MKL1/2 shRNA were lysed and equal amounts 
of total protein were subjected to immunoblotting using anti-Rb and anti-HSP90 antibodies. 
6.2.15 Requirement of the p16Ink4a-Rb pathway for the MKL1/2 knockdown mediated 
senescence response  
As the p16Ink4a -Rb pathway plays a critical role in the induction of a senescence response, we 
intended to demonstrate that induction of p16Ink4a expression upon MKL1/2 knockdown is 
required for the senescence response. Prior to lentiviral transduction with MKL1/2 shRNA, 
HuH7 cells were transfected with siRNA targeting p16Ink4a and thereafter the phosphorylation 
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state of the Rb protein was analyzed. Due to the low endogenous expression levels of the 
p16Ink4a protein in HuH7 cells, only a slight reduction of the p16Ink4a expression was detectable 
in HuH7 cells transfected with p16Ink4a specific siRNA. Downregulation of the p16Ink4a 
expression abolished hypophosphorylation of the Rb protein upon MKL1/2 knockdown (Figure 
41). As Rb lies at the core of the senescence response, the lack of Rb hypophosphorylation 
upon reduction of p16Ink4a expression substantiates the importance of the p16Ink4a-Rb signaling 
pathway for the execution of the MKL1/2 knockdown-mediated growth arrest in DLC1-deficient 
HCC cells. 
 
Figure 41: Activation of the p16Ink4a -Rb pathway is required for the senescence induction upon MKL1/2 
knockdown.  
HuH7 cells were transfected with p16Ink4a siRNA (50 nM) and after 24 hours, cells were transduced with control 
shRNA or MKL1/2 shRNA. At day 5 postinfection, cells were lysed and subjected to immunoblotting using anti-
p16Ink4a, anti-Rb and anti-HSP90 antibodies. 
6.2.16 Depletion of MKL1/2 in DLC1-deficient HCC cells induces a DNA-damage 
response 
Induction of a DNA damage response (DDR) is well established as a crucial effector 
mechanism for the induction of the oncogene-induced senescence response. Di Micco and 
colleagues showed that oncogene-induced senescence was caused by the activation of the 
DNA damage response which was characterized by increased phosphorylation of p53 on 
serine 15 (Di Micco et al, 2006).  Therefore we evaluated the phosphorylation status of p53 on 
serine 15 as an indicator for the DNA damage response. The results from immunoblotting 
demonstrated enhanced phosphorylation levels of p53 on serine 15 upon MKL1/2 depletion in 
HuH7 and HuH6 cells whereas HepG2 MKL1/2 KD cells were excluded (Figure 42).   
 
 
Figure 42: MKL1/2 knockdown induces a DNA damage response by increased phosphorylation levels of 
p53 on serine 15.  
Lysates of HuH7, HuH6 and HepG2 cells expressing control shRNA or MKL1/2 shRNA were prepared and equal 
amounts of total protein were immunoblotted with anti-phospho p53 serine 15 and total anti-p53 antibodies.  
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6.2.17 Formation of senescence-associated heterochromatin foci (SAHF) in MKL1/2 
depleted DLC1-deficient HCC cells 
Another requirement for the induction of oncogene-induced senescence is the remodeling of 
chromatin structure. Cells undergoing senescence display the formation of facultative 
heterochromatin structures, termed senescence-associated heterochromatin foci that are 
specifically enriched with heterochromatin structures like histone 3 trimethylated on lysine 9 
(H3K9me3) (Narita et al, 2003). Accumulation of SAHF suppresses the expression of 
proliferation-promoting genes like E2F target genes and induces the recruitment of Rb and 
other heterochromatin proteins (Adams, 2007; Narita et al, 2003). We tested whether MKL1/2 
knockdown affects SAHF formation by analyzing the expression level of H3K9me3 (Di Micco 
et al, 2011). Expression of H3K9me3 was elevated in HuH7 and HuH6 cells upon MKL1/2 
knockdown, but remained almost unchanged in HepG2 MKL1/2 KD cells (Figure 43). 
 
 
Figure 43: Formation of senescence-associated heterochromatin foci upon MKL1/2 knockdown. 
Lysates of HuH7, HuH6 and HepG2 cells expressing control shRNA or MKL1/2 shRNA were prepared and equal 
amounts of total protein were immunoblotted with anti-H3K9me3 and total anti-HSP90 antibodies.  
6.2.18 Senescence-messaging secretome – induction of CXCL10 and TNFSF10 
expression in MKL1/2 depleted DLC1-deficient HCC cells 
Senescent cells secrete a plethora of different interleukins, inflammatory cytokines and growth 
factors, collectively known as the senescence-messaging secretome (SMS) or senescence- 
associated secretory phenotype (SASP) (Coppe et al, 2010; Kuilman & Peeper, 2009). 
Induction of the SMS has multiple facets, it can feature pro-tumorigenic as well as tumor 
suppressive functions by reinforcing a permanent cell cycle arrest (Acosta et al, 2008a; Krtolica 
et al, 2001). Expression of the chemokine (C-S-C motif) ligand 10 (CXCL10) and tumor 
necrosis factor (ligand) superfamily member 10 (TNFSF10) promote the senescence response 
of human cancers (Braumuller et al, 2013). We analyzed the mRNA expression levels of 
CXCL10 and TNFSF10 in our HCC cell lines with a stable MKL1/2 knockdown. We found a 
significant upregulation of the CXCL10 mRNA expression in HuH7 MKL1/2 KD cells in 
comparison to the HuH7 control cells (Figure 44a). Besides, CXCL10 mRNA expression was 
4-fold induced in HuH6 cells upon MKL1/2 knockdown whereas no effect was observed in 
HepG2 cells depleted of MKL1/2. Simultaneously, TNFSF10 mRNA expression was 
significantly increased in HuH7 MKL1/2 KD cells in contrast to HepG2 cells where MKL1/2 
knockdown did not influence the mRNA expression levels of TNFSF10 (Figure 44b).  
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Figure 44: Upregulation of CXCL10 and TNFSF10 mRNA expression in DLC1-deficient HuH7 and HuH6 
cells upon MKL1/2 depletion. 
Total RNA was isolated from HuH7, HuH6 and HepG2 cells transduced with control shRNA or MKL1/2 shRNA and 
subjected to quantitative RT-PCR using (A) CXCL10 and (B) TNFSF10-specific primers. The amount of RNA of 
each sample was normalized to the endogenous housekeeping gene 18S rRNA. Shown is the fold increase of (A) 
CXCL10 and (B) TNFSF10 specific mRNA expression. Values are mean ± SD of three independent experiments. 
Quantification of HuH6 cells is based on two independent experiments. 
6.2.19 Overexpression of the constitutively activated Ras allele (H-RasV12) induces 
senescence in DLC1-deficient HCC cells  
So far MKL1/2 depletion in DLC1-deficient HCC cells provokes a growth arrest. Evaluation of 
different senescence markers indicated that oncogene-induced senescence is the underlying 
mechanism of the growth arrest. Ras and its downstream targets were well established as 
inducers of the oncogene-induced senescence response (Michaloglou et al, 2005; Serrano et 
al, 1997; Zhu et al, 1998). Assuming that the increase of the Ras activity caused by MKL1/2 
knockdown is the critical trigger for the induction of the oncogene-induced senescence 
response in DLC1-deficient HCC cells, we expressed the constitutively active ras allele (H-
rasV12) in HuH7 and HuH6 cells. HuH7 and HuH6 cells were retrovirally transduced with a 
plasmid encoding human H-RasV12 or with the corresponding control vector and at day 5 
posttransduction the expression of the oncogene-induced senescence markers was evaluated 
by immunoblotting. Expression of constitutively active H-rasV12 in HuH7 and HuH6 cells 
induced increased phosphorylation of ERK1/2, accumulation of p16Ink4a expression, 
hypophosphorylation of Rb and enhanced phosphorylation of p53 on serine 15 (Figure 45). 
Obviously, the expression of active Ras triggered oncogene-induced senescence in human 
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hepatocellular carcinoma cells, deficient in DLC1. Expression of active Ras resulted in the 
same expression pattern of oncogene-induced senescence markers like MKL1/2 depletion. 
Therefore we conclude that the activation of Ras signaling upon MKL1/2 knockdown triggers 
the proliferation arrest caused by the oncogene-induced senescence response.  
 
 
Figure 45: Expression of the constitutively active ras allel (H-rasV12) provokes oncogene-induced 
senescence in DLC1-deficient HCC cells. 
HuH7 and HuH6 cells were retrovirally infected with pBabe H-RasV12 or pBabe control vector. At day 5 
posttransduction, cells were harvested and lysed. Equal amounts of total protein were subjected to immunoblotting 
using anti-ERKpT202/pY204, total anti-ERK, anti-p16Ink4a, anti-Rb, anti-phospho p53 serine 15, total anti-p53 and anti-
HSP90 antibodies. 
6.2.20 Reconstitution of DLC1 expression in HuH7 cells induces cellular senescence 
We recently published that MKL1/2 depletion counteracts the tumorigenic properties of loss of 
the tumor suppressor DLC1 in hepatocellular and breast carcinoma cells (Muehlich et al, 
2012). To check whether MKL1/2 knockdown in DLC1-negative cells may substitute for the 
tumor suppressive function of DLC1, we generated a stable Tet-off HuH7 cell line expressing 
human GFP-DLC1 upon removal of doxycycline. HuH7 cells stably expressing the tet-
responsive transactivator were transfected with human GFP-DLC1 which expression is 
regulated by a doxycycline regulated promoter. The expression vector of GFP-DLC1 
coexpressed a hygromycin gene that allowed the selection of transfected cells. Removal of 
doxycycline induced the exogenous expression of DLC1 in HuH7 cells which featured a 
concomitant lower proliferation rate in comparison to HuH7 control cells lacking endogenous 
DLC1 expression (Figure 46a+b). Addition of doxycycline also slightly reduced the cell 
proliferation rate that was presumably due to the residual exogenous DLC1 as shown by 
immunoblotting. Flow cytometry analysis revealed that upon reconstitution of DLC1 expression 
HuH7 cells accumulated in the G1 phase and exhibited a concomitant reduction of the S-phase 
(Figure 46c).  
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Figure 46: Reconstitution of DLC1 expression in DLC1-negative HuH7 cells reduces tumor cell 
proliferation. 
(A) HuH7 cells stably expressing the tet-responsive transactivator (HuH7 Tet off) were transfected with a plasmid 
encoding human GFP-DLC1. Transfected cells were selected with hygromycin for 7 days and thereafter cells were 
treated with and without 0.5 µg/mL doxycycline (dox). Cells were harvested, lysed and equal amounts of total protein 
were subjected to immunoblotting using anti-DLC1 and anti-HSP90 antibodies. (B) The indicated cell lines were 
counted daily for 4 days. Values are mean ± SEM of two independent experiments. (C) Cell cycle phase distribution 
of HuH7 Tet-off and HuH7 Tet-off DLC1 cells in the absence of doxycycline was determined by flow cytometry 
analysis. Values are mean ± SD of three individual experiments. Flow cytometry analysis was kindly done by Natalie 
Frank. 
As DLC1 reconstitution in HuH7 cells resembled to the effects of MKL1/2 depletion on tumor 
cell proliferation, we investigated if cellular senescence was the underlying mechanism. 
Overexpression of DLC1 significantly elevated the percentage of SA-ß-gal positive HuH7 cells 
(Figure 47a). DLC1-expressing HuH7 cells revealed an enlarged flat cell morphology and the 
cytoplasm was enriched with vacuoles (Figure 47a). Analysis of different senescence markers 
demonstrated that the reconstitution of DLC1 expression in HuH7 cells induced increased 
ERK1/2 phosphorylation, enhancement of p16Ink4a expression, hypophosphorylation of Rb, 
increased methylation of histone H3 at lysine 9 and enriched phosphorylation of p53 on serine 
15 (Figure 47b). Addition of doxycycline eliminated the induction of the senescence markers. 
These data led to the conclusion that the induction of cellular senescence is part of the tumor 
suppressive properties of DLC1. In relation to our previous results we assume that 
downregulation of MKL1/2 expression mimics the effects of DLC1 reconstitution.  
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Figure 47 : Induction of cellular senescence in HuH7 cells upon DLC1 reconstitution. 
(A) HuH7 Tet-off and HuH7 Tet-off DLC1 cells cultivated without doxycycline were assessed for senescence- 
associated ß-galactosidase activity. Values are mean ± SD of three independent experiments. Representative 
images of the cell morphology are shown. (B) HuH7 Tet-off and HuH7 Tet-off DLC1 cells cultivated without and with 
0.5 µg/mL doxycycline (dox) were immunoblotted with anti-ERKpT202/pY204, total anti-ERK, anti-p16Ink4a, anti-Rb, anti-
H3K9me3, anti-phospho p53 serine 15, total anti-p53 and anti-HSP90 antibodies. (With experimental help of 
Claudia Martin)  
6.2.21 Evaluation of MKL1/2 as efficient anti-tumor targets in vivo 
Our results obtained in vitro demonstrated that MKL1/2 represent efficient anti-tumor targets 
for the treatment of DLC1-deficient hepatocellular carcinoma cells by inducing the tumor 
suppressive oncogene-induced senescence response. A recently published study 
demonstrated that the injection of MKL1/2 depleted breast carcinoma cells into the mouse tail 
vein abolished the formation of lung metastases (Medjkane et al, 2009).  However, there is 
little knowledge about the function role of MKL1/2 expression on tumor progression in vivo. 
One major aim of our study was to analyze the influence of MKL1/2 expression on the tumor 
growth of DLC1-deficient HCC cells in vivo. We decided to use a RNA-interference approach 
to evaluate the therapeutic efficacy of MKL1/2 downregulation as this method allows to explore 
the specific function of disease-related genes in vivo. The delivery of small molecules in vivo 
is very limited due to their instability, charge and low molecular weights and requires specific 
nanoparticle formulations for their in vivo application. SiRNA molecules were complexed with 
the low molecular weight branched polyethylenimine (PEI) F25-LMW which is well established 
as an efficient carrier system for the delivery of siRNA molecules in vivo due to its low 
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cytotoxicity and high biological activity (Hobel & Aigner, 2010; Hobel & Aigner, 2013). 
Polyethylenimine complexation protects siRNAs from nucleolytic degradation and allows the 
delivery of intact siRNA molecules into different organs like subcutaneous tumors, muscle, 
liver, kidney and to a lesser extent to lung and brain (Urban-Klein et al, 2005). Moreover, 
polyethylenimine complexation allows the systemic, intraperitoneal application of siRNA 
molecules which was preferred in our setting due to the higher relevance in a therapeutic 
setting (Hobel et al, 2010).  
 Functional characterization of siRNAs targeting MKL1 and MKL2. 
First of all, we validated different siRNAs targeting MKL1 and MKL2 for their ability to efficiently 
downregulate the protein expression of MKL1 and MKL2 in HuH7 cells. We used an MKL1/2 
siRNA that simultaneously targets both MKL1 and MKL2 and corresponds to the MKL1/2 
shRNA sequence. Furthermore, we used a combination of MKL1 and MKL2-specific siRNAs 
and MKL1 siRNA alone, as we intended to examine the influence of a single knockdown. The 
results from immunoblotting indicated that the MKL1 and MKL2 specific siRNAs are sufficient 
to downregulate the protein expression of MKL1 and MKL2 in HuH7 cells (Figure 48a). 
Knockdown efficiency of the MKL1/2 siRNA had already been shown in chapter 6.2.12. For 
the evaluation of the functional depletion of MKL1 and MKL2, we examined the protein 
expression levels of the well-established MKL1/2 dependent target gene smooth muscle actin 
(Cen et al, 2003). As shown by immunoblotting, SMA protein expression was strongly 
suppressed in HuH7 cells transfected with MKL1/2 siRNA, MKL1+MKL2 siRNA and MKL1 
siRNA (Figure 48b). 
 
Figure 48: Validation of siRNAs targeting MKL1 and MKL2. 
(A) HuH7 cells were transfected with either Neg. ctrl siRNA (50 nM), MKL1 siRNA (50 nM) or a combination of 
MKL1 and MKL2 siRNAs (each 25 nM). 48 hours after transfection, cells were harvested and equal amounts of total 
protein were immunoblotted with anti-MKL1, anti-MKL2 and anti-HSP90 antibodies. (B) Lysates of HuH7 cells 
transfected with Neg. ctrl siRNA, MKL1/2 siRNA, MKL1 siRNA or a combination of MKL1 and MKL2 siRNAs were 
prepared and equal amounts of total protein were subjected to immunoblotting using anti-SMA and anti-HSP90 
antibodies. 
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 Downregulation of MKL1/2 expression reduces tumor growth of DLC1-
deficient HCC xenografts 
To investigate whether MKL1/2 depletion affects the tumor growth of DLC1-deficient HCC cells 
in vivo, we aimed to treat well established tumor xenografts derived from HuH7 cells 
systemically by the intraperitoneal injection of PEI-complexed siRNAs targeting MKL1 and 
MKL2. Additionally, we were interested if MKL1 and MKL2 can act redundantly in the context 
of HCC tumor growth and intended therefore to evaluate the effect of the MKL1-specfic siRNA 
on tumor growth. For the generation of the subcutaneous tumors, HuH7 cells were implanted 
into the left and right flank of 6 week old female, athymic nude mice. Within 7 days solid tumors 
were established and mice were treated systemically by intraperitoneal injection of PEI 
complexed siRNAs three times a week. As control groups, we used mice which remained 
untreated and one control group was treated with PEI-complexed control siRNA that does not 
target known genes. 28 days after tumor cell implantation, the tumor growth of HuH7 derived 
xenografts treated with MKL1/2 and MKL1 specific siRNAs was completely suppressed (Figure 
49a). By contrast, in the MKL1+2 specific treatment group, one out of six mice carried a tumor, 
but its tumor volume was lesser compared to the tumors of the control groups (Figure 49a). At 
day 28 after HuH7 cell injection, downregulation of MKL1 and MKL2 expression in the tumors 
was analyzed by quantitative real-time PCR. Tumors treated with MKL1+2 siRNA revealed a 
strong reduction of the mRNA expression levels of both MKL1 and MKL2 (Figure 49b). In 
addition, we found that the regression of the tumors of mice treated with MKL1+2 specific 
siRNA correlated with decreased mRNA expression of the proliferation marker Ki-67 (Figure 
49c). 
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Figure 49: Anti-tumor effects of therapeutic MKL1/2 knockdown in vivo. 
(A) HuH7 cells were subcutaneously injected into the right and left flank of 6-week old, female athymic nude mice. 
Upon establishment of subcutaneous HuH7 cells derived tumor xenografts, tumor-bearing mice were randomized 
into control and treatment groups. Three times per week, mice were systemically treated by intraperitoneal injection 
of 15 µg Neg. ctrl siRNA, MKL1/2 siRNA, MKL1+2 siRNA and MKL1-specific siRNA, each complexed with 
polyethylenimine (PEI). One control group remained untreated. Values are mean ± SEM. Upper panel represents 
example of mice of each treatment and control group and tumors are indicated by arrows.  
(B) Total RNA from HCC xenografts treated with Neg. ctrl siRNA and MKL1+2 siRNA was isolated and subjected 
to quantitative RT-PCR using MKL1 and MKL2-specific primers. The RNA amount of each tumor sample was 
normalized to the endogenous housekeeping gene 18S rRNA. Shown is the fold decrease of MKL1 and MKL2 
mRNA expression in MKL1+2 siRNA treated tumors in comparison to Neg. ctrl siRNA treated tumors. Values are 
expressed as mean ± SD of two independent RNA isolations from one xenograft specimen.  
(C) Relative Ki-67 mRNA expression of MKL1+2 siRNA and Neg. ctrl siRNA treated tumors was determined by 
quantitative real-time PCR as described in (B) using Ki-67-specific gene primers. Values are represented as mean 
± SD of two independent RNA isolations from one xenograft specimen.  
 MKL1/2 depletion in HCC xenografts induces senescence in vivo 
Our findings demonstrated that depletion of MKL1/2 inhibited growth of DLC1-deficient HCC 
xenografts. These findings prompted us to investigate the underlying molecular mechanism of 
the observed tumor growth inhibition in vivo. We analyzed the HCC xenografts from mice 
treated with MKL1+2 specific siRNA for the different oncogene-induced senescence markers 
which were regulated by the MKL1/2 knockdown mediated oncogene-induced senescence 
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response in vitro. The results from the quantitative real-time PCR analysis showed strongly 
induced p16Ink4a mRNA expression levels in MKL1+2 siRNA treated tumors in comparison to 
neg. ctrl treated tumors (Figure 50a). Results from immunoblotting revealed increased 
expression levels of histone H3 methylated on lysine 3 (H3K9me3) and an accumulation of 
p53 phosphorylated on serine 15 in tumors of mice treated with MKL1+2 siRNA (Figure 50b). 
Additionally, we detected enhanced CXCL10 mRNA expression in MKL1+2 siRNA treated 
tumors that has been identified as a component of the senescence-messaging secretome 
upon MKL1/2 knockdown (Figure 50c). These data demonstrate that downregulation of MKL1 
and MKL2 expression inhibits HCC xenograft growth by inducing senescence in vivo. 
 
 
Figure 50: MKL1/2 downregulation induces senescence in vivo. 
(A) Total RNA from HCC xenografts treated with Neg. ctrl siRNA and MKL1+2 siRNA was isolated and subjected 
to quantitative RT-PCR using p16Ink4a -specific primers. The RNA amount of each tumor sample was normalized to 
the endogenous housekeeping gene 18S rRNA. Shown is the fold induction of p16Ink4a mRNA expression in 
MKL1+2 siRNA treated tumors in comparison to Neg. ctrl siRNA treated tumors. Values are expressed as mean ± 
SD of two independent RNA isolations from one xenograft specimen. (B) Lysates from xenografts treated with either 
Neg. ctrl siRNA or MKL1+2 siRNA were prepared and equal amounts of total protein were analyzed by 
immunoblotting using anti-H3K9me3, anti-phospho p53 serine 15, total anti-p53 and anti-HSP90 antibodies. (C) 
Relative CXCL10 mRNA expression of Neg. ctrl siRNA and MKL1+2 siRNA treated tumors was analyzed by 
quantitative RT-PCR as described in (A) using CXCL10-specific gene primers. Values are expressed as mean ± 
SD of two independent RNA isolations from one xenograft specimen. 
6.2.22 MKL1/2 knockdown does not influence the RhoA activity of DLC1-deficient 
HuH7 cells 
Our data provided evidence that MKL1/2 depletion activated oncogenic Ras signaling in DLC1-
deficient HCC cells thereby triggering the oncogene-induced senescence response. However, 
it remained to be clarified how MKL1/2 depletion can mechanistically induce Ras activation by 
enhancing the GTP-bound levels of Ras. An inverse correlation between RhoA and ERK 
activity was reported by Morin and colleagues who showed a reduced ERK activity in cells 
overexpressing constitutively active RhoA (Morin et al, 2009). As DLC1-deficient carcinoma 
cells are characterized by constitutive activation of RhoA, we tested whether activation of Ras-
ERK signaling upon MKL1/2 depletion was due to changes in the RhoA activity. We studied 
the RhoA activation status in HuH7 cells expressing control shRNA and MKL1/2 shRNA by a 
RhoA GLISA assay. The amount of active GTP-bound RhoA was not changed upon MKL1/2 
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depletion in HuH7 cells (Figure 51). We concluded that MKL1/2 knockdown does not influence 
the RhoA activity.  
 
Figure 51: RhoA activation status in MKL1/2 depleted HuH7 cells. 
Active RhoA-GTP levels of HuH7 cells expressing either control shRNA or MKL1/2 shRNA were assessed by an 
ELISA assay. Values are mean ± SD of three independent experiments. 
6.2.23 MKL1/2 depletion does not affect the expression levels of mig6 
We hypothesized that a target gene of MKL1/2 could mediate the effect on Ras activation. 
Descot and colleagues had described a negative feedback mechanism between the actin-
MKL1 and the EGFR-MAPK signaling pathway via the MKL target gene mig6 (Descot et al, 
2009). To learn whether mig6 has an influence on the activation of the MAPK cascade in our 
model, we determined the mig6 mRNA expression levels in MKL1/2 depleted HuH7 cells. 
Quantitative RT-PCR analysis revealed no distinctive difference in the amount of mig6 mRNA 
expression levels between MKL1/2 depleted HuH7 cells and the corresponding control cells 
(Figure 52). Obviously, mig6 expression is not addressed by MKL1/2 in DLC1-deficient 
hepatocellular carcinoma cells.  
 
Figure 52: Mig6 mRNA expression in MKL1/2 depleted HuH7 cells. 
Total RNA from HuH7 cells expressing control shRNA or MKL1/2 shRNA was isolated and subjected to quantitative 
RT-PCR using mig6-specific primers. The amount of RNA of each sample was normalized in respect to the 
endogenous housekeeping gene 18S rRNA. Shown is the fold change of mig6-specific mRNA expression. Data are 
represented as mean ± SD of two independent experiments.  
Results 
 
85 
6.3 Identification and characterization of novel MKL1/2 dependent target 
genes in DLC1-deficient hepatocellular carcinoma cells 
6.3.1 DNA-microarray analysis of MKL1/2 depleted HuH7 cells 
It appears that depletion of MKL1/2 expression abolish the tumor growth of hepatocellular 
carcinomas with DLC1-deficiency. We aimed to identify target genes that are regulated by 
MKL1/2 expression and are functionally implicated the in the regression of the tumor growth. 
We analyzed the transcriptome of HuH7 control cells and MKL1/2 depleted HuH7 cells by a 
DNA-microarray study. To identify the target genes which expression was controlled MKL1/2 
signaling, we compared the datasets of both settings and found that 8 genes were 
downregulated more than 2.5 fold upon MKL1/2 depletion (Table 4).  
 
 
Table 4: DNA-microarray based transcriptome analysis of MKL1/2 depleted HuH7 cells. 
The transcriptome of HuH7 cells expressing either control shRNA or MKL1/2 shRNA was analyzed by a DNA 
microarray analysis. Genes are sorted according to the average fold of downregulation upon MKL1/2 depletion and 
the corresponding p-values are given. The threshold for MKL1/2 dependence was taken as 2.5 fold downregulation. 
We validated the results obtained from DNA microarray analysis by quantitative real-time PCR 
analysis. Our data confirmed that MKL1/2 depletion in the DLC1-deficient HuH7 cells 
significantly suppressed the mRNA expression levels of transgelin (SM22), GLI-pathogenesis 
related 1 (GLIPR1), calponin (CNN1), heavy chain 9, non-muscle (MYH9), transforming growth 
factor beta 1 (TGFß1), vestigial like 3 (VGLL3), microtubule-associated protein 1B (MAPB1) 
and myoferlin (MYOF) (Figure 53). We concluded that the expression of these target genes 
are regulated by the transcriptional coactivators MKL1 and MKL2 in the DLC1-negative HuH7 
cells. Numerous gene expression studies already reported that the expression of transgelin is 
controlled by MKL/SRF dependent signaling in different cell types like human fibroblasts or 
smooth muscle cells (Cen et al, 2003; Descot et al, 2009; Du et al, 2004; Wang et al, 2002). 
Calponin was described as a target gene which expression is regulated by actin-MKL1 
signaling (Descot et al, 2009). A recent conducted gene expression analysis in human breast 
gene 
assignment 
gene symbol fold 
change 
p-value 
NM_001152 Transgelin / smooth muscle protein 22-alpha 
(SM22) 
6.42 0.0047 
NM_006851 GLI pathogenesis – related 1 (GLIPR1) 5.68 0.0010 
NM_001299 Calponin (CNN1) 5.58 0.005 
NM_002473 Heavy chain 9, non – muscle MYH9 4.78 0.014 
NM_000660 Transforming growth factor beta 1 (TGFß1) 3.82 0.015 
NM_016206 Vestigial like 3 (VGLL3) 3.67 0.0083 
NM_005909 Microtubule-associated protein 1B (MAPB1) 3.17 0.0012 
NM_013451 Myoferlin (MYOF) 2.86 0.0063 
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carcinoma cells revealed that MYH9 and VGLL3 are target genes of MKL1/2 (Medjkane et al, 
2009). Notably, MKL1/2 dependent target gene expression of GLIPR1, TGFß1, MAP1B and 
MYOF has not been noticed before and constitute a novel cluster of target genes which 
expression is regulated by MKL1/2 signaling in DLC1-deficient HuH7 cells. 
 
Figure 53: Validation of MKL1/2 dependent target gene expression in HuH7 cells. 
HuH7 cells were lentivirally transduced with either control shRNA or MKL1/2 shRNA and total RNA was extracted. 
MRNA expression was measured by quantitative RT-PCR using gene specific primers for SM22, GLIPR1, CNN1, 
MYH9, TGFß1, VGLL3, MAPB1 and MYOF. The amount of each RNA sample was normalized to the endogenous 
housekeeping gene 18S rRNA. Shown is the fold decrease of gene specific mRNA expression of MKL1/2 depleted 
HuH7 cells in comparison to HuH7 control cells. Values are represented as mean ± SD of three independent 
experiments. 
Next we analyzed their mRNA expression levels in HuH7 cells derived tumor xenografts that 
were treated with MKL1+2 specific siRNA as described in chapter 6.2.21.2. 
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Figure 54: Analysis of the MKL1/2 dependent target gene expression in HCC xenografts in vivo. 
Total RNA from xenografts treated with either PEI/Neg. ctrl siRNA or PEI/MKL1+2 specific siRNA was isolated and 
subjected to quantitative RT-PCR using gene specific primers for SM22, GLIPR1, CNN1, MYH9, TGFß1, VGLL3, 
MAPB1 and MYOF. The RNA amount of each tumor sample was normalized with respect to the endogenous 
housekeeping gene 18S rRNA. Shown is the fold change of gene specific mRNA expression in PEI/MKL1+2 siRNA 
treated tumors in comparison to PEI/Neg. ctrl siRNA treated tumors. Values are represented as mean ± SD of two 
RNA isolations from one xenograft specimen.  
Results from quantitative RT-PCR analysis revealed that mRNA expression of GLIPR1, CNN1, 
MYH9, TGFß1, MAPB1 and MYOF was strongly reduced in tumors from mice treated with 
PEI/MKL1+2 siRNA in comparison to tumors treated with PEI/Neg.ctrl siRNA (Figure 54). On 
the contrary, SM22 mRNA expression was upregulated in xenografts treated with MKL1+2 
specific siRNA. Therefore the observed upregulation of SM22 mRNA expression in vivo is 
opposite to the downregulation of SM22 expression upon MKL1/2 depletion in vitro. VGLL3 
mRNA expression levels were not reduced upon MKL1/2 knockdown in vivo suggesting that 
VGLL3 expression is not influenced by MKL1/2 in HCC xenograft growth in vivo. 
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6.3.2 Regulation of MYOF expression by the transcriptional coactivators MKL1/2 
In order to prove that MYOF expression is regulated by the transcriptional coactivators MKL1 
and MKL2, we studied the influence of exogenous expression of MKL1 on MYOF expression. 
HuH7 cells were transiently transfected with MKL1+2 specific siRNA. As the MKL1-specific 
siRNA targets MKL1 within the first 100 N-terminal amino acids, MKL1 expression was 
reconstituted by the transfection of the siRNA-resistant ΔN100 MKL1 mutant lacking the first 
100 N-terminal amino acids of MKL1 that contain the RPEL motifs required for actin binding. It 
was shown that the ΔN100 MKL1 mutant is nuclear localized and is transcriptionally 
constitutively activated (Miralles et al, 2003). MYOF mRNA expression analysis by quantitative 
real-time PCR illustrated that MYOF mRNA expression was significantly reduced upon MKL1/2 
knockdown in comparison to HuH7 cells transfected with inert siRNA. In contrast, exogenous 
expression of the ΔN100 MKL1 mutant in MKL1/2 depleted HuH7 cells induced a 4-fold 
upregulation of MYOF mRNA expression compared to the control cells (Figure 55a). 
Expression of the ΔN100 MKL1 mutant was analyzed by immunoblotting for its expression of 
the Flag-tag (Figure 55b). Downregulation of MKL1 expression in MKL1+2 specific siRNA 
transfected HuH7 cells was confirmed by immunoblotting (Figure 55b). Reconstitution of MKL1 
expression was shown by enhanced MKL1 protein expression levels. Thus, MYOF gene 
expression was directly controlled by transcriptional coactivators MKL1 and MKL2.  
 
 
Figure 55: MYOF mRNA expression is directly regulated by the transcriptional coactivators MKL1 and 
MKL2. 
(A) HuH7 cells were transiently transfected with Neg. ctrl siRNA (50 nM) and MKL1 and MKL2 specific siRNAs 
(each 25 nM). After 18 hours, cells were transfected with a DNA plasmid encoding the Flag-ΔN100 MKL1 mutant. 
After additional 24 hours, cells were harvested and total cellular RNA was extracted and subjected to quantitative 
RT-PCR using MYOF-specific gene primers. The amount of RNA each sample was normalized with respect to the 
endogenous housekeeping gene 18S rRNA. Shown is the fold change of MYOF mRNA expression referring to 
HuH7 cells transfected with Neg. ctrl siRNA. Values are mean ± SD of three independent experiments. (B) Lysates 
of HuH7 cells transfected as described in (A) were prepared and equal amounts of total protein were immunoblotted 
with anti-Flag, anti-MKL1, anti-MKL2 and anti-HSP90 antibodies. 
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6.3.3 Myoferlin is a SRF dependent target gene 
To date, MYOF has not been functionally characterized as a SRF target gene nor has a 
conserved SRF binding site within the promoter of MYOF been reported. As MKL1/2 were 
transcriptional coactivators of the nuclear transcription factor SRF, we were interested whether 
MYOF expression directly depends on the expression of SRF. HuH7 cells were transfected 
with siRNA targeting SRF and afterwards MYOF expression was analyzed by quantitative real-
time PCR. The results demonstrated that downregulation of SRF mRNA expression in HuH7 
cells simultaneously reduced MYOF mRNA expression (Figure 56). This put MYOF in the 
position as a novel SRF target gene and we assumed that a SRF binding site resides within 
the transcription start site of the MYOF gene. 
 
   
 
Figure 56: Myoferlin expression depends on SRF expression. 
HuH7 cells were transiently transfected with Neg. ctrl siRNA and SRF-specific siRNA (50 nM). 72 hours after 
transfection, total RNA was extracted and subjected to quantitative RT-PCR using SRF and MYOF-specific primers. 
The amount of each sample was normalized to 18S rRNA expression. Shown is fold change of mRNA expression 
of SRF-specific siRNA transfected HuH7 cells in comparison to Neg. ctrl transfected HuH7 cells. Values are 
expressed as mean ± SD of three independent experiments.  
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6.3.4 Downregulation of DLC1 expression activates mRNA expression of myoferlin 
MYOF was identified as a gene the expression of which is regulated by MKL/SRF signaling in 
hepatocellular carcinoma cells lacking endogenous DLC1 expression. We aimed to identify 
whether the expression level of DLC1 has an influence on the MKL/SRF dependent target 
gene expression of MYOF. DLC1 expression was downregulated in HepG2 cells via an RNAi 
mediated approach and the resulting MYOF mRNA expression levels were determined by 
quantitative real-time PCR. Transfection of endogenous DLC1-expressing HepG2 cells with 
DLC1-specific siRNA strongly reduced the mRNA expression levels of DLC1 compared to 
HepG2 cells transfected with Neg. ctrl siRNA (Figure 57). In contrast, downregulation of DLC1 
expression led to a significant upregulation of MYOF mRNA expression. These findings 
indicate that loss of DLC1 promotes MYOF expression. We concluded that increased MYOF 
expression upon DLC1 downregulation was due to the nuclear localization of MKL1/2 that was 
linked to the activation of the transcription of MKL/SRF dependent target genes. 
 
 
 
Figure 57: Downregulation of DLC1 expression increases MYOF mRNA expression. 
HepG2 cells were transfected with Neg. ctrl siRNA or DLC1-specific siRNA (50 nM) and 96 hours after transfection, 
total RNA was isolated. MRNA expression was measured by quantitative RT-PCR analysis using gene specific 
primers for DLC1 and MYOF. The RNA amount of each sample was normalized with respect to 18S rRNA 
expression. Shown is the fold change of DLC1 and MYOF mRNA expression in HepG2 cells transfected with DLC1-
specific siRNA in comparison to Neg. ctrl transfected HepG2 cells. Values are means ± SD of three independent 
experiments. 
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6.3.5 Knockdown of myoferlin reduces tumor cell invasion of HuH7 cells 
To investigate the functional role of MYOF expression in DLC1-deficient hepatocellular 
carcinoma cells, we analyzed its effect on tumor cell invasion. MYOF expression was silenced 
by an RNAi approach in HuH7 cells, and we analyzed their ability to invade through inserts 
coated with extracellular matrix (ECM) in response to FCS stimulation as a chemoattractant 
for a period of 24 hours. Reduction of MYOF expression strongly diminished the number of 
invaded HuH7 cells compared to the control cells (Figure 58a). Downregulation of MYOF 
expression in HuH7 cells transfected with MYOF-specific siRNA was confirmed by 
immunoblotting (Figure 58b). Essentially, MYOF expression affects the invasiveness of 
hepatocellular carcinoma cells characterized by a DLC1-deficient background. 
 
Figure 58: Myoferlin depletion inhibits tumor cell invasion of HuH7 cells. 
(A) HuH7 cells were transfected with Neg. ctrl siRNA and MYOF-specific siRNA (50 nM). 48 hours after transfection, 
cells were seeded into the upper well of a Transwell® insert and allowed to invade through extracellular matrix 
towards the lower chamber containing 10 % FCS for a period of 24 hours. Invaded cells were fixed with methanol 
and visualized by toluidine blue staining. Representative images are shown. The graph illustrates the relative 
invasion of HuH7 cells with Neg. ctrl siRNA transfected HuH7 cells set to 100 %. (B) Lysates of cells transfected as 
described in (A) were prepared and equal amounts of total protein were subjected to immunoblotting using the anti-
MYOF antibody. Loading was controlled by re-probing the blot for HSP90.  
6.3.6 Depletion of myoferlin inhibits tumor cell proliferation of HuH7 cells 
To study the influence of MYOF expression on tumor cell proliferation, we generated a cell line 
with stable knockdown of MYOF that allows long-term analysis of cell proliferation. HuH7 cells 
were transduced with a shRNA vector that targets specifically human MYOF. The shRNA 
expression vector coexpressed a puromycin-resistance gene that enabled the selection of 
transduced cells within 7 days. As shown by immunoblotting, lentiviral transduction of HuH7 
cells with MYOF shRNA strongly reduced the protein expression levels of MYOF (Figure 59a). 
Analysis of the cell proliferation demonstrated that downregulation of MYOF expression 
significantly inhibited the proliferation rate of HuH7 cells in comparison to the control cells 
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(Figure 59b). These findings highlighted that MYOF expression influences the cell proliferation 
of DLC1-deficient hepatocellular carcinoma cells.  
 
 
Figure 59: Myoferlin depletion inhibits tumor cell proliferation of HuH7 cells.  
(A) HuH7 cells expressing control shRNA or MYOF shRNA were lysed and equal amounts of total protein were 
immunoblotted using anti-MYOF antibody. Loading was controlled by re-probing the blot for HSP90. (B) Indicated 
HuH7 cells were counted daily for 5 days. Values are expressed as mean ± SEM of three independent experiments.  
6.3.7 Depletion of myoferlin augments senescence-associated ß-galactosidase 
activity 
The effect of MYOF expression on tumor cell proliferation attracted our interest as MKL1/2 
depletion caused the identical phenotype by the induction of cellular senescence. Was cellular 
senescence the underlying mechanism of the growth arrest upon MYOF depletion? We 
assessed MYOF-depleted HuH7 cells for their senescence-associated ß-galactosidase 
activity. Quantification demonstrated that downregulation of MYOF expression highly 
augmented the percentage of SA-ß-gal positive HuH7 cells (Figure 60). These findings showed 
that MYOF depletion triggers the phenotype of cellular senescence that is commensurate with 
the observed anti-proliferative effect.  
 
 
Figure 60: Increased senescence-associated ß-galactosidase activity in HuH7 cells upon MYOF depletion. 
HuH7 cells expressing control shRNA or MYOF shRNA were stained for senescence-associated ß-galactosidase 
activity. The number of SA-ß-gal positive HuH7 cells was counted under an inverted microscope.  
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6.3.8 Increased ERK1/2 phosphorylation upon myoferlin depletion  
Next, we intended to analyze whether MYOF depletion in HuH7 cells is able to induce the 
senescence response via activation of the Raf-MEK-ERK1/2 pathway that has already been 
shown for MKL1/2 depletion. We tested for ERK1/2 activation by determining its 
phosphorylation status. The results from immunoblotting revealed that ERK1/2 
phosphorylation was strongly increased upon MYOF depletion in HuH7 cells. This effect was 
comparable to the extent of ERK1/2 phosphorylation upon MKL1/2 knockdown. Determination 
of the MYOF protein expression levels revealed that increased ERK1/2 phosphorylation was 
due to the reduction of MYOF expression upon MYOF and MKL1/2 knockdown in HuH7 cells 
(Figure 61). This is evidence for the MKL1/2 dependent target gene MYOF leading to the 
activation of MAP kinase signaling, thereby inducing the senescence response. 
  
 
 
 
Figure 61: Increased phosphorylation of ERK1/2 upon downregulation of MYOF expression. 
HuH7 cells stably expressing either control shRNA, MKL1/2 shRNA or MYOF shRNA were lysed and equal amounts 
of total protein were immunoblotted with anti-ERKpT202/pY204, total anti-ERK, anti-MYOF and anti-HSP90 antibodies. 
  
Results 
 
94 
6.3.9 Myoferlin depletion induces oncogene-induced senescence in DLC1-deficient 
HuH7 cells 
To corroborate our findings we assessed MYOF-depleted HuH7 cells for their expression of 
the oncogene-induced senescence markers p16Ink4a and the phosphorylation status of p53 on 
serine 15. In contrast to HuH7 control cells, MYOF depleted HuH7 cells revealed a strong 
accumulation of p16Ink4a protein expression. Phosphorylation of p53 on serine 15 was clearly 
enhanced upon MYOF downregulation in HuH7 cells (Figure 62). This was evidence that 
MYOF depletion in DLC1-deficient HuH7 cells abrogates cell proliferation via activation of the 
oncogene-induced senescence response. 
  
 
Figure 62: Induction of oncogene-induced senescence upon MYOF depletion in HuH7 cells. 
HuH7 cells transduced with either control shRNA or MYOF shRNA were lysed and equal amounts of total protein 
were subjected to immunoblotting using anti-p16Ink4a, anti-phospho p53 serine 15, total anti-p53 and anti-HSP90 
antibodies. 
6.3.10 Myoferlin depletion elevates mRNA expression levels of c-fos 
As shown, MYOF depletion in DLC1-deficient HuH7 cells led to sustained ERK1/2 activation. 
By analyzing downstream targets of ERK1/2, we focused us on the immediate early gene c-
fos encoding a transcription factor that is known to govern ERK signaling (Murphy et al 2002). 
ERK signaling can stimulate c-fos expression via different stimuli, however the best studied 
mechanism is the stimulation of c-fos transcription via the transcription cofactor Elk-1 which 
interacts with the serum response factor to activate the c-fos promoter (Monje et al, 2003). 
Consequently, the mRNA expression levels of c-fos in MYOF depleted HuH7 cells were 
determined by quantitative real-time PCR. The results demonstrated that the downregulation 
of MYOF mRNA expression in HuH7 cells caused a 20-fold upregulation of c-fos mRNA 
expression in comparison to HuH7 control cells (Figure 63). These findings indicated that the 
increase of the c-fos mRNA expression levels upon MYOF depletion reflects the activation of 
ERK signaling.  
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Figure 63: Induction of c-fos mRNA expression in HuH7 cells upon MYOF depletion. 
Total cellular RNA from HuH7 cells transduced with control shRNA or MYOF shRNA was isolated. MRNA 
expression was analyzed by quantitative real-time PCR using c-fos and MYOF-specific primers. Shown is the fold 
change of c-fos and MYOF specific mRNA expression in MYOF depleted HuH7 cells in comparison to HuH7 control 
cells. Quantification is based on two independent experiments and data are expressed as mean ± SD. 
6.3.11 Myoferlin depletion increases the activity of the human epidermal growth factor 
receptor 
The underlying molecular mechanism of MYOF depletion mediated upregulation of MAPK 
signaling still remained to be investigated. A recently published study by Turtoi and colleagues 
described that MYOF downregulation increased the activity of the epidermal growth factor 
receptor (EGFR) in breast carcinoma cells (Turtoi et al, 2013). The EGF receptor is a key 
upstream effector of Ras signaling and it is well established that activation of the tyrosine 
kinase receptor is able to activate Ras which in turn leads to an upregulation of MAPK signaling 
(Gale et al, 1993). Thus, we addressed the question whether MYOF expression can directly 
influence the EGFR activity in DLC1-deficient hepatocellular carcinoma cells and thereby 
activating MAP kinase signaling that contributes to the oncogene-induced senescence 
response. To test whether activation of the EGF receptor is able to induce MAPK signaling in 
HuH7 cells, HuH7 cells were serum-starved and stimulated with human recombinant epidermal 
growth factor (EGF) that binds and activates the tyrosine kinase activity of the human EGF 
receptor. Activation of MAPK signaling was checked by the determination of the 
phosphorylation status of ERK1/2. The results from immunoblotting showed that EGF 
treatment of HuH7 cells increased the phosphorylation levels of ERK1/2 compared to 
untreated, serum-starved HuH7 control cells (Figure 64). However, the protein expression 
levels of total ERK were not affected by EGF stimulation. EGF stimulation for 5 minutes was 
sufficient to induce ERK1/2 phosphorylation and EGF treatment for longer time periods 
potentiated the phosphorylation levels of ERK1/2 (Figure 64). This indicated that activation of 
the EGF receptor in DLC1-deficient HuH7 cells upregulates the Raf-MEK1-ERK1/2 pathway.  
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Figure 64: EGF stimulation of HuH7 cells induces phosphorylation of ERK1/2. 
HuH7 cells were serum-starved for 16 hours and thereafter stimulated with 10 ng/mL EGF for the indicated time 
points. Afterwards cells were harvested, lysed and equal amounts of total protein were immunoblotted using anti-
ERKpT202/pY204 and total anti-ERK antibodies. 
In order to learn if depletion of MKL1/2 and MYOF can directly activate the EGF receptor, 
activation of the EGF receptor was analyzed by the determination of its phosphorylation status 
at tyrosine 1173 that is considered to reflect activation of MAP kinase signaling (Hsu et al, 
2011). HuH7 cells were transduced with MKL1/2 shRNA and MYOF shRNA and 24 hours after 
posttransduction, the phosphorylation levels of the EGF receptor at tyrosine 1173 were 
analyzed by immunoblotting. Compared to HuH7 control cells, HuH7 cells transduced with 
MKL1/2 shRNA and MYOF shRNA demonstrated increased phosphorylation levels of the EGF 
receptor at tyrosine 1173. The expression levels of total EGF receptor remained unchanged 
upon MKL1/2 and MYOF knockdown suggesting that MKL1/2 and MYOF expression influence 
the activation state of the EGF receptor. Determination of the MYOF expression levels by 
immunoblotting revealed that HuH7 cells expressing MKL1/2 shRNA and MYOF shRNA 
expressed reduced MYOF protein levels in comparison to HuH7 control cells. This provided 
evidence that reduction of MYOF expression in HuH7 cells contributes to the activation of the 
EGF receptor.  
 
 
Figure 65: Downregulation of MYOF expression increases the phosphorylation levels of the EGF receptor 
at tyrosine 1173. 
HuH7 cells were transduced with control shRNA, MKL1/2 shRNA or MYOF shRNA and 24 hours posttransduction, 
cells were harvested and lysed. Equal amounts of total protein were analyzed by immunoblotting using anti-
EGFRpTyr1173, total anti-EGFR, anti-MYOF and anti-HSP90 antibodies.  
The ultimate verification that MYOF is the target gene of MKL1/2 and mediates the activation 
of MAPK kinase signaling, came when we reconstituted MYOF expression in MKL1/2 depleted 
HuH7 cells and analyzed its influence on the activation status of the EGF receptor. HuH7 cells 
were transfected with a plasmid encoding human HA-tagged MYOF and after 24 hours cells 
were transduced with MKL1/2 shRNA. Transduction of HuH7 cells with MKL1/2 shRNA 
reduced the protein expression level of MKL1 compared to HuH7 control cells. However, 
transfection of HuH7 cells with human HA-tagged MYOF was able to restore MYOF expression 
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in HuH7 cells expressing MKL1/2 shRNA (Figure 66). Analysis of the activation state of the 
EGF receptor revealed that downregulation of MYOF expression in MKL1/2 shRNA transduced 
HuH7 cells increased the phosphorylation of EGFR at tyrosine 1173. On the contrary, 
restoration of MYOF expression in MKL1/2 depleted HuH7 cells suppressed the induction of 
EGFR phosphorylation at tyrosine 1173. With this experimental setup, we found that the 
expression levels of MYOF concomitantly affected the total expression levels of the EGF 
receptor. Reduction of MYOF expression contributed to an increase of total EGFR levels 
whereas MYOF overexpression diminished total EFGR expression levels. These data are 
preliminary and it remains to be resolved whether MYOF depletion influences in the first 
instance the phosphorylation status of EGFR or the total expression levels. So our data 
highlight for the first time that MYOF constitutes a novel MKL1/2 dependent target gene 
involved in the regulation of the EGF receptor activity. 
 
 
Figure 66: MYOF mediates the effects of MKL1/2 on the activation of EGFR signaling. 
HuH7 cells were transfected with human HA-MYOF and after 24 hours, cells were transduced with MKL1/2 shRNA. 
After additional 24 hours, cells were lysed and equal amounts of total protein were subjected to immunoblotting 
using anti-EGFRpTyr1173, total anti-EGF, anti-MKL1, anti-MYOF, anti-HA and anti-HSP90 antibodies.  
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7 Discussion 
7.1 Molecular mechanism which drive MKL1/2 signaling in human cancer 
cells 
7.1.1 Nuclear accumulation of MKL1 and MKL2 in human hepatocellular and breast 
carcinoma cells with DLC1 loss 
We investigated the subcellular localization of MKL1 and MKL2 in different human 
hepatocellular and breast carcinoma cell lines. A correlation between the subcellular 
distribution of MKL1 and MKL2 and the endogenous expression levels of the tumor suppressor 
Deleted in Liver Cancer 1 (DLC1) in both hepatocellular and breast carcinoma cell lines was 
identified. Initially DLC1 was recognized as the human homolog of the rat p122RhoGAP. It 
was found to be frequently absent in primary human hepatocellular carcinoma (Yuan et al, 
1998). DLC1 is located at chromosome 8p21.2-22, a region that is prominent for loss of 
hererozygosity (LOH) in a large number of different tumors (Arbieva et al, 2000; Yuan et al, 
1998). A representative oligonucleotide microarray analysis (ROMA) pointed to a 
heterozygous deletion of DLC1 in about 50 % of liver, breast, lung and 70 % of colon cancers 
almost frequently as p53 in these cancers (Xue et al, 2008). DLC1 encoded a RhoGAP protein 
the functional role of which was to turn off Rho-mediated signaling. DLC1 showed some 
specificity for RhoA, B, C and to a lesser extent to cdc42 (Wong et al, 2003). Our data 
demonstrated a predominantly nuclear MKL1/2 localization in human hepatocellular and breast 
carcinoma cells who have lost endogenous DLC1 expression. By contrast, DLC1-expressing 
cancer cells were marked by a clear cytoplasmic localization of MKL1/2. To ascertain that the 
observed nuclear accumulation of MKL1/2 in DLC1-deficient cancer cell lines was not due to 
other functional characteristics in the genetic background of the cancer cell lines, we 
investigated the influence of DLC1 expression on the subcellular localization of MKL1/2 in 
hepatocytes by an RNAi approach. Established murine hepatocytes lacking p53 expression 
and coexpressing the oncogene MYC were used which resembles to the common genetic 
background of HCC (Zender et al, 2006). Downregulation of DLC1 expression in these murine 
hepatocytes led to the nuclear translocation of both MKL1 and MKL2. Restoration of DLC1 
expression in HuH7 cells provoked a relocalization of both MKL1 and MKL2 back from the 
nucleus to the cytoplasm. These data provided evidence that DLC1 expression is directly 
involved in the regulation of the subcellular distribution of MKL1 and MKL2 which has not been 
noticed before. The first described mechanism for loss of DLC1 expression is attributed to its 
frequent heterozygous deletion, however aberrant hypermethylation of CpG islands within the 
promoter region of DLC1 also contributes to silencing of its expression (Wong et al, 2003; Yuan 
et al, 2003a). Somatic mutations of DLC1 were thought to be rare until it was discovered to 
occur in prostate and colon cancers, accompanied by the loss of the tumor-suppressive 
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properties of DLC1 (Liao et al, 2008). It was interesting to see whether epigenetic silencing of 
DLC1 expression or missense mutations also affected the subcellular localization of MKL1/2 
in human cancer cells. 
7.1.2 Increased RhoA signaling upon loss of DLC1 in human cancer cells 
We addressed the question, how the DLC1 expression status would influence the subcellular 
localization of MKL1/2? As it is well established that nuclear translocation of MKL1/2 requires 
RhoA-actin signaling, the influence of DLC1 expression on the RhoA activation state in human 
hepatocellular and breast carcinoma cells was analyzed. Our data documented that the lack 
of endogenous DLC1 expression in HuH7 and MDA-MB-468 cells caused the constitutive 
activation of RhoA. This result was in line with previous studies demonstrating a significant 
influence of DLC1 expression on the RhoA activity (Healy et al, 2008; Wong et al, 2003; Xue 
et al, 2008). It was quite surprising that the deletion of DLC1, one out of 67 RhoGAPs, was 
sufficient to cause the constitutive activation of RhoA in human cancer cells.  A similar crosstalk 
was reported for the tumor suppressor neurofibromin (NF1) encoding a RasGAP protein which 
loss contributed to the hyperactivation of Ras in human tumor cells (Basu et al, 1992; Bollag 
et al, 1996). RhoA overexpression was also found in numerous cancers but the underlying 
mechanism of RhoA activation has been not well understood (Gomez del Pulgar et al, 2005). 
In agreement with other studies, we identified the tumor suppressor DLC1 as a specific 
regulator of RhoA activity in hepatocellular and breast carcinoma cells (Xue et al, 2008). Our 
findings provide mechanistic insights into the underlying mechanism of RhoA activation in 
human tumor cells. Xue and colleagues were able to show that the increase of RhoA activation 
upon DLC1 loss drives hepatocarcinogenesis in vivo (Xue et al, 2008). As increased RhoA 
signaling causes the F-actin polymerization and stress fibers formation, we investigated the 
influence of DLC1 expression on the actin cytoskeleton of human cancer cells. The DLC1-
deficient HuH7 and MDA-MD-468 cells were marked by a significant increase in the amount 
of actin stress fibers, which are composed of filamentous actin. Quantitative assessment of G- 
and F-actin levels revealed a significant elevation of the F-actin levels in DLC1-deficient cancer 
cells (Muehlich et al, 2012). Other groups had also shown that DLC1 expression exerted an 
inhibitory effect on stress fiber formation and was critically implicated in the remodeling of the 
actin cytoskeleton (Holeiter et al, 2008; Wong et al, 2008). These findings allowed us to 
interpret the nuclear localization of MKL1/2 in DLC1-deficient human cancer cells. Based on 
the established nuclear import mechanism of MKL1/2 in fibroblasts, we propose that DLC1 
loss activates RhoA, which controls F-actin formation thereby leading to the nuclear 
translocation of MKL1/2. The concomitant G-actin depletion in DLC1-deficient cancer cells 
abrogates G-actin binding to the N-terminal RPEL domains within MKL1/2 which are required 
for the cytoplasmic sequestration of MKL1/2. Pawlowski and colleagues recently demonstrated 
that the dissociation of MKL1 from G-actin leads to the exposition of a nuclear localization 
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sequence within the RPEL actin binding domain, which is required for the nuclear import of 
MKL1 via the importin (Imp)α/β dependent pathway (Pawlowski et al, 2010). We conclude that 
the DLC1-deficiency in hepatocellular and breast carcinoma cells addresses different aspects 
of the nuclear import mechanism of MKL1/2 thereby favoring their constitutive nuclear 
localization.  
7.1.3 Defective nuclear export mechanism of MKL1 in DLC1-deficient cancer cells 
Besides the importance of RhoA/actin signaling for the nuclear import of MKL1/2, we focused 
us on the nuclear export mechanism of MKL1 in DLC1-deficient hepatocellular carcinoma cells.  
Vartiainen and colleagues showed that nuclear export, rather than import, constituted the key 
regulatory step of the subcellular distribution of MKL1 (Vartiainen et al, 2007). ERK1/2 
mediated phosphorylation of MKL1 at serine 454 enhances binding between nuclear G-actin 
and MKL1 which was required for the Crm1-dependent nuclear export of MKL1 (Muehlich et 
al, 2008; Vartiainen et al, 2007). Our data pointed to a lack of ERK1/2 mediated 
phosphorylation of MKL1 at Serine 454 in HuH7 and MDA-MB-468 cells, both characterized 
by DLC1 deficiency. The lack of MKL1 phosphorylation was presumably due to the observed 
suppression of ERK1/2 activity in DLC1-deficient cancer cells. Morin and colleagues reported 
reduced ERK activity in cells overexpressing active RhoA and therefore the observed 
constitutive RhoA activation in DLC1-deficient cancer cells provides a imaginable explanation 
for the obtained effect (Morin et al, 2009). Our group substantiated these findings by showing 
that the suppression of RhoA activity by simvastatin treatment enabled phosphorylation of 
MKL1 in DLC1-deficient cancer cells (Muehlich et al, 2012). We analyzed the nuclear export 
mechanism of MKL1 due to its extensive description in the literature but we suppose the same 
nuclear export mechanism for MKL2 as it can be phosphorylated at the same residue like 
MKL1 and the phospho-specific MKL1 antibody also recognizes phosphorylated MKL2 (data 
are unpublished, personnel communication). However, we did not test whether the deficiency 
of DLC1 expression in the cancer cells directly affects the ability of MKL1 to associate with 
nuclear G-actin, a prerequisite for its nuclear export. Recently, a nuclear-cytoplasmic shuttle 
mechanism was reported for DLC1 (Chan et al, 2011; Yuan et al, 2007). The nuclear 
translocation of DLC1 depends on a bipartite nuclear localization sequence (NLS), but two 
contradictory studies, each report different residues for the NLS sequence, possibly arising 
from differences in the cellular context (Chan et al, 2011; Yuan et al, 2007). It was reported 
that the nuclear localization of DLC1 is associated with decreased tumor suppressive 
properties and the nuclear translocation could be viewed as a spatial regulatory mechanism 
(Chan et al, 2011). Scholz and colleagues found that phorbol-ester induced phosphorylation 
of DLC1 blocked the nuclear import by masking a nuclear localization sequence (Scholz et al, 
2009). A similar mechanism was reported for MKL1 where TPA induced MKL1 phosphorylation 
thereby causing its cytoplasmic localization (Muehlich et al, 2008). We performed an in-silico 
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analysis of DLC1 and found the expected leucin-rich nuclear export signal which resembled to 
a mitogen-activated protein kinase phosphorylation site. As the nuclear import and export of 
both MKL1 and DLC1 features similarity in their mechanism we speculated that MKL1 and 
DLC1 can interact mechanistically, thereby influencing their subcellular distribution.  
7.1.4 Activation of MKL1/2 and SRF dependent target gene expression in DLC1-
deficient cancer cells 
So far, our data pointed to the constitutive nuclear accumulation of MKL1/2 in human DLC1-
deficient cancer cells, due to the activation of RhoA/actin signaling required for the nuclear 
import and impairment of the nuclear export mechanism. It is well established that nuclear 
localization is required but not sufficient for the association with SRF and activation of 
MKL/SRF dependent target gene expression because MKL1 has to dissociate from G-actin to 
obtain transcriptional activity (Vartiainen et al, 2007). Recently, Baarlink and colleagues 
demonstrated that serum stimulation promoted formin-regulated actin polymerization in the 
nucleus (Baarlink et al, 2013). Nuclear actin polymerization was sufficient to drive MKL1-
mediated SRF signaling, so this study described initially that nuclear F-actin structures regulate 
the transcriptional activity of MKLs. It has been reported that the group of ternary complex 
factors, acting as transcriptional coactivators of SRF, repress the transcription of some MKL1/2 
target genes (Lee et al, 2010b). We were interested whether the constitutive nuclear 
accumulation of MKL1/2 is sufficient to activate their target gene expression. We analyzed the 
expression levels of the immediate early gene CTGF, a member of the CCN family classified 
as a MKL/SRF dependent target gene (Medjkane et al, 2009; Muehlich et al, 2007). CTGF 
expression was constitutively activated in DLC1-deficient HuH7 and MDA-MB-468 cells 
whereas endogenous DLC1-expressing HepG2 and MCF7 cells displayed low basal 
expression levels of CTGF which were strongly upregulated by serum-stimulation. Silencing of 
DLC1 expression in HepG2 cells enhanced the expression of CTGF, while restoration of DLC1 
expression in HuH7 cells reverted this effect by suppressing CTGF expression. We 
investigated the expression levels of Cyr61, a further member of the CCN family which 
expression has been described to be dependent on SRF and MKL1/2 (Lee et al, 2010b; 
Medjkane et al, 2009). Cyr61 revealed the same expression pattern like CTGF, defined by low 
basal expression levels in DLC1-expressing HepG2 cells and constitutively activated Cyr61 
expression in DLC1-deficient HuH7 cells. These findings suggest that DLC1 loss caused 
nuclear translocation of MKL1/2 directly contributes to the constitutive activation of MKL/SRF 
dependent target gene expression. Both CTGF and Cyr61 are aberrantly expressed in 
hepatocellular and breast carcinoma cells, thereby promoting tumor progression (Li et al, 
2012b; Mazzocca et al, 2010; Tsai et al, 2002; Xie et al, 2001; Xiu et al, 2012). Our data provide 
evidence that activation of MKL/SRF signaling in tumor cells features oncogenic properties by 
promoting the expression of tumor-relevant target genes. We concluded that loss of DLC1 
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expression promotes tumorigenesis via direct activation of MKL/SRF dependent target gene 
signaling. A similar effect was obtained for MKL1 fused with the RBM15 gene in 
megakaryoblastic leukemia cells (Ma et al, 2001). The RBM15-MKL1 fusion protein revealed 
a constitutive nuclear localization and activation of SRF and its target genes thereby promoting 
megakaryoblastic leukemia (Cen et al, 2003; Descot et al, 2008; Mercher et al, 2009). These 
results led to the conclusion that the nuclear accumulation of MKL1/2 accompanied by the 
constitutive activation of target gene expression is directly linked to tumor progression.  
7.1.5 MKL1/2 depletion induces alterations in the actin cytoskeleton of DLC1-deficient 
cancer cells 
Our group showed that downregulation of MKL1/2 expression reverted the pro-migratory effect 
caused by DLC1 loss (Muehlich et al, 2012). The involvement of DLC1 signaling in the 
migratory behavior of human cancer cells has already been reported before (Holeiter et al, 
2008; Kim et al, 2008; Ullmannova & Popescu, 2007). As changes in the cell motility are tightly 
associated with cytoskeletal reorganization, the effect of MKL1/2 expression on the actin 
cytoskeleton of DLC1-deficient HuH7 and MDA-MB-468 cells was analyzed. Stress fibers are 
required as contractile forces for cell migration and the decrease in the amount of stress fibers 
upon MKL1/2 depletion might reflect the observed anti-migratory effect of MKL1/2 depletion in 
DLC1-deficient HuH7 and MDA-MB-468 cells. The protrusive structures at the edges of the 
cells, named filopodia, were strongly diminished in DLC1-deficient HuH7 and MDA-MB-468 
cells depleted of MKL1/2. Filopodia are considered as typical features of invasive tumor cells 
(Mattila & Lappalainen, 2008). Since loss of DLC1 expression stimulates tumor cell invasion, 
we assumed that MKL1/2 depletion might revert the invasive behavior of DLC1-deficient 
carcinoma cells (Tripathi et al, 2013; Wong et al, 2005). Our assumption is supported by a 
previously reported study by Medjkane and colleagues who demonstrated that MKL1/2 are 
required for cell adhesion, migration and experimental metastasis (Medjkane et al, 2009). The 
reduction of filopodia upon MKL1/2 depletion resembles to the phenotype for SRF knockout in 
endothelial cells where SRF depletion abolished filopodia formation, thereby disrupting 
angiogenesis (Franco et al, 2013). We assume that the effect of MKL1/2 depletion on the 
structure of the actin cytoskeleton is due to the involvement of MKL/SRF signaling in the 
transcription of genes involved in actin dynamics (Olson & Nordheim, 2010).  
7.2 Influence of MKL1/2 expression on the tumor growth of hepatocellular 
carcinoma cells  
7.2.1 Depletion of MKL1/2 in DLC1-deficient HCC cells inhibits tumor cell proliferation 
Studies conducted by our group showed that loss of DLC1 expression correlated well with the 
nuclear accumulation of MKL1 in primary human hepatocellular carcinoma in vivo, 
accompanied by an increased expression of the proliferation marker Ki-67 (Muehlich et al, 
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2012). Expression of the human Ki-67 protein correlated directly with cell proliferation and 
progression of the disease. Its expression was detectable during all active phases of the cell 
cycle whereas it was lacking in resting cells (Scholzen & Gerdes, 2000). These data led to the 
assumption that MKL1/2 expression might affect the proliferation of hepatocellular carcinoma 
cells. The tumor suppressor DLC1 was initially identified to be frequently deleted in human 
hepatocellular carcinoma, the sixth most frequent type of cancer in the human population and 
the third highest cause of cancer-related death. We focused on the influence of MKL1/2 
expression on the growth of hepatocellular carcinoma cells characterized by a DLC1-deficient 
background.  
Our data highlighted, for the first time, that RNA-interference mediated downregulation of both 
MKL1 and MKL2 expression significantly suppressed the proliferation of the human HCC cells 
HuH6 and HuH7, both lacking endogenous DLC1 expression. As cell proliferation of 
endogenous DLC1-expressing HepG2 and HLF cells was not affected by MKL1/2 knockdown 
we hypothesized that DLC1 expression plays a crucial role in the MKL1/2 knockdown mediated 
growth arrest. Silencing of DLC1 expression in HepG2 cells increased the proliferation of the 
HCC cells which is in accordance with reported studies (Wong et al, 2005; Xue et al, 2008). 
However, depletion of MKL1/2 expression abolished the pro-proliferative effect caused by 
DLC1 loss. These data provided evidence that loss of DLC1 expression was a prerequisite to 
render HCC cells responsive to the effect of MKL1/2 knockdown on cell proliferation. Additional 
analysis revealed that expression of constitutively active RhoA in DLC1-expressing HepG2 
cells not responding to the MKL1/2 knockdown, caused the nuclear translocation of MKL1 and 
enabled inhibition of cell proliferation upon MKL1/2 knockdown. As increased RhoA activity 
and the concomitant nuclear localization of MKL1/2 are direct consequences of DLC1 loss, it 
was evident why especially DLC1-deficient HCC cells responded to the MKL1/2 knockdown. 
Investigations by Medjkane and colleagues demonstrated that MKL1/2 depletion reduces the 
invasiveness and motility but does not affect the proliferative capacity of tumor cells (Medjkane 
et al, 2009). We presume that this discrepancy arises from the fact that Medjkane and 
colleagues analyzed DLC1-expressing tumor cells characterized by low RhoA activity and 
inactive, cytoplasmic sequestered MKL1/2. Their observations are in agreement with ours on 
endogenous DLC1-expressing HepG2 and HLF cells where MKL1/2 knockdown did not 
change their cell proliferation rate. These findings substantiated our data and document that 
the depletion of transcriptionally active, nuclear MKL1/2 provokes an anti-proliferative effect 
corresponding to our previous suggestion that nuclear targeted MKL1/2 feature oncogenic 
properties. On the other hand, our findings are contradictory to the study conducted by Descot 
and colleagues reporting that the overexpression of nuclear targeted MKL1 exerted a strong 
anti-proliferative effect on human fibroblasts by addressing target genes with a proven anti-
proliferative function (Descot et al, 2009). A similar inverse effect of MKL1/2 expression has 
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been reported for cell migration, as MKL1/2 knockdown in fibroblasts enhanced cell migration, 
whereas it was blocked in tumor cells upon MKL1/2 depletion (Leitner et al, 2011; Medjkane 
et al, 2009; Muehlich et al, 2012). Consequently, we postulate that these effects of MKL1/2 
expression constitute a cell type specific feature and argue that genes are differentially 
targeted by MKL1/2 depending on the cellular context. We were able to exclude apoptosis 
accounting for the observed anti-proliferative effect, as MKL1/2 have been described to be 
implicated in apoptotic signaling via their proapoptotic target genes Bok and Noxa 
(Shaposhnikov et al, 2012). At the cellular level, we identified cellular senescence as the 
underlying mechanism of the MKL1/2 depletion mediated growth arrest in DLC1-deficient 
HuH7 and HuH6 cells. The phenotype of cellular senescence was associated with 
morphological and structural alterations of MKL1/2 depleted HCC cells characterized by the 
induction of an enlarged, flat and vacuole-rich morphology which was devoid of actin stress 
fibers. Increased senescence-associated ß-galactosidase activity was detected in DLC1-
deficient HuH7 and HuH6 cells depleted of MKL1/2, a well-established biomarker of senescent 
cells in vitro and in vivo (Debacq-Chainiaux et al, 2009). Silencing of DLC1 expression in 
HepG2 cells enabled the induction of cellular senescence upon MKL1/2 knockdown thereby 
verifying that the DLC1 expression status is critical for the MKL1/2 knockdown mediated 
senescence response. Furthermore, DLC1-deficient HuH7 cells accumulated upon MKL1/2 
depletion in the G1-phase of the cell cycle, a prominent characteristic of cells undergoing the 
senescence response (Afshari et al, 1993; Gorman & Cristofalo, 1986; Sherwood et al, 1988). 
Cellular senescence is defined as a stable cycle arrest where cells are incapable to regain the 
proliferative capacity. Thus our data describe cellular senescence as the underlying 
mechanism of the obtained anti-proliferative effect of MKL1/2 knockdown in DLC1-deficient 
HCC cells. One of the classical definitions of senescence is that senescent cells are incapable 
of triggering the expression of genes required for proliferation (Seshadri & Campisi, 1990). As 
MKL1 and MKL2 function as transcriptional coactivators of SRF thereby controlling processes 
such as proliferation by transducing growth factor signaling into gene expression, we assumed 
that MKL1/2 depletion may affect the expression of genes which are involved in the cell cycle 
machinery. This assumption is substantiated by the findings reported by Shaposhnikov and 
colleagues showing that MKL1/2 expression is required for proper cell cycle progression 
(Shaposhnikov et al, 2013).  Consequently these data led to the conclusion that MKL1/2 
constitute novel, hitherto unnoticed modulators of the cellular senescence response in human 
HCC cells characterized by a DLC1-deficient background. In agreement with this, it has already 
been reported that homozygous inactivation of SRF in murine colon-derived SMCs led to a 
senescent phenotype (Angstenberger et al, 2007).  
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So far, MKL1/2 depletion provokes the phenotype of cellular senescence constituting a 
multifaceted process. We were thus interested in the exact underlying molecular mechanism 
of the senescence response.  
We demonstrated that MKL1/2 depletion in DLC1-deficient HCC cells contributed to the 
activation of oncogenic Ras, indicated by the increased amount of GTP-bound Ras levels. 
Activated Ras signaling resulted in increased phosphorylation of ERK1/2 thereby reflecting the 
activation state of ERK1/2 (Crews et al, 1992; Zheng & Guan, 1993). Interestingly, Descot and 
colleagues reported a similar negative crosstalk between actin-MKL1 and the MAPK kinase 
pathway via the MKL1 target gene mig6 (Descot et al, 2009). We hypothesized that mig6 could 
mediate the effect upon MKL1/2 depletion on Ras activation, but experiments showing that 
mig6 expression was transcriptionally regulated by MKL1/2 expression in DLC1-deficient 
HuH7 cells were negative. According to reports from Morin and colleagues there exists an 
inverse correlation between RhoA and ERK activity like reduced ERK activity in cells 
expressing active RhoA (Morin et al, 2009). Therefore we tested whether MKL1/2 depletion 
can modify the constitutive RhoA activity in DLC1-deficient HuH7 cells but no influence of 
MKL1/2 expression on the RhoA activation status was detected. Consequently, we argued that 
a hitherto unknown gene might modulate the activation of MAPK signaling upon MKL1/2 
depletion in DLC1-deficient HCC cells. We found that the Ras-activated ERK1/2 pathway was 
responsible for the growth arrest upon MKL1/2 depletion in DLC1-deficient HuH7 cells, 
because the MEK1 inhibitor UO126 abolished the anti-proliferative effect of MKL1/2 
knockdown. According to a recent study, UO126 might also suppress senescence by inhibiting 
the MEK/mTOR pathway (Demidenko et al, 2009). It is conceivable that mTOR might also 
contribute to the pro-proliferative effect of UO126 in MKL1/2 depleted HuH7 cells. Initially, 
Serrano and colleagues demonstrated that the aberrant activation of the Ras/MAPK pathway 
by oncogenic Ras triggers a senescence response referred to as “oncogene-induced 
senescence” (Serrano et al, 1997). In response, it has been become a central issue that the 
overactivation of oncogenes can trigger the oncogene-induced senescence response that is 
supposed to act as a failsafe mechanism (Lin et al, 1998; Michaloglou et al, 2005; Serrano et 
al, 1997; Zhu et al, 1998). Our data demonstrate for the first time that oncogenic Ras signaling 
upon MKL1/2 depletion drives human DLC1-deficient HCC cells into the oncogene-induced 
senescence response. Studies by Serrano and colleagues showed that oncogenic Ras can 
induce premature senescence via activation of the tumor suppressors p16Ink4a and p53 
(Serrano et al, 1997). P16Ink4a expression was significantly elevated in DLC1-deficient HuH7 
and HuH6 cells upon MKL1/2 knockdown, but remained unchanged in endogenous DLC1-
expressing HepG2 cells. The used HCC cells displayed very low endogenous expression 
levels of p16Ink4a corresponding to the assumption that p16Ink4a is commonly underexpressed 
in human cancer cell lines due to promoter methylation, mutation or homozygous deletion (Kim 
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& Sharpless, 2006; Nobori et al, 1994; Okamoto et al, 1994). In agreement with our findings, 
p16Ink4a expression is mostly induced in senescent cells and plays a key role in the 
establishment of the stable cell cycle arrest by activating the downstream tumor suppressor 
retinoblastoma protein (Rb) lying at the core of the senescence response (Alcorta et al, 1996; 
Hara et al, 1996; Lowe et al, 2004; Serrano & Blasco, 2001). Rb is considered as a master 
regulator of cell cycle progression because it represses the transcription of genes required for 
G1-S phase transition and DNA replication mediated by members of the E2F transcription 
factor family (Burkhart & Sage, 2008; Chicas et al, 2010). Our data demonstrated that 
downregulation of MKL1/2 expression in DLC1-deficient HuH7 and HuH6 cells provoked a 
hypophosphorylated form of the Rb protein which is consistent with the observations from other 
research groups reporting hypophosphorylation of Rb in cells undergoing the senescence 
response (Lin et al, 1998; Serrano et al, 1997; Stein et al, 1990). Hypophosphorylation of Rb 
reflects its activity and is linked to the inhibition of G1 progression (Yen & Sturgill, 1998). The 
observed G1-arrest in MKL1/2 depleted HuH7 cells is consistent with the hypophosphorylated 
form of the Rb protein. To demonstrate the importance of the p16Ink4a-Rb tumor suppressor 
pathway in the MKL1/2 depletion mediated senescence response, p16Ink4a expression was 
silenced via RNA-interference and as a consequence hypophosphorylation of Rb was 
abrogated upon MKL1/2 knockdown. These data indicated that p16Ink4a constitutes a key 
effector protein of the MKL1/2 knockdown mediated senescence response corresponding to 
the previous notes that the lack of p16Ink4a expression can prevent the onset of the senescence 
response upon oncogenic signaling (Haferkamp et al, 2009; Lin et al, 1998). The establishment 
of the oncogene-induced senescence response was further substantiated by the findings that 
MKL1/2 depletion in DLC1-deficient HuH7 and HuH6 cells caused a DNA damage response 
documented by elevated phosphorylation of p53 on serine 15. In line with this observed effect, 
investigations by Di Micco and colleagues already demonstrated that oncogene-induced 
senescence arises from the induction of a robust DNA-damage response marked by increased 
phosphorylation of p53 on serine 15 (Di Micco et al, 2006). However, according to several 
reports, the induction of a DDR seems not to be obligatory for the establishment of oncogene-
induced senescence (Efeyan et al, 2009; Olsen et al, 2002) 
 
Oncogene-induced senescence is associated with chromatin remodeling resulting in the 
formation of heterochromatin structures termed senescence-associated heterochromatin foci 
(SAHF) which has been initially described by Narita and colleagues (Narita et al, 2003). SAHF 
plays a critical role in sequestering proliferation-promoting genes like E2F target genes thereby 
contributing to the cell cycle arrest. MKL1/2 depletion triggered the formation SAHFs in DLC1-
negative HuH7 and HuH6 cells indicated by the accumulation of histone-3 trimethylated on 
lysine 9, specifically enriched in SAHFs (Narita et al, 2003). As SAHF formation upon 
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oncogene activation is well established, we conclude that the activation of oncogenic RAS 
signaling upon MKL1/2 depletion provokes SAHF formation thereby contributing to the 
irreversible cell cycle arrest (Michaloglou et al, 2005; Narita et al, 2003). 
A further hallmark of cells undergoing the oncogene-induced senescence response are 
changes in their secretome collectively termed “senescence-messaging secretome” (SMS) 
(Kuilman & Peeper, 2009). The induction of the SMS is characterized by the upregulation of 
secretory factors like inflammatory cytokines, chemokines or growth factors that govern a 
variety of cellular responses (Coppe et al, 2010). Amongst the SMS factors, MKL1/2 depletion 
significantly upregulated the expression of the chemokine (C-S-C motif) ligand 10 (CXCL10) 
and tumor necrosis factor (ligand) superfamily member 10 (TNFSF10) in DLC1-deficient HuH7 
and HuH6 cells which have been reported to be secreted by senescent cells (Braumuller et al, 
2013; Cahu et al, 2012; Dabrowska et al, 2011). For both CXCL10 and TNFSF10 it has been 
shown that their expression push human cancers into the senescence response (Braumuller 
et al, 2013). Based on these findings we supposed that the enhanced CXCL10 and TNFSF10 
expression in DLC1-deficient HCC cells depleted of MKL1/2 reinforce the senescence 
response and contribute to the maintenance of the stable cell cycle arrest.  
7.2.2 Induction of cellular senescence upon reconstitution of DLC1 expression 
We found that the oncogene-induced senescence response occurred exclusively in DLC1-
negative HCC cells upon MKL1/2 depletion. After reports that MKL1/2 mediate the effects upon 
loss of the tumor suppressor DLC1, we addressed the question whether MKL1/2 
downregulation may substitute for the tumor suppressive actions of DLC1. Reconstitution of 
DLC1 expression in the human hepatocellular carcinoma cells HuH7 reduced the cell 
proliferation due to the accumulation of DLC1-reconstituted HuH7 cells in the G1-phase of the 
cell cycle. The cell morphology of DLC1-reconstituted HuH7 cells adopted a senescence-like 
phenotype characterized by an enlarged morphology and vacuole enriched cytoplasm. 
Analysis of the oncogene-induced senescence markers demonstrated that the re-expression 
of DLC1 in HuH7 cells caused the induction of p16Ink4a expression and provoked the 
hypophosphorylation of the Rb protein accounting for the obtained G1-arrest. In addition, DLC1 
reconstitution provoked an accumulation of the SAHF component histone 3 trimethylated on 
lysine 9 and induced a DDR indicated by elevated phosphorylation of p53 on serine 15. Based 
on the findings we concluded that the restoration of DLC1 expression in HCC cells induced 
cellular senescence that constitutes a novel hitherto unnoticed tumor suppressive property of 
DLC1. According to this note, restoration of the famous tumor suppressor p53 has already 
been reported to cause senescence (Ventura et al, 2007; Xue et al, 2007). It might be possible 
that senescence is a common feature of the restoration of tumor suppressors. As the 
expression of the senescence markers upon DLC1 reconstitution resembled to the effect of 
MKL1/2 depletion in DLC1-deficient HCC cells we suppose that MKL1/2 depletion mimics the 
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effects of DLC1 reconstitution. Zhang and colleagues observed a cell cycle arrest in the G1-
phase upon DLC1 re-expression but proposed apoptosis as the underlying mechanism (Zhang 
et al, 2009). We speculate that this discrepancy is due to the use of different tumor cell lines. 
The senescence response upon DLC1 reconstitution has not been noticed before, possibly 
due to the use of transient transfection methods which does not allow long-term analysis of 
cell proliferation and senescence induction (Qin et al, 2013; Yuan et al, 2004; Zhang et al, 
2009; Zhou et al, 2004). Our notice of the senescence response upon DLC1 restoration is 
substantiated by the work of Qian and colleagues who reported a direct correlation between 
DLC1 and p16Ink4a expression, a crucial effector protein of the cellular senescence response 
(Qian et al, 2012).  
7.2.3 Evaluation of MKL1/2 as novel anti-tumor target in vivo 
Our in vitro data make MKL1/2 likely anti-tumor targets for the treatment of hepatocellular 
carcinoma cells characterized by loss of DLC1 expression. We studied the therapeutic efficacy 
of MKL1/2 knockdown by a therapeutic knockdown approach, using RNA-interference in vivo 
as a highly efficient tool for the exploration of novel targets. We employed polymer-based 
nanoparticles for siRNA delivery into established subcutaneous HCC xenografts derived from 
DLC1-deficient HuH7 cells. Due to a higher relevance in a therapeutic setting, we preferred 
the systemic application of siRNAs by intraperitoneal injection rather than the intratumoral 
application. SiRNA targeting both MKL1 and MKL2, a combination of MKL1 and MKL2 specific 
siRNAs and MKL1 siRNA alone were complexed with polyethylenimine for systemic delivery 
(Hobel et al, 2010). The systemic application of PEI complexed MKL1/2 siRNA for a treatment 
period of 22 days completely abolished tumor growth of HCC xenografts. The combination of 
MKL1+2 specific siRNAs also reduced tumor growth albeit somewhat less efficiently, 
compared to the siRNA targeting both MKL1 and 2. We assume that this may be due to the 
lower dose of MKL1 and MKL2 siRNAs: the combination of MKL1 and 2 consists of 7.5 µg 
MKL1 and 7.5 µg MKL2 siRNA, whereas 15 µg MKL1/2 siRNA targeting both MKL1 and 2 was 
used. We used comparably low siRNAs amounts that have been proven in this tumor model 
for inhibition of HCC xenograft growth. The systemic application of MKL1 siRNA alone was 
sufficient to completely abrogate HCC xenograft growth. These findings indicated that MKL1 
and MKL2 may not act redundantly in the context of tumor growth. In addition, these data are 
substantiated by preliminary findings of our group which indicate that MKL1 depletion in HuH7 
cells is sufficient to suppress tumor-relevant target gene expression. By contrast, in human 
fibroblasts MKL1 depletion was not sufficient to reduce target gene expression because MKL1 
and MKL2 bind mainly in their heterodimerized form to SRF (Cen et al, 2003). At the moment 
we speculate whether in DLC1-deficient HuH7 cells MKL1 may bind in its homodimerized form 
to SRF that would argue for its unique role in HCC tumor growth. Nevertheless, the 
involvement of MKL2 expression in HCC xenograft growth remains to be clearly investigated. 
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Moreover it would be interesting to evaluate the consequences of either MKL1 or MKL2 
depletion on the onset of the oncogene-induced senescence response in vitro. Remarkably, 
no adverse side effects were detected upon systemic therapy with PEI/complexed siRNAs 
targeting MKL1 and MKL2. It has been reported that MKL1 knockout mice are viable and fertile 
but fail to nurse their offspring (Li et al, 2006; Sun et al, 2006b). Moreover, it was recognized 
that MKL1 expression is required for the maturation of megakaryocytes and platelet formation 
whereas global MKL2 deletion contributes to embryonic lethality due to defects in the cardiac 
development (Cheng et al, 2009; Oh et al, 2005; Ragu et al, 2010). Long-term treatment may 
lead to unexpected adverse side effects, owing to other physiological functions of MKL1 and 
MKL2. It raised the question whether the regression of the tumors was due to a senescence 
response in vivo. Evaluation of oncogene-induced senescence markers in HCC xenografts 
treated with MKL1+2 siRNA revealed a significant induction of the tumor suppressor p16Ink4a. 
Induction of p16Ink4a expression has been reported to occur in senescent mouse and human 
lesions in vivo (Collado et al, 2005; Michaloglou et al, 2005). An accumulation of the SAHF 
component histone H3 trimethylated on lysine 9 and increased phosphorylation of the DDR 
marker p53 on serine 15 was detected in HCC xenografts treated with the combination of MKL1 
and MKL2 specific siRNAs. The regression of the tumors was associated with enhanced 
expression of the senescence-associated chemokine ligand CXCL10. Several groups reported 
that the secretion of SMS factors plays a critical role in the induction of an immune response 
against premalignant cells which triggers the clearance of pre-cancerous senescent cells in 
vivo and in vitro, thereby limiting the development of liver cancer (Kang et al, 2011; 
Krizhanovsky et al, 2008; Xue et al, 2007). We speculated whether the increase of CXCL10 
expression in MKL1+2 treated tumors influences the clearance of senescent cells thereby 
accounting to the distinctive phenotype of HCC xenograft growth inhibition in vivo. Our data 
highlight for the first time that downregulation of MKL1/2 expression abolish tumor growth of 
DLC1-deficient hepatocellular carcinoma by inducing oncogene-induced senescence in vivo. 
In concert with this, induction of oncogene-induced senescence in vivo has already been 
reported to act as a failsafe mechanism limiting tumor progression (Braig et al, 2005; 
Michaloglou et al, 2005). We conclude that depletion of oncogenic MKL1/2 signaling provokes 
oncogene-induced senescence to counteract DLC1-loss driven hepatocarcinogenesis. A 
future goal might be to evaluate whether MKL1/2 depletion can trigger the oncogene-induced 
senescence response in vitro and in vivo in other tumor identities characterized by a DLC1-
deficient background like breast or colon carcinoma cells. In agreement with this suggestion, 
our group could already show that silencing of MKL1/2 expression in human DLC1-deficient 
breast carcinoma cells reduced their cell proliferation (Muehlich et al, 2012). It might interesting 
to investigate whether cellular senescence is a common mechanism of the MKL1/2 depletion 
mediated proliferation arrest. 
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7.3 Analysis of MKL1/2 dependent target gene expression in human 
DLC1-deficient hepatocellular carcinoma cells 
7.3.1 Transcriptome analysis of MKL1/2 depleted hepatocellular carcinoma cells with 
DLC1-deficiency 
To date, our data illustrate that MKL1/2 expression is required for the tumor growth of DLC1-
deficient hepatocellular carcinoma cells in vitro and in vivo. We aimed to identify which MKL1/2 
dependent target genes are involved in regression of the tumor growth and induction of the 
oncogene-induced senescence response. The transcriptome of DLC1-deficient HuH7 cells 
stably depleted of MKL1/2 expression was analyzed. One key aspect of our gene expression 
analysis was the identification of transcriptionally regulated genes upon depletion of active 
nuclear MKL1/2. Comparison with the list of target genes regulated by MKL1/2 expression in 
human breast cancer cells from the microarray study conducted by Medjkane and colleagues 
suggested that there is only little consistency with our MKL1/2 regulated target genes 
(Medjkane et al, 2009). We assume that this effect is due to the fact that Medjkane and 
colleagues analyzed genes that were regulated upon depletion of cytoplasmic, quiescent 
MKL1/2 whereas we analyzed the consequences of nuclear, active MKL1/2. Some genes 
described to be regulated by G-actin-MKL1 signaling like transgelin/ smooth muscle protein 
alpha 22 (SM22) and calponin also appeared in our gene list (Descot et al, 2009). Our 
microarray approach was validated to be selective for MKL1/2 regulated genes because known 
TCF-dependent target genes like c-fos or egr-1 did not appear in the list. Our differentially 
regulated genes were nicely validated in HCC xenografts treated with MKL1+2 siRNA. SM22, 
which is aberrantly expressed in smooth muscle cells, was found to be downregulated upon 
MKL1/2 depletion in vitro. SM22 is known to have both pro-neoplastic and anti-neoplastic 
functions (Assinder et al, 2009; Lee et al, 2010a). Contradictory to our findings in vitro, we 
observed a significant upregulation of SM22 expression upon MKL1/2 downregulation in vivo. 
With regard to the increased SM22 expression in senescent cells, we assumed that the 
augmented expression of SM22 in HCC xenografts was due to the observed senescence 
response (Thompson et al, 2012). Our microarray approach revealed that the Glioma-
pathogenesis related 1 gene (GLIPR1) was transcriptionally downregulated by MKL1/2 
depletion in vitro and in vivo. GLIPR1 has been initially reported to act as a tumor suppressor 
which is frequently downregulated in prostate cancer and seems to be a target gene of p53 
(Ren et al, 2002; Ren et al, 2004; Ren et al, 2006). Conversely, GLIPR1 was found to be 
specifically expressed in glioma and Wilm`s tumor, where its expression featured oncogenic 
properties (Chilukamarri et al, 2007; Murphy et al, 1995; Rich et al, 1996). It seems to be a 
cell-type specific feature whether GLIPR1 exerts oncogenic or tumor suppressive functions.  
In the context of hepatocarcinogenesis, GLIPR1 has not been noticed before and its functional 
implication remains to be addressed. Nevertheless, we assume that the suppressed GLIPR1 
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expression levels upon MKL1/2 depletion contributed to the tumor regression of DLC1-
deficient HuH7 cells.  In addition, non-muscle heavy chain 9 (MYH9) was transcriptionally 
suppressed upon MKL1/2 depletion in vitro and in vivo. These findings are in agreement with 
the study from Medjkane and colleagues describing MYH9 as a MKL1/2 controlled gene the 
expression of which is implicated in tumor cell invasion of breast carcinoma cells (Betapudi et 
al, 2006; Medjkane et al, 2009). We conclude that MYH9 expression is involved in the invasive 
behavior of DLC1-deficient HuH7 cells. A hereto unnoticed MKL1/2 regulated target gene 
constitutes the transforming growth factor beta 1 (TGFß1) the expression of which was 
reduced upon MKL1/2 depletion in vitro and in vivo. Whether increased TGFß1 expression is 
associated with the induction of a senescence response is controversial because we found 
decreased TGFß1 expression in senescent HuH7 cells depleted of MKL1/2 (Acosta et al, 2013; 
Senturk et al, 2010). In our setting of DLC1-deficient HuH7 cells, TGFß1 is unlikely to 
participate directly in the senescence response. Another aspect of TGFß1 expression is its 
implication in the mechanism of epithelial to mesenchymal transition (EMT), a fundamental 
step in the process of cancer progression where epithelial cells are converted to migratory and 
invasive cells (Thiery, 2002). Consistent with the observation that MKL1/2 are required for 
TGFß1-induced EMT reported by Morita and colleagues, we supposed that decreased TGFß1 
expression in vitro and in vivo upon MKL1/2 downregulation accounted for the limitation of the 
malignant progression of DLC1-deficient HuH7 cells (Morita et al, 2007). In agreement with 
Medjkane and colleagues, we found decreased expression of the vestigial-like protein 3 
(VGLL3) in MKL1/2 depleted HuH7 cells. However, its expression was not regulated by 
MKL1/2 in HCC xenografts in vivo (Medjkane et al, 2009). VGLL3 was described as a cofactor 
of the TEAD transcription factors and there is some evidence for their role in tumor progression 
(Pobbati & Hong, 2013). It might be possible that the transcriptional downregulation of VGLL3 
expression upon MKL1/2 depletion contributes to the limitation of the malignant phenotype of 
DLC1-deficient HuH7 cells. Our data showed that the microtubule-associated protein 1B 
(MAP1B), encoding a structural microtubule-associated protein, constitutes a new member of 
the group of cytoskeletal proteins the expression of which is regulated by MKL1/2 signaling in 
vitro and in vivo. MAP1B is described to have a special role in the stability of the cytoskeleton 
of neuronal cells and its expression influenced neuronal migration and growth (Lu et al, 2004; 
Tymanskyj et al, 2012). This raises the important question whether its expression affects the 
growth and migratory behavior of DLC1-deficient HCC cells. MAP1B appeared for the first time 
in our microarray study and we speculate that it has a special relevance in our setting of DLC1-
deficient HuH7 cells. In addition, another interesting aspect of our microarray analysis was the 
identification of myoferlin, encoding a transmembrane protein the expression of which was 
transcriptionally downregulated in DLC1-deficient HuH7 cells depleted of MKL1/2 and in HCC 
xenografts treated with MKL1+2 siRNA. The influence of myoferlin expression on tumor growth 
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in our setting of DLC1-deficient HuH7 cells will be discussed below in detail. We postulate that 
each target gene whose expression was transcriptionally suppressed upon MKL1/2 depletion, 
was functionally implicated in the process of tumor regression of DLC1-deficient HCC cells. 
Evaluation of the functional role of each MKL1/2 regulated target gene provide mechanistic 
insights into MKL1/2 promoted tumor growth and onset of the oncogene-induced senescence 
response.  
7.3.2 Functional characterization of Myoferlin 
Of particular interest to us was myoferlin, a member of the conserved family of ferlin proteins 
which reportedly has a role in variety of membrane processes like endocytosis, membrane 
repair and vesicular transport (Bernatchez et al, 2009; Cipta & Patel, 2009; Sharma et al, 
2010). We were able to demonstrate that loss of the tumor suppressor DLC1 directly activated 
the expression of myoferlin, which was proven to be transcriptionally regulated by the MKL1/2 
and SRF signaling axis. Thus one major aspect of our study was the analysis of the functional 
role of myoferlin expression in relation to hepatocellular carcinoma cells characterized by a 
DLC1-deficient background. Interestingly, silencing of myoferlin expression strongly reduced 
the invasiveness of human DLC1-deficient HuH7 cells. Similar findings were reported by Li 
and colleagues and by Eisenberg and colleagues both showing that myoferlin depletion 
impairs the invasion of breast cancer cells (Eisenberg et al, 2011; Li et al, 2012a). Based on 
our findings, we suppose that besides MYH9, which has already been described to be required 
for MKL1/2 promoted tumor cell invasion, myoferlin constitutes a new MKL1/2 dependent 
target gene whose expression is functionally implicated in the invasive behavior of DLC1-
deficient HuH7 cells. Moreover short-hairpin mediated myoferlin depletion significantly 
inhibited the tumor cell proliferation of HuH7 cells. These results are in close agreement with 
those obtained by Leung and colleagues, who demonstrated that myoferlin downregulation 
reduced the cell proliferation of mouse Lewis lung carcinoma cells (Leung et al, 2013). 
Depletion of myoferlin exhibited a similar anti-proliferative effect on the tumor growth of DLC1-
deficient HuH7 cells like MKL1/2 knockdown. The reduction of MYOF expression enhanced 
the senescence-associated ß-galactosidase activity and contributed to the activation of MAPK 
signaling as indicated by increased ERK1/2 phosphorylation. Analysis of oncogene-induced 
senescence markers demonstrated that MYOF depletion caused the activation of the DNA-
damage response documented by increased phosphorylation of p53 on serine 15 and led to 
the induction of p16Ink4a expression, a key inducer of the senescence response. Hence, the 
expression of the MKL1/2 dependent target gene myoferlin is functionally involved in the 
oncogene-induced senescence response of human hepatocellular carcinoma cells marked by 
loss of DLC1 expression. We found that myoferlin depletion led to sustained EGFR activation 
as documented by prominent phosphorylation of tyrosine 1173 residue. Myoferlin was 
specified as the target gene mediating the effects of MKL1/2 expression on EGF receptor 
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signaling. Preliminary data provided evidence that myoferlin depletion not only affects the 
EGFR phosphorylation status but even the overall expression levels of the EGF receptor. 
Silencing of MKL1/2 expression suppressed myoferlin expression and, as a consequence, 
alleviation of EGFR signaling occurred. Our observations are consistent with a previously 
reported study by Turtoi and colleagues, who highlighted myoferlin as a key regulator of EGFR 
activity in breast cancer cells (Turtoi et al, 2013). Turtoi and colleagues found that increased 
EGFR activity was due to impaired degradation of phosphorylated EGF receptors upon 
myoferlin depletion (Turtoi et al, 2013). A similar effect was reported by Bernatchez and 
colleagues, demonstrating that myoferlin expression stabilized VEGF receptor expression in 
endothelial cells (Bernatchez et al, 2007). Myoferlin expression blocked the polyubiquitination 
of activated VEGF receptors which is mediated by the E3-ubiquitin ligase CBL, thereby labeling 
the receptors for their subsequent proteasomal degradation. It was supposed that myoferlin is 
functionally implicated in the mechanism of receptor dependent endocytosis, part of the 
process of receptor internalization which functions as a negative feedback mechanism 
controlling the intensity and duration of receptor signaling (Wells et al, 1990). Receptor 
dependent endocytosis is characterized by the fission of endocytotic vesicles which require 
the coat proteins clathrin and caveolin and plasma membrane fission is facilitated by the family 
of dynamin proteins. Bernatchez and colleagues found that in endothelial cells myoferlin 
colocalized with caveolin and dynamin 2 and assumed a functional role of myoferlin in the 
receptor dependent endocytosis (Bernatchez et al, 2009). Mechanistically, we speculate 
whether in our setting of DLC1-deficient HuH7 cells, downregulation of myoferlin expression 
may interfere with the activity of the CBL ubiquitin ligase, thereby preventing the ubiquitination 
of active EGF receptors and inhibiting their degradation. Along with the study of Turtoi and 
colleagues, there is given evidence for another scenario, where myoferlin depletion may 
disrupt the formation of plasma membrane caveolae which is required for proper endocytosis. 
It might be interesting to investigate the mechanism of increased EGFR signaling upon 
myoferlin depletion in DLC1-deficient human hepatocellular carcinoma cells. So, the functional 
characterization of myoferlin links MKL1/2 depletion to the onset of the oncogene-induced 
senescence response. Based on our data we established the following model for MKL1/2 as 
novel modulators of the oncogene-induced senescence response in human DLC1-deficient 
HCC cells in vitro and in vivo. 
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Figure 67: Proposed model for the induction of the oncogene-induced senescence response upon 
MKL1/2 depletion in human DLC1-deficient HCC cells.  
 
We found that loss of the tumor suppressor DLC1 in human HCC cells provokes constitutive 
RhoA activation, thereby causing the nuclear accumulation of MKL1/2 and the concomitant 
activation of target gene expression. Depletion of nuclear, active MKL1/2 expression induces 
the transcriptional suppression of myoferlin expression that causes elevated EGFR signaling 
thereby activating downstream oncogenic Ras signaling. Oncogenic Ras activation provokes 
the activation of MAPK signaling and triggers via the p16Ink4a/Rb tumor suppressor pathway 
the senescence response, characterized by an irreversible growth arrest. This model provides 
a mechanistic explanation for the observed oncogene-induced senescence response upon 
DLC1 reconstitution. As we have already demonstrated that restoration of DLC1 expression 
targets MKL1/2 into the cytoplasm and diminishes the expression of MKL/SRF dependent 
target genes, we suggest that restoration of DLC1 expression in HCC cells suppresses the 
expression of myoferlin, comparable to the effect of MKL1/2 silencing and enables thereby 
activation of EGFR signaling and the subsequent oncogene-induced senescence response. 
7.4 Novel pharmacological targets for the treatment of DLC1-deficient 
HCC cells 
The proposed model provides several novel options for the pharmacological treatment of HCC 
characterized by loss of DLC1 expression. One approach is the pharmacological reactivation 
of the tumor suppressive functions of DLC1, but this is conceptually and technically difficult.  
Tumor suppressors like DLC1 are not directly accessible for therapeutic intervention. Blocking 
of RhoA by geranylgeranyltransferase inhibition appears to be less desirable due to the 
ubiquitous cellular distribution of geranylgeranylation of proteins. Nuclear MKL1/2 constitute 
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potent anti-tumor targets as their depletion causes the tumor suppressive oncogene-induced 
senescence response. Inhibition of nuclear MKL1/2 signaling simultaneously suppresses the 
expression of multiple tumor-promoting target genes involved in growth, migration and invasion 
of DLC1-deficient HCC cells. Their inhibition would have multiple beneficial therapeutic effects. 
Recently, Bell and colleagues established a new chemical compound, named CCG-1423, 
together with its related structural analogues as a new class of inhibitors of Rho/MKL1/SRF 
dependent gene transcription (Bell et al, 2013a; Bell et al, 2013b). So far the exact molecular 
target of these compounds remains to be investigated, but it was shown that treatment with 
CCG-1423 block the nuclear localization of MKL1 (Jin et al, 2011). Given that depletion of 
nuclear MKL1 is sufficient to abrogate HCC tumor growth in vivo, it might be attractive to 
evaluate the therapeutic efficacy of the new compounds to inhibit the tumor growth of DLC1-
deficient HCC cells. The pharmacological blocking of myoferlin expression might be another 
attractive candidate as its suppression initiates the oncogene-induced senescence response 
and the concomitant reduction of the invasiveness of DLC1-deficient HCC cells would have a 
beneficial therapeutic effect. In DLC1-deficient HCC cells, we found that activation of sustained 
EGFR-Ras-MEK-ERK signaling modulates the tumor suppressive oncogene-induced 
senescence response. Aberrant activation of EGFR-Ras-Raf-MEK-ERK signaling is a 
consistent finding in numerous cancers but, in contrast, there it is tightly linked to the promotion 
of cell proliferation, cell survival and metastasis (Roberts & Der, 2007). Therefore, the 
molecular components of the EGFR-Ras-Raf-MEK-ERK signaling pathway are subjects of 
intensive scientific investigations to find new inhibitors that provide an efficient treatment of 
human malignancies. It is documented that EGFR signaling is involved in 
hepatocarcinogenesis and pharmacologically targeting the EGFR system for HCC treatment 
is clinically proven. One approach relies on the small molecules gefitinib and erlotinib, both 
inhibiting the tyrosine kinase activity of the EGF receptor. Another approach is the application 
of EGFR targeted antibodies like cetuximab. However, only a subset of HCC patients 
responded to the therapy. At the moment, the multikinase inhibitor sorafenib is used for the 
therapy of advanced HCC but exerted only modest clinical benefit. A reasonable explanation 
of the limited responsiveness of HCC to targeting EGFR-MAPK signaling is given by our 
evidence that inhibition of EGFR-Ras-MEK-ERK signaling blocks the onset of the oncogene-
induced senescence response. We found that activation of EGFR-MAPK signaling results 
exclusively in the oncogene-induced senescence response in human HCC cells lacking 
endogenous expression of the tumor suppressor DLC1 accounting for approximately 50 % of 
HCC cases. Consequently we argue that the molecular heterogeneity of HCC may account for 
suboptimal therapeutic outcomes. Genomic profiling of HCC allows an appropriate therapeutic 
strategy for optimal medical outcomes and our data emphasize the necessity of personalized 
health care approaches. Our studies provide mechanistic insights into the underlying 
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pathomechanism that drives hepatocarcinogenesis upon loss of the tumor suppressor DLC1. 
Silencing of MKL1/2 expression was evaluated as an efficient approach to antagonize the 
growth of HCC lacking DLC1 by inducing the oncogene-induced senescence response. A 
future challenge will be to discover novel senescence inducing drugs, as some DNA-damaging 
agents have already been reported to cause oncogene-induced senescence (Chang et al, 
1999; Schmitt et al, 2002; te Poele et al, 2002). It is conceivable that the pharmacological 
induction of oncogene-induced senescence in a therapeutic setting reverts malignant cells into 
resting, senescent cells thereby limiting tumor progression.  
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